
<html lang="en"     class="pb-page"  data-request-id="8d7d0fe6-b51d-4a41-82d2-012e192c67f7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/jm800506v;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2008.51.issue-21;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Prevention of Drug-Induced Memory Impairment by Immunopharmacotherapy" /></meta><meta name="dc.Creator" content="Jennifer B.  Treweek" /></meta><meta name="dc.Creator" content="Chengzao  Sun" /></meta><meta name="dc.Creator" content="Alexander V.  Mayorov" /></meta><meta name="dc.Creator" content="Longwu  Qi" /></meta><meta name="dc.Creator" content="Coree L.  Levy" /></meta><meta name="dc.Creator" content="Amanda J.  Roberts" /></meta><meta name="dc.Creator" content="Tobin J.  Dickerson" /></meta><meta name="dc.Creator" content="Kim D.  Janda" /></meta><meta name="dc.Description" content="One approach to treating drug abuse uses antidrug antibodies to immunize subjects against the illicit substance rather than administering therapeutics that target the specific CNS site of action. A..." /></meta><meta name="Description" content="One approach to treating drug abuse uses antidrug antibodies to immunize subjects against the illicit substance rather than administering therapeutics that target the specific CNS site of action. A..." /></meta><meta name="dc.Publisher" content=" American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 16, 2008" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm800506v" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2008 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm800506v" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm800506v" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm800506v" /></link>
        
    
    

<title>Prevention of Drug-Induced Memory Impairment by Immunopharmacotherapy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm800506v" /></meta><meta property="og:title" content="Prevention of Drug-Induced Memory Impairment by Immunopharmacotherapy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0002.jpeg" /></meta><meta property="og:description" content=" One approach to treating drug abuse uses antidrug antibodies to immunize subjects against the illicit substance rather than administering therapeutics that target the specific CNS site of action. At present, passive vaccination has recognized efficacy in treating certain gross symptoms of drug misuse, namely, motor activation, self-administration, and overdose. However, the potential for antibodies to prevent drug-induced changes involving finer cognitive processes, such as benzodiazepine-associated amnesia, remains unexplored. To address this concept, a flunitrazepam hapten was synthesized and employed in the generation of a panel of high affinity monoclonal antibodies. Anti-flunitrazepam mAb RCA3A3 (Kd,app = 200 nM) was tested in a mouse model of passive immunization and subsequent mole-equivalent challenge with flunitrazepam. Not only was flunitrazepam-induced sedation prevented but immunization also conferred protection to memory consolidation as assessed through contextual and cued fear conditioning paradigms. These results provide evidence that immunopharmacotherapeutic blockade of drug intoxication also preserves complex cognitive function." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm800506v"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm800506v">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm800506v&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm800506v&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm800506v&amp;href=/doi/10.1021/jm800506v" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2008</span><span class="cit-fg-volume">, 51</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 6866-6875</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/51/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm800967h" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm8006728" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Prevention of Drug-Induced Memory Impairment by Immunopharmacotherapy</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer+B.++Treweek">Jennifer B. Treweek</a></span><span class="author-xref-symbol "><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chengzao++Sun">Chengzao Sun</a></span><span class="author-xref-symbol "><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander+V.++Mayorov">Alexander V. Mayorov</a></span><span class="author-xref-symbol "><sup>â </sup></span><span class="author-xref-symbol "><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Longwu++Qi">Longwu Qi</a></span><span class="author-xref-symbol "><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Coree+L.++Levy">Coree L. Levy</a></span><span class="author-xref-symbol "><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Amanda+J.++Roberts">Amanda J. Roberts</a></span><span class="author-xref-symbol "><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tobin+J.++Dickerson">Tobin J. Dickerson</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol "><sup>â </sup></span><span class="author-xref-symbol "><sup>â¡</sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kim+D.++Janda">Kim D. Janda</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol "><sup>â </sup></span><span class="author-xref-symbol "><sup>â¡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info"><span class="aff-text">Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Molecular and Integrative Neurosciences Department (MIND), and Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037</span></div><div class="corresp-info"><strong>*</strong> To whom correspondence should be addressed. For T.J.D.: phone, (858) 784-2522; fax, (858) 784-2590; e-mail, <a href="/cdn-cgi/l/email-protection#22564d404b4c625141504b5252510c474657"><span class="__cf_email__" data-cfemail="4c38232e25220c3f2f3e253c3c3f62292839">[emailÂ protected]</span></a>. For K.D.J.: phone, (858) 784-2516; fax, (858) 784-2595; e-mail, <a href="/cdn-cgi/l/email-protection#a7ccc3cdc6c9c3c6e7d4c4d5ced7d7d489c2c3d2"><span class="__cf_email__" data-cfemail="ff949b959e919b9ebf8c9c8d968f8f8cd19a9b8a">[emailÂ protected]</span></a></div><div class="corresp-fn" id="afn1">â Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology.</div><div class="corresp-fn" id="afn3">â¡Worm Institute for Research and Medicine (WIRM).</div><div class="corresp-fn" id="afn2">Â§Molecular and Integrated Neurosciences Department (MIND).</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm800506v&amp;href=/doi/10.1021%2Fjm800506v" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2008</span></span><span class="cit-volume">, 51</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 6866â6875</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 15, 2008</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 May 2008</li><li><span class="item_label"><b>Published</b> online</span>16 October 2008</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 November 2008</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm800506v" title="DOI URL">https://doi.org/10.1021/jm800506v</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2008 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6866%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJennifer%2BB.%2BTreweek%252C%2BChengzao%2BSun%252C%2BAlexander%2BV.%2BMayorov%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D51%26issueNum%3D21%26contentID%3Djm800506v%26title%3DPrevention%2Bof%2BDrug-Induced%2BMemory%2BImpairment%2Bby%2BImmunopharmacotherapy%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6875%26publicationDate%3DNovember%2B2008">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm800506v"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1031</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm800506v" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Prevention of Drug-Induced Memory Impairment by Immunopharmacotherapy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;B. Treweek&quot;},{&quot;first_name&quot;:&quot;Chengzao&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;V. Mayorov&quot;},{&quot;first_name&quot;:&quot;Longwu&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Coree&quot;,&quot;last_name&quot;:&quot;L. Levy&quot;},{&quot;first_name&quot;:&quot;Amanda&quot;,&quot;last_name&quot;:&quot;J. Roberts&quot;},{&quot;first_name&quot;:&quot;Tobin&quot;,&quot;last_name&quot;:&quot;J. Dickerson&quot;},{&quot;first_name&quot;:&quot;Kim&quot;,&quot;last_name&quot;:&quot;D. Janda&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2008&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;51&quot;,&quot;pages&quot;:&quot;6866-6875&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm800506v&quot;},&quot;abstract&quot;:&quot;One approach to treating drug abuse uses antidrug antibodies to immunize subjects against the illicit substance rather than administering therapeutics that target the specific CNS site of action. At present, passive vaccination has recognized efficacy in treating certain gross symptoms of drug misuse, namely, motor activation, self-administration, and overdose. However, the potential for antibodies to prevent drug-induced changes involving finer cognitive processes, such as benzodiazepine-associated amnesia, remains unexplored. To address this concept, a flunitrazepam hapten was synthesized and employed in the generation of a panel of high affinity monoclonal antibodies. Anti-flunitrazepam mAb RCA3A3 (Kd,app = 200 nM) was tested in a mouse model of passive immunization and subsequent mole-equivalent challenge with flunitrazepam. Not only was flunitrazepam-induced sedation prevented but immunization also conferred protection to memory consolidation as assessed through contextual and cued fear conditioning para&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm800506v&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm800506v" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm800506v&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm800506v" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm800506v&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm800506v" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm800506v&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm800506v&amp;href=/doi/10.1021/jm800506v" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm800506v" /></input><a href="/doi/pdf/10.1021/jm800506v" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (338 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm800506v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm800506v%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DTreweek%26date%3D2008%26atitle%3DPrevention%2Bof%2BDrug-Induced%2BMemory%2BImpairment%2Bby%2BImmunopharmacotherapy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D51%26issue%3D21%26spage%3D6866%26epage%3D6875%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290792" title="Circuits">Circuits</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/51/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0002.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">One approach to treating drug abuse uses antidrug antibodies to immunize subjects against the illicit substance rather than administering therapeutics that target the specific CNS site of action. At present, passive vaccination has recognized efficacy in treating certain gross symptoms of drug misuse, namely, motor activation, self-administration, and overdose. However, the potential for antibodies to prevent drug-induced changes involving finer cognitive processes, such as benzodiazepine-associated amnesia, remains unexplored. To address this concept, a flunitrazepam hapten was synthesized and employed in the generation of a panel of high affinity monoclonal antibodies. Anti-flunitrazepam mAb RCA3A3 (<i>K</i><sub>d,app</sub> = 200 nM) was tested in a mouse model of passive immunization and subsequent mole-equivalent challenge with flunitrazepam. Not only was flunitrazepam-induced sedation prevented but immunization also conferred protection to memory consolidation as assessed through contextual and cued fear conditioning paradigms. These results provide evidence that immunopharmacotherapeutic blockade of drug intoxication also preserves complex cognitive function.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The challenge of drug development rests not only in identifying a novel lead compound for a given therapeutic application but also in finding a delivery method through which the druggable compound may reach its in vivo target. Small molecule therapeutics prescribed to modify mental or psychological states require a mechanism for transport across the bloodâbrain barrier when their site of action is within the central nervous system (CNS). For example, catecholamine and serotonin mimetics, which often contain the arylethylamine moiety common to monoamine neurotransmitters, function as agonists or antagonists of the respective neurotransmitter system. However, such direct manipulation of neural pathways by CNS-targeted therapies may incur noticeable side effects. To treat drug abuse, other routes have been explored for affecting the signaling networks altered by the illicit substance. For example, small molecule therapies that compete for the same CNS site may block drug binding. This technique either circumvents the corresponding drug high or overdose or supports user abstinence by supplying a drug substitute that endows a similar high of diminished intensity but prolonged duration. The latter instance has been used with limited success in drug-specific cases for the management of addiction (e.g., methadone, buprenorphine, and naloxone to treat heroin abuse). However, this strategy is not without drawbacks, with the most notable being the inherent addictive quality of the therapeutic agent. Further diminishing the utility of small molecule therapeutics is their incompatibility with prophylactic treatment.</div><div class="NLM_p">In this study, we sought to demonstrate the use of immunopharmacotherapy as a prophylactic antidrug therapeutic with the capacity to stave off drug-induced cognitive impairment despite its exclusion from the CNS. Whereas immunopharmacotherapy has been validated within the scenario of attenuating the psychomotor symptoms of drug intoxication from a comparatively large drug dose that potentially overwhelms the drug-binding capacity of the administered mAbÊ¼s,<a class="ref internalNav" href="#fnabbrev" aria-label="a">a</a><div class="NLM_fn" id="fnabbrev">a<p class="last">Abbreviations: mAb, monoclonal antibody; IgG, immunoglobulin; GABA, Î³-aminobutyric acid; iv, intravenous; ip, intraperitoneal; VS, vehicle saline (ip); VF, vehicle flunitrazepam (ip); RS, RCA3A3-immunized saline (ip); RF, RCA3A3-immunized flunitrazepam (ip); GS, GNC92H2-immunized saline (ip); CS, conditioned stimulus (tone); US, unconditioned stimulus (foot shock); CS+ test, conditioned stimulus test session of the conditioned fear assay; NIDA, National Institute on Drug Abuse.</p></div> the opposite scenario is rarely examined. As an immunotherapeutic target, benzodiazepines contrast with the traditional psychostimulants because a comparatively small number of drug molecules escaping mAb-mediated sequestration may precipitate measurable changes in cognitive processes. Protection from benzodiazepines does not probe the efficacy of a maximum mAb dose against a potential molar excess of drug, but instead it examines whether the rate of mAb-mediated drug scavenging in the periphery is sufficient to block even a minimal amount of drug from entering the CNS. To explore passive immunization against a highly potent abused small molecule, a hapten against flunitrazepam was designed and the monoclonal antibody (mAb) therapy evaluated for its ability to prevent flunitrazepam-induced memory deficits.</div><div class="NLM_p">To date, the implementation of passive immunization strategies has been limited in scope despite a major recognized benefit over other antiaddiction therapies (methadone maintenance, nicotine patch). In particular, immunization incurs minimal physiological consequences when drug use or exposure is avoided. Currently, attempts to diminish drug dependence or attenuate drug inebriation with antidrug mAbÊ¼s have been explored for morphine, PCP, cocaine, methamphetamine, mescaline, and nicotine.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1-4)</a> These investigations into mAb-mediated pharmacokinetic antagonism have focused on the attenuation of drug self-administration, restoration or protection of basic motor skills, prevention of intoxication upon future drug intake, and reversal of lethality from drug overdose in rodent models.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9 ref10">(5-10)</a> Here, immunopharmacotherapy has been proven effective, and consequently, the pursuit of mAb therapeutics for nicotine and cocaine has advanced into clinical trials.<a onclick="showRef(event, 'ref1 ref2 ref11'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref11">(1, 2, 11)</a></div><div class="NLM_p">All of the drugs previously targeted by immunopharmacotherapy produce gross symptoms of intoxication that obstruct an examination of more subtle drug-induced cognitive deficits. Alternatively, the CNS depressant flunitrazepam (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>A) was selected for this study because of its ability to effect higher order cognitive processes and its suitability for immunopharmacotherapy as a DEA Schedule IV abused substance.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Flunitrazepam binds with high affinity to benzodiazepine sites (BZ<sub>1</sub> and BZ<sub>2</sub><sup>+</sup>) on GABA receptors to allosterically modulate GABA neurotransmission.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The requirement for pre-existing GABAergic tone for flunitrazepam-induced intoxication reinforces the coabuse of flunitrazepam with other drugs by potentiating the effect of GABA receptor agonists.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Indeed, addicts often combine flunitrazepam with other substances to temper a given drug high or to self-medicate during drug withdrawal.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15-17)</a> In such potentially lethal cases, the available post hoc treatment is limited to administration of the benzodiazepine site antagonist flumazenil or activated charcoal.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The more alarming use statistic is the dramatic rise of facilitated sexual assault using ârophiesâ, in which even mild exposure to flunitrazepam spurs behavioral disinhibition.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> In response, the World Health Organization moved this benzodiazepine from a Schedule IV to Schedule III class drug, and the DEA began to track flunitrazepam use statistics more closely.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> While administration of flunitrazepam results in the sedation and muscle-relaxation characteristic of benzodiazepines, the concurrent hypnotic and amnesic effects have also promoted its abuse. Correspondingly, the ability of flunitrazepam to cause impairment at comparatively low doses<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> make flunitrazepam intoxication amenable for study using classical rodent behavioral assays. Targeting flunitrazepam by immunopharmacotherapy presents both a worthwhile and pharmacologically interesting endeavor; the former point concerns the social hazards inherent to its abuse, and the latter point relates to the necessity of preventing the sedative as well as cognitive effects of flunitrazepam.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design and preparation of flunitrazepam hapten RCA: (A) molecular structure of flunitrazepam; (B) synthesis of hapten RCA. Reagents and conditions are as follows: (i) <i>N</i>,<i>O</i>-dimethylhydroxylamine, EtOH; (ii) <sup><i>n</i></sup>BuLi, 2-fluorobromobenzene, â100 Â°C, THF, then HCl; (iii) Boc-Glu-(O<i>t</i>Bu)-OH, HATU, DIEA, 75 Â°C, 1,2-dichloroethane; (iv) TFA/CH<sub>2</sub>Cl<sub>2</sub>, then pyridine, 75 Â°C; (v) NaH, 0 Â°C, THF, then CH<sub>3</sub>I; (vi) KNO<sub>3</sub>, fuming H<sub>2</sub>SO<sub>4</sub>, room temp, then ice-cold DCM/water; (vii) <i>tert</i>-butyl aminobutyrate hydrochloride, PyBOP, DIEA, DCM, then TFA/CH<sub>2</sub>Cl<sub>2</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44528" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44528" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Generation of an Anti-Flunitrazepam Monoclonal Antibody</h3><div class="NLM_p">The synthesis of hapten RCA commenced from isatoic anhydride to generate 2â²-fluoro-2-aminobenzophenone <b>3</b> in two steps (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>B). Slight modifications of the published methods were made in order to increase the resulting yield; specifically, the intermediate Weinreb amide <b>2</b> was pretreated with <sup><i>n</i></sup>BuLi to form a lithium amide before it was added to preformed 2-fluorophenyllithium.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This procedure limited the formation of the major side product 2-butylcarbonylaniline and generated <b>3</b> in 57% yield. Coupling of <b>3</b> with a stoichiometric amount of Boc-Glu(O<i>t</i>Bu)-OH in the presence of HBTU at 75 Â°C over 2 days proved slow and inefficient, producing only <10% conversion; however, the reaction rate and the yield were increased by switching to HATU<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> as coupling reagent and using a 6-fold excess of Boc-Glu(O<i>t</i>Bu)-OH. By use of methods previously described by Hoffmann-LaRoche, deprotection of the <i>tert</i>-butyl ester followed by heating in pyridine yielded the seven-membered ring in excellent yield.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Subsequent 1-<i>N</i>-methylation and <i>para</i>-nitration proceeded smoothly in the presence of the free carboxylic acid group of the linker to afford <b>7</b>.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The linker was extended to a total length of 10â12 Ã by addition of an aminobutyrate moiety to give the hapten RCA. To generate the immunoconjugates, hapten RCA was coupled to BSA or KLH carrier proteins using EDC and sulfo-NHS activation, as previously reported.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> MALDI-TOF analysis revealed that an average of 12 hapten molecules were conjugated to BSA.</div><div class="NLM_p last">Immunization of two 4-week old 129 GIX+ mice with RCA immunoconjugates and RIBI adjuvant generated specific antibody titers (>12800) to the RCA hapten. In this immunization procedure, four injections were delivered 3â4 days apart, and then 1 month later, a fifth injection containing 50 Î¼g of immunoconjugate and 250 Î¼g of alum was administered. Mice were bled 1 week after the fourth and fifth injections for monitoring of antibody titers and specificities using ELISA. Two months after the last bleed, a final booster injection of immunoconjugate (50 Î¼g) was administered, followed by removal of the spleen 3 days later. The spleen cells were fused with a myeloma cell line to produce hybridomas according to standard techniques.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The hybridomas were cloned into 96-well plates and screened against the respective RCAâBSA conjugate by ELISA during the cloning process. Colonies producing antibodies that bound RCAâBSA were subcloned twice, after which 29 retained hapten binding. These were injected into mice to generate ascitic fluid, and IgG was obtained and purified using salt precipitation, anion exchange chromatography (DEAE), and affinity chromatography (protein G). In addition, the 29 members of the final panel were assessed for hapten binding and specificity to flunitrazepam using competition ELISA (<i>K</i><sub>d,app</sub> = 24 Î¼M to 200 nM). Of these antibodies, mAb RCA3A3 was shown to have the highest affinity for flunitrazepam (<i>K</i><sub>d,app</sub> = 200 nM) and was selected for further in vivo study.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Optimization of in Vivo Flunitrazepam Dose</h3><div class="NLM_p">After undergoing rotarod training, drug naive mice were randomly divided into groups according to flunitrazepam dose (0.03, 0.06, and 0.09 mg/kg) and then tested on rotarod after drug injection. The normalized data for speed at fall of each subject were averaged across group, and a one-way ANOVA (group, 0.0, 0.03, 0.06, 0.09 mg/kg dose) confirmed the significant effect of drug dose on rotarod agility [<i>F</i>(3,20) = 32.731, <i>p</i> < 0.0001] (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Mice receiving the 0.09 mg/kg drug dose were significantly impaired relative to vehicle control, 0.03 mg/kg, and 0.06 mg/kg groups (<i>p</i> < 0.0001) but were not sedated; thus, the 0.09 mg/kg dose was selected for subsequent experiments. Motor skills returned to within baseline levels in all mice 24 h after drug exposure (data not shown).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Flunitrazepam dose dependent impairment on rotarod performance. Approximately 20 min before testing, mouse groups received an ip injection of 0.03, 0.06, or 0.09 mg/kg flunitrazepam dissolved in 0.5% Tween-80 in isotonic saline, or an equivalent volume of 0.5% Tween-80 in isotonic saline. Values are expressed as the mean Â± SEM of three balance attempts on the test day, with the speed of the rotating rod at fall for each attempt normalized to the subjectâs average peak performance during rotarod training.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Immunization with RCA3A3 Prevents Flunitrazepam-Induced Sedation</h3><div class="NLM_p">The rotarod test, which aided in the flunitrazepam dose selection, was also employed as an initial screen of the therapeutic value of RCA3A3. Administration of the flunitrazepam-based mAb prior to drug exposure attenuated the deterioration of motor skills caused by flunitrazepam intoxication. Three-way repeated measures ANOVA (group Ã treatment Ã balance trials in a session) confirmed the significance of flunitrazepam-induced impairment and RCA3A3-mediated protection (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) in that there was a significant interaction between treatment and the repeated measure [<i>F</i>(2,82) = 3.805 (<i>p</i> < 0.05)]. Thus, two-way ANOVA (group Ã treatment) and Fisherâs PLSD were implemented for comparisons within balance sessions and between groups, respectively. Intoxication significantly impacted motor ability of VF mice relative to VS, RS, and GS groups (<i>p</i> < 0.005), while immunization against flunitrazepam protected RF mice from drug effects compared to VF mice (<i>p</i> < 0.0001) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Importantly, the immunization procedure had little effect on mice as demonstrated by the comparison of the performance of RF mice to RS mice in the rotarod assay (<i>p</i> = 0.95).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Statistical Analysis of Rotarod Agility and Locomotor Activity Test Results</div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top"><td colspan="3" align="left">Motor Activity, Rotarod</td></tr><tr valign="top"><td align="left">Three-way ANOVA<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></td><td align="left">VS, VF, RS, RF</td><td align="left"><i>F</i>(2,82) = 3.805 (<i>p</i> < 0.05)</td></tr><tr valign="top"><td align="left">Â </td><td align="left">VF vs VS</td><td align="left"><i>p</i> < 0.005</td></tr><tr valign="top"><td align="left">Two-way ANOVA (group Ã treatment)</td><td align="left">VF vs RF</td><td align="left"><i>p</i> < 0.0001</td></tr><tr valign="top"><td align="left">Â </td><td align="left">RF vs RS</td><td align="left"><i>p</i> = 0.95</td></tr><tr valign="top"><td colspan="3" align="left">Motor Activity, Locomotor</td></tr><tr valign="top"><td align="left">Â </td><td align="left">Â </td><td align="left"><i>F</i>(4,186) = 4.017 (<i>p</i> < 0.005)<a class="ref internalNav" href="#tbl2-fn2" aria-label="b">b</a></td></tr><tr valign="top"><td align="left">Three-way ANOVA</td><td align="left">VS, VF, RS, RF</td><td align="left"><i>F</i>(4,186) = 10.656 (<i>p</i> < 0.0001)<a class="ref internalNav" href="#tbl2-fn3" aria-label="c">c</a></td></tr><tr valign="top"><td align="left">Â </td><td align="left">Â </td><td align="left"><i>F</i>(4,186) = 4.017 (<i>p</i> < 0.05)<a class="ref internalNav" href="#tbl2-fn4" aria-label="d">d</a></td></tr><tr valign="top"><td align="left">Â </td><td align="left">VF vs VS</td><td align="left"><i>F</i>(4,92) = 8.645 (<i>p</i> < 0.0001)</td></tr><tr valign="top"><td align="left">Three-way ANOVA<a class="ref internalNav" href="#tbl2-fn4" aria-label="d">d</a></td><td align="left">VF vs RF</td><td align="left"><i>F</i>(4,84) = 3.967 (<i>p</i> = 0.006)</td></tr><tr valign="top"><td align="left">Â </td><td align="left">RF vs RS</td><td align="left"><i>F</i>(4,76) = 3.505 (<i>p</i> < 0.05)</td></tr><tr valign="top"><td align="left">Â </td><td align="left">VF vs VS</td><td align="left"><i>p</i> < 0.05, 0.05, 0.005</td></tr><tr valign="top"><td align="left">Studentâs <i>t</i> test<a class="ref internalNav" href="#tbl2-fn5" aria-label="e">e</a></td><td align="left">VF vs RF</td><td align="left"><i>p</i> < 0.05, all</td></tr><tr valign="top"><td align="left">Â </td><td align="left">RF vs RS</td><td align="left"><i>p</i> â« 0.05, all</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">(Group Ã treatment Ã balance trial), balance trials as repeated measure.</p></div><div class="footnote" id="tbl2-fn2"><sup>b</sup><p class="last">(Group Ã time interval Ã session).</p></div><div class="footnote" id="tbl2-fn3"><sup>c</sup><p class="last">(Treatment Ã time interval Ã session).</p></div><div class="footnote" id="tbl2-fn4"><sup>d</sup><p class="last">(Group Ã treatment Ã time interval), time interval as repeated measure.</p></div><div class="footnote" id="tbl2-fn5"><sup>e</sup><p class="last"><i>p</i> values shown for 3<sup>rd</sup>, 4<sup>th</sup>, and 5<sup>th</sup> intervals.</p></div></div></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of flunitrazepam intoxication and immunization with mAb RCA3A3 (RF, RS groups) on rotarod performance. Flunitrazepam (VF, RF; black bars) or 0.5% Tween-80 in isotonic saline (VS, RS; gray bars) ip injections were given 20 min prior to rotarod testing. Bars indicate the group mean Â± SEM for all rotarod balance trials on the day of drug administration. Individual subject data were calculated by normalizing the speed of the rotating rod upon the subjectâs fall for all balance attempts on the test day to the average peak performance (e.g., mean speed upon fall) of that subject from the last training day. A repeated measures ANOVA was used to evaluate the statistical significance of rotarod impairment in VF mice compared VS, RS, and RF mice: (â) <i>p</i> < 0.05; (â ) <i>p</i> = 0.058.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the utility of the rotarod test in highlighting the potential of our antiflunitrazepam vaccine to influence agility and motor skills, we conducted a locomotor activity test in order to observe the time-sensitive progression of both flunitrazepam-induced sedation and RCA3A3-mediated protection. One-way repeated measures ANOVA revealed the significance of time interval on activity level in all locomotor activity recording sessions. Specifically, all mice demonstrated transient arousal to a novel environment, a trait inherent to the assay (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> This arousal or hyperactivity decreased across time intervals and over subsequent sessions as mice became habituated to the testing cage. To confirm that locomotor activity data of VF mice portrayed the initial motor activation and then stereotyped sedative effects characteristic of benzodiazepines, interactions between interval and group or between interval and treatment were examined for the five intervals of the test session via three-way ANOVA (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Further comparative statistics using two-way ANOVA indicated that treatment had a significant main effect on locomotion in the first time interval [<i>F</i>(1,42) = 6.044, <i>p</i> < 0.05], which was attributed to the initial motor activation caused by flunitrazepam. A significant interaction between group Ã treatment (<i>p</i> < 0.05) persisted in the third through fifth time intervals, in which flunitrazepam caused sedation in the VF group but not in the immunized RF group.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Flunitrazepam-induced sedation as depicted by locomotor activity response. Mice were passively immunized (iv) with mAb RCA3A3 (dashed line) or vehicle isotonic saline solution (solid line) 3 days before ip injection of flunitrazepam ((â¼) VF, (â) RF) or 0.5% Tween-80 in isotonic saline ((â») VS, (â) RS). Data, which reflect locomotor activity monitoring for 15 min following ip injection, are expressed as the group mean Â± SEM of activity counts (photobeam breaks) summated across 3 min intervals for each mouse. Statistical significance is shown for the third through fifth time intervals: (â) <i>p</i> < 0.05 and (ââ) <i>p</i> < 0.01 for comparison of VF and VS mice; (â ) <i>p</i> < 0.05 for comparison of VF and RF mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Locomotor data analysis by three-way ANOVA with repeated measures (group Ã treatment Ã time interval) and the Studentâs <i>t</i> test proved that immunization with RCA3A3 prevented flunitrazepam-induced sedation (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Specifically, statistical analysis confirmed the significant differences in locomotor activity between VS and VF mice, between VF and RF mice, and between RF and RS mice. This latter result that the behavior of RS and RF mice is statistically distinguishable suggests that a portion of the injected flunitrazepam may have entered the CNS in RF mice. However, upon performing the Studentâs <i>t</i> test for between group comparisons at individual time intervals, the repeated measures ANOVA result for the RS versus RF comparison is refuted (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Analysis of shorter observation intervals allows for more sensitive detection of dynamic changes in activity level specific to group or treatment effects as opposed to overall behavioral trends. No statistically significant difference was found in locomotor activity for comparisons between VS and RF groups, RS and RF groups, and RS and VS groups when intervals were analyzed separately. This substantiated the conclusion that passive immunization alone imparted no significant change in locomotor activity (vide supra). The Studentâs <i>t</i> test was also employed to verify that immunization prevented flunitrazepam intoxication and the corresponding activity changes. Gratifyingly, the locomotor activity of VF mice was significantly altered in comparison to VS and RF mice in the third, fourth, and fifth time intervals (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). In sum, when flunitrazepam was given to RCA3A3-immunized mice, drug-induced changes in locomotor activity were prevented (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Acquisition of Fear Memory in Flunitrazepam-Intoxicated and RCA3A3-Immunized Mice</h3><div class="NLM_p last">Of the four testing days (habituation, conditioning, context test, and CS+ test), data were analyzed for total time spent freezing within each test session. There were no differences between the groups in freezing behavior during the habituation trials. In addition, all mice were examined for freezing and/or hyperactivity in response to the foot shocks during the conditioning session. The presence of altered activity in all mice reflected that flunitrazepam did not severely interrupt either proprioception or motor response to the aversive foot shock despite heavy sedation. It follows that changes in freezing behavior of intoxicated mice were directly attributable to disruption of associative fear memory, and the potential antinociceptive effect of flunitrazepam was not sufficient to minimize the perception of the shock as aversive. Lastly, to ensure that no negative effects resulted from the immunization procedure, one experimental group (GS) included mice immunized with the anticocaine mAb GNC92H2 and injected with saline (ip) as the treatment condition. The freezing behavior of GS, VS, and RS mice was statistically indistinguishable in the context test session, as evaluated by one-way ANOVA [group: <i>F</i>(2,30) = 1.305, <i>p</i> > 0.05] and two-way repeated measures ANOVA [group Ã time interval: <i>F</i>(1,19) = 0.508, <i>p</i> = 0.48]. Furthermore, GS mice displayed freezing behavior similar to VS and RS mice in the CS+ test [group Ã time interval: <i>F</i>(1,19) = 0.185, <i>p</i> > 0.5]. In light of this data, we concluded that mAb therapy conferred minimal effects on fear conditioning and memory, and as such, the GS group data were excluded from subsequent analyses of conditioned fear test data.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Restoration of Contextual Fear Memory Formation</h3><div class="NLM_p">Conditioned mice were examined for their contextual memory of the environment in which they received the tone-foot shock pairing 24 h prior (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). There were dramatic differences in freezing behavior between mice conditioned during flunitrazepam exposure (VF) and mice receiving the immunotherapy (RF), as confirmed by three-way ANOVA, two-way ANOVA (group Ã treatment) for individual time intervals, and two-way repeated measures ANOVA (group Ã time interval) (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Specifically, VF mice failed to freeze in response to the contextual stimulus, whereas control and immunized mice froze upon re-exposure to the conditioning box during context test sessions (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). The freezing behavior of RF mice was restored to levels statistically indistinguishable from VS and RS groups as evaluated by ANOVA and unpaired Studentâs <i>t</i> tests (data not shown), confirming that immunization with RCA3A3 effectively blocked flunitrazepam-induced impairment of contextual memory. Analysis by Studentâs <i>t</i> test for each time interval supported the above conclusions in that VF mice showed significantly less freezing relative to VS mice (first interval, <i>p</i> < 0.0001; second interval, <i>p</i> = 0.016) and RF mice (first interval, <i>p</i> = 0.0017; second interval, <i>p</i> < 0.005). Any differences in freezing behavior between RF, VS, and RS groups were statistically undetectable, implying that immunization alone incurred no changes to freezing response and that immunization with RCA3A3 before flunitrazepam exposure protected the formation of contextual fear memory.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Fear behavior resulting from contextual conditioning in vehicle (left) and RCA3A3-immunized (right) mice. Gray bars depict ip injection of vehicle (0.5% Tween-80 in isotonic saline; VS, VF), and black bars indicate ip injection of flunitrazepam (dissolved in 0.5% Tween-80 in isotonic saline; VF, RF). Mice were fear conditioned to the cage context 20 min after ip injection and then tested for their contextual fear memory 24 h later. A decrease in freezing behavior reflects a disruption of fear memory consolidation. Data for time spent freezing over the entire context test session are presented as the mean Â± SEM. Statistical significance, as calculated using the unpaired Studentâs <i>t</i> test, compares the freezing behavior of the VF group to that of VS, RS, and RF groups: (ââ) <i>p</i> < 0.01; (âââ) <i>p</i> < 0.005; (â ) <i>p</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Statistical Analysis of Conditioned Fear Context Test Results</div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top"><th colspan="2" align="center">Three-Way ANOVA</th></tr></thead><tbody><tr valign="top"><td align="center">group</td><td align="center"><i>F</i>(1,38) = 8.543 (<i>p</i> = 0.0058)<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></td></tr><tr valign="top"><td align="center">group Ã treatment</td><td align="center"><i>F</i>(1,38) = 10.578 (<i>p</i> < 0.005)<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></td></tr></tbody></table><table class="table frame_topbot"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top"><th colspan="3" align="center">Two-Way ANOVA</th></tr><tr valign="top"><th align="center">Â </th><th align="center">context: 1st interval</th><th align="center">context: 2nd interval</th></tr></thead><tbody><tr valign="top"><td align="center">group Ã time interval</td><td align="center"><i>F</i>(1,38) = 6.260 (<i>p</i> < 0.05)</td><td align="center"><i>F</i>(1,38) = 8.760 (<i>p</i> = 0.0053)</td></tr><tr valign="top"><td align="center">group Ã treatment</td><td align="center"><i>F</i>(1,38) = 12.026 (<i>p</i> = 0.0013)</td><td align="center"><i>F</i>(1,38) = 7.571 (<i>p</i> < 0.01)</td></tr></tbody></table><table class="table frame_topbot"><colgroup><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top"><th colspan="2" align="center">Two-Way ANOVA of repeated measures, group Ã time interval</th></tr></thead><tbody><tr valign="top"><td align="center">RF vs VS, RS</td><td align="center">statistically indistinguishable</td></tr><tr valign="top"><td align="center">VF vs VS</td><td align="center"><i>F</i>(1,20) = 22.162 (<i>p</i> = 0.0001)</td></tr><tr valign="top"><td align="center">VF vs RF</td><td align="center"><i>F</i>(1,18) = 12.838 (<i>p</i> < 0.005)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">Group Ã treatment Ã time interval, repeated measure.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Immunization Protects Associative Aversive Learning Cued Stimulus</h3><div class="NLM_p">The CS+ test assessed the presence of a lingering associative memory between the tone and the aversive shock despite the novel context. CS+ test session data were divided into two parts with the first 3 min representing baseline activity in the novel context (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A) and the last 3 min testing memory of the cued stimulus by exposing mice to the conditioned tone (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B). As with the context session, there was no significant difference in freezing behavior between GS and RS mice either before the tone [group Ã time interval, <i>F</i>(1,17) = 3.350, <i>p</i> > 0.05] or during the tone [group Ã time interval, <i>F</i>(1,17) = 0.022, <i>p</i> > 0.5]. All mice behaved similarly during the first 3 min of the CS+ session in that they exhibited hyperactive, exploratory activity in response to the novel environment and thus spent minimal time freezing regardless of group or treatment (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Freezing response to the cued stimulus in the CS+ test. Vehicle (VS, VF) and immunized (RS, RF) mice were evaluated for their cued fear memory 48 h after ip injection (VF, RF, flunitrazepam, black bars; VS, RS, vehicle, gray bars) and fear conditioning. All mice spent minimal time freezing before presentation of the tone (A), which indicates that the cage was adequately disguised to mask any contextual cues. Upon exposure to the cued stimulus (tone) during the second time interval (B), VS, RS, and RF mice showed significant increases in freezing behavior while VF mice display less freezing compared to control levels. Data are expressed as the mean Â± SEM of time spent freezing within either interval (A or B) of the CS+ test, and statistical significance represents results from the unpaired Studentâs <i>t</i> test comparing VF group data to VS, RS, and RF group data: (â) <i>p</i> < 0.05; (ââ) <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Statistical Analysis of Conditioned Fear CS+ Test Results</div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead valign="bottom"><tr valign="top"><th colspan="2" align="center" valign="bottom">Conditioned Fear: CS+ Test, Before Tone</th></tr></thead><tbody><tr valign="top"><td colspan="2" align="center">Three-Way ANOVA<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></td></tr><tr valign="top"><td align="left">group Ã time interval</td><td align="left"><i>F</i>(1,37) = 0.358, (<i>p</i> > 0.5)</td></tr><tr valign="top"><td align="left">group Ã treatment</td><td align="left"><i>F</i>(1,37) = 0.474, (<i>p</i> = 0.495)</td></tr><tr valign="top"><td align="left">treatment Ã time interval</td><td align="left"><i>F</i>(1,37) = 1.621, (<i>p</i> = 0.211)</td></tr></tbody></table><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top"><th colspan="2" align="center">Conditioned Fear: CS+ Test, After Tone</th></tr></thead><tbody><tr valign="top"><td colspan="2" align="center">Three-Way ANOVA<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></td></tr><tr valign="top"><td align="left">group Ã time interval</td><td align="left"><i>F</i>(1,38) = 4.168 (<i>p</i> < 0.05)</td></tr><tr valign="top"><td colspan="2" align="center">Studentâs <i>t</i> Test</td></tr><tr valign="top"><td align="left">H<sub>0</sub>: VF = VS</td><td align="left"><i>p</i> < 0.01</td></tr><tr valign="top"><td align="left">H<sub>0</sub>: VF = RF</td><td align="left"><i>p</i> = 0.014</td></tr><tr valign="top"><td align="left">H<sub>0</sub>: RF = VS, VS = RS, RF = RS</td><td align="left">statistically indistinguishable</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>a</sup><p class="last">Group Ã treatment Ã time interval.</p></div></div></div><div class="NLM_p last">During the second 3 min of the CS+ session during which mice were exposed to the conditioned stimulus, freezing behavior reappeared in all mice but those in the VF group (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B). Results of a three-way ANOVA with group and treatment as between factors and time interval as the within factor justified further statistical analysis (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). VF mice exhibited significantly less freezing behavior than mice in all other groups (H<sub>O</sub>, VF = VS, <i>p</i> < 0.01; H<sub>O</sub>, VF = RF, <i>p</i> = 0.014), while there was no statistically significant difference in behavior between RF, RS, and VS mice, as concluded using the Studentâs <i>t</i> test.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To test the hypothesis that passive immunization offers an effective treatment against drug-induced cognitive impairment, we embarked upon the design of a hapten capable of eliciting antibodies that could bind flunitrazepam with high affinity (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>A). This process followed from previous experience in the preparation of haptens for other drugs of abuse including cocaine, nicotine, and Î<sup>9</sup>-tetrahydrocannabinol.<a onclick="showRef(event, 'ref25 ref28 ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref25 ref28 ref29 ref30 ref31 ref32">(25, 28-32)</a> The molecular features of flunitrazepam, specifically the rigid hydrophobic core, were expected to elicit complementary aromatic residues that are favored in antibody binding pockets.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In addition, the general structure of flunitrazepam-like hapten RCA incorporated a linker at the C-3 position of the 1,4-benzodiazepine-2-one ring for covalent attachment to carrier proteins (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>B). An aminobutyrate moiety was incorporated into the linker given that increased linker length has been shown to afford superior hapten recognition upon immunization.<a onclick="showRef(event, 'ref29 ref34'); return false;" href="javascript:void(0);" class="ref ref29 ref34">(29, 34)</a></div><div class="NLM_p">To examine the efficacy of flunitrazepam binding and sequestration by RCA3A3, a doseâresponse relationship for flunitrazepam-induced locomotor effects was generated in a mouse model. While reports of flunitrazepam-induced immobilization, decreased exploratory behavior, and overall sedation were used for initial drug dose parameters,<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> the limited number of studies using this specific benzodiazepine necessitated further pharmacodynamic characterization of drug effects in mice. The rotarod assay for motor coordination was used to create a qualitative dose-motor response curve and thereby confirms reports in the literature of the appropriate dose of flunitrazepam conferring substantial locomotor impairment. The dose range tested here illustrated the biphasic dose response curve common to benzodiazepines, ethanol, and other abused substances in that agility and coordination improved with a low flunitrazepam dose (0.03 mg/kg), while motor impairment and sedation resulted at higher doses (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Doses exceeding 0.09 mg/kg were not explored, as it was critical that sedated mice maintain consciousness for assessment of the drug-induced memory deficits in behavioral tests. The rotarod assay thus served as an appropriate behavioral screen for measuring motor deficits upon intoxication and permitted selection of the 0.09 mg/kg drug dose for subsequent psychomotor testing.</div><div class="NLM_p">The primary behavioral paradigms employed to investigate mAb efficacy in vivo have included tests of locomotor activity and drug self-administration. Analogous to these studies, locomotor activity and agility were measured to assess flunitrazepam-induced sedation and the corresponding benefit derived from passive immunization with mAb RCA3A3. Intoxicated mice (VF) exhibited some hyperlocomotion during the first time interval of the locomotor assay, reflecting both the initial motor activating effect of the drug, which precedes sedation, and the anxiolytic effect of benzodiazepines, with heightened âfearlessnessâ translating to increased exploratory behavior. When flunitrazepam was administered to RCA3A3-treated mice (RF), these drug-induced changes in locomotor activity were prevented (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Similarly, RCA3A3 also protected mice from the acute deterioration in motor coordination following drug exposure, as assessed by the rotarod test (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Given the severe memory deficits produced by flunitrazepam alongside this demonstrated motor impairment, testing of the in vivo efficacy of RCA3A3 also presented an ideal scenario for extending immunopharmacotherapeutic strategies to the prevention of drug-mediated cognitive impairment. Thus, following rotarod and locomotor activity testing, the conditioned fear assay was implemented to then examine the potential of mAb RCA3A3 to protect normal memory consolidation in drug-exposed mice.</div><div class="NLM_p">Conditioned fear is commonly used to probe the neural mechanisms of memory. Not only is fear memory comparatively robust, facilitating comparison between initial memory consolidation versus long-term memory, but also fear-potentiated startle experiments are easily adapted to rodent models for studies of learning and memory processes. More importantly, the conditioned fear assay has previously been implemented to show the propensity of benzodiazepines or benzodiazepine site ligands to elicit anterograde amnesia as assessed by weakened associations between an environmental context and cue to an aversive foot shock in mice and in other animal models.<a onclick="showRef(event, 'ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40 ref41">(38-41)</a> In this study, we determined the ability of an antiflunitrazepam mAb that is inherently localized to the periphery to protect fear memory of such associations despite flunitrazepam administration during the conditioning phase of the experiment. Subjects administered drug or saline (control) injections were twice exposed to a 30 s tone and white light, both co-terminating with a 1.0 mA foot shock during the conditioning session. Upon re-exposure to the foot shock chamber 24 h after conditioning, mice that spend a substantial amount of time freezing possess intact memory of the aversive foot shock delivered in the conditioning cage. However, any flunitrazepam-induced deficit in fear learning translates to a blunted freezing response in mice. Our results were in agreement with the initial hypothesis because drug-naive mice (VS) spent more time freezing to the contextual stimuli than intoxicated mice (VF). This flunitrazepam-induced deficit in the retrieval of fear memory seen in VF mice was not observed in RF mice. Passive immunization with RCA3A3 enabled the formation and retention of memory for the shock-associated context as shown by their normal freezing response (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><div class="NLM_p">Because the conditioned fear assay discriminates between contextual hippocampal-dependent and cued hippocampal-independent learning,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> it has been used previously to show that the effect of benzodiazepines on fear conditioning may be specific to the environmental context,<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> a conclusion supported by our results. However, we obtained similar results for the CS+ test as in the context test. Analysis of freezing behavior during tone presentation in CS+ sessions confirmed the significant detrimental effect of flunitrazepam on fear memory, which was blocked by pretreatment with RCA3A3 (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B). This finding challenges previous studies that found benzodiazepine-mediated disruption of associations between the conditioned stimulus (cue) and unconditioned stimulus (foot shock) to be under contextual control.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> As evidenced by the absence in freezing of VF mice to the tone, flunitrazepam induced inhibition of fear memory of the cued stimulus-foot shock association. VS, RS, and RF mice all exhibited freezing upon tone presentation, or retrieval of intact associative memory between the tone and the aversive shock, regardless of the novel context. There was no significant difference in freezing behavior between RF, RS, and VS groups, suggesting that treatment with RCA3A3 protected memory of the aversive stimulus and the associated auditory cue. In addition, passive immunization had no detectable effect on general anxiety-like behavior given the similar fear responses shown by VS, RS, and GS mice in both the context and CS+ tests. The first interval of the CS+ test, which entailed monitoring the exploratory behavior of all mice in response to the disguised cage, served as an internal assay control (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A). All groups displayed similar behavior before exposure to the conditioned tone.</div><div class="NLM_p last">The value of applying immunopharmacotherapy to the treatment of cognitive dysfunction has been highlighted by the procurement of an anti-flunitrazepam mAb capable of attenuating both the sedative and amnesic central effects of intoxication. In terms of therapeutic value, mAb RCA3A3 blocked the appearance of contextual learning impairments caused by exposure to a benzodiazepine and it preserved the subsequent retrieval of fear memory for the conditioned cue, or tone, when it was presented outside the conditioning context. This result, a finding of pharmacological relevance in addition to validation of our original hypothesis, refutes the assumption that the conditioned-unconditioned stimuli association was solely under contextual control. Because mAb RCA3A3 abolished deficits in both motor activity and memory, this study illustrates that immunopharmacotherapeutic strategies possess applications beyond the treatment of addictive behavior and the prevention of gross symptoms of intoxication, such as overdose, hyperlocomotion, and seizures. Instead, immunopharmacotherapy represents a valid approach for addressing even the more subtle cognitive effects incurred by drug exposure.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20345" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20345" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Hapten Synthesis</h3><div class="NLM_p last"><sup>1</sup>H and APT <sup>13</sup>C NMR spectra were recorded on a Bruker DRX-500 spectrometer, and chemical shifts (ppm) were referenced to internal CDCl<sub>3</sub> standard (<sup>1</sup>H, 7.26 ppm; <sup>13</sup>C, 77.0 ppm). Carbon signals marked with an asterisk represent methyl and methyne carbons as determined by APT experiments. High-resolution mass spectra were recorded using electrospray ionization (ESI) or MALDI-TOF techniques. All chemical reagents and solvents were from Aldrich Chemical Co., unless otherwise noted, and used without further purification. Glassware and solvents were dried by standard methods. Flash chromatography was performed on silica gel 60 (230â400 mesh) and thin layer chromatography on glass plates coated with a 0.02, 0.5, or 1.0 mm layer of silica gel 60 F-254. Analytical RP-HPLC was performed on a Hitachi Elite LaChrom L-2000 series HPLC chromatograph using a Vydac 218TP5415 column at a flow rate of 1 mL/min, with detection at 254 nm during a linear gradient of 10â95% acetonitrile/0.09% TFA over 40 min at 35 Â°C. Preparative RP-HPLC was performed using a custom-packed, 2-in. bore C18 column at a flow rate of 10 mL/min, with detection at 254 and 280 nm; fractions were analyzed off-line using an ABI/Sciex 150EX single quadrupole mass spectrometer. Compounds <b>2</b> and <b>3</b> have been previously reported, and their spectral data were consistent with prior literature.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 2â²-Fluoro-2-aminobenzophenone (<b>3</b>)</h3><div class="NLM_p last">To a stirred solution of <b>2</b> (4.90 g, 27.2 mmol) in THF at â100 Â°C under argon was added 1.5 M <i>n</i>BuLi in hexanes (18.1 mL, 27.2 mmol). In a separate flask, 1.5 M <i>n</i>BuLi in hexanes (18.1 mL, 27.2 mmol) was added to a solution of 2-fluorobromobenzene (4.76 g, 27.2 mmol) in THF at â100 Â°C under argon. After 10 min, the solution of 2-fluorophenyllithium was transferred to the first flask containing the lithium amide via cannula. After a further 10 min of stirring, 1 M HCl (aq) was added and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude product was purified on silica gel with EtOAc/hexanes (15:85) as the eluent to give <b>3</b> (3.33 g, 57%).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <i>tert</i>-Butyl 4-(<i>tert</i>-Butoxycarbonylamino)-5-(2-(2-fluorobenzoyl)phenylamino)-5-oxopentanoate (<b>4</b>)</h3><div class="NLM_p last">Boc-Glu(O<i>t</i>Bu)-OH (3.38 g, 11.1 mmol) and HATU (4.24 g, 11.1 mmol) were suspended in anhydrous 1,2-dichloroethane (20 mL). Diisopropylethylamine (5.8 mL, 33.3 mmol) was added, and the mixture was stirred under an atmosphere of argon at ambient temperature until a nearly clear yellow solution was obtained (15 min). <b>3</b> (400 mg, 1.86 mmol) was added, and the mixture was heated at 75 Â°C for 16 h, after which the mixture was cooled, diluted with ethyl acetate (40 mL), and transferred into a separatory funnel. The organic phase was washed consecutively with water, saturated aqueous sodium bicarbonate (3Ã), 10% aqueous citric acid (2Ã) and dried over anhydrous sodium sulfate. The organic solvents were evaporated under reduced pressure and the dark syrupy residue was purified by column chromatography on silica gel using hexaneâethyl acetate (5:1 â 3:1 â 2:1, v/v) as eluent, yielding 0.74 g (80%) of <b>4</b> as yellow syrup. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) Î´ 11.85 (s, 1H), 8.76 (d, 1H, <i>J</i> = 8.4 Hz), 7.58 (t, 1H, <i>J</i> = 7.6 Hz), 7.55â7.48 (m, 2H), 7.44 (dt, 1H, <i>J</i> = 1.6, 7.5 Hz), 7.26 (dt, 1H, <i>J</i> = 0.7, 7.6 Hz), 7.16 (t, 1H, <i>J</i> = 9.1 Hz), 7.07 (t, 1H, <i>J</i> = 7.5 Hz), 5.45 (d, 1H, <i>J</i> = 6.1 Hz), 4.32 (m, 1H), 2.42 (m, 2H), 2.28 (m, 1H), 2.05 (ddd, 1H, <i>J</i> = 7.4, 14.8, 15.0 Hz), 1.43 (s, 18H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz) Î´ 196.5, 172.3, 171.3, 160.4, 158.4, 155.5, 140.6, 135.3*, 134.0*, 132.9*, 132.9*, 130.2*, 127.6, 127.5, 124.2*, 122.8, 122.6*, 120.8*, 116.3*, 116.1*, 80.8, 80.2, 56.0*, 32.0, 28.2*, 28.0*, 27.4. FTMS calcd for C<sub>27</sub>H<sub>33</sub>N<sub>2</sub>O<sub>6</sub>F [M + Na]<sup>+</sup>: 523.2220, found 523.2230.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 3-(5-(2-Fluorophenyl)-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>e</i>][1,4]diazepin-3-yl)propanoic Acid (<b>5</b>)</h3><div class="NLM_p last"><b>4</b> (345 mg) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (10 mL) was added while stirring. Stirring was continued for 1 h, after which the volatile components where evaporated under reduced pressure. The dark syrupy residue was dissolved in pyridine (10 mL) and heated at 75 Â°C for 14 h. The reaction was monitored by TLC (10:1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH) and ESI-Q MS. Pyridine was evaporated under vacuum and the dark syrupy residue was purified by column chromatography on silica gel using dichloromethaneâmethanol (20:1, v/v) as eluent, yielding <b>5</b> (221 mg, 98%) as an amber syrup. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) Î´ 9.90 (d, 1H, <i>J</i> = 4.2 Hz), 7.53 (dt, 1H, <i>J</i> = 1.4, 7.5 Hz), 7.49 (m, 1H), 7.41 (m, 1H), 7.20 (m, 3H), 7.12 (t, 1H, <i>J</i> = 7.6 Hz), 7.03 (t, 1H, <i>J</i> = 9.2 Hz), 3.73 (dd, 1H, <i>J</i> = 5.2, 8.1 Hz), 2.74 (m, 2H), 2.61 (ddd, 1H, <i>J</i> = 6.6, 14.5 Hz), 2.46 (ddd, 1H, <i>J</i> = 7.1, 14.0 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz) Î´ 177.8, 171.8, 167.0, 161.4, 159.4, 137.2*, 132.2*, 132.1*, 131.6*, 130.1*, 128.1, 127.3, 127.2, 125.3*, 124.3*, 124.3*, 124.0*, 121.3*, 116.2*, 116.1*, 61.8*, 53.4, 30.6, 25.7. FTMS calcd for C<sub>18</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub>F [M + H]<sup>+</sup>: 327.1145, found 327.1125.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 3-(5-(2-Fluorophenyl)-1-methyl-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>e</i>][1,4]diazepin-3-yl)propanoic Acid (<b>6</b>)</h3><div class="NLM_p last">A 60% suspension of NaH in mineral oil (84 mg, 2.1 mmol) was washed thrice with hexane, suspended in dry THF, and added to a stirred solution of the <b>5</b> (229 mg, 0.70 mmol) in dry THF (1 mL) at 0 Â°C. The mixture was stirred for 10 min at 0 Â°C, and methyl iodide (175 Î¼L, 2.8 mmol) was added via syringe. The mixture was stirred at 0 Â°C for 1 h, then allowed to warm to ambient temperature and stirred for 1 h. The excess sodium hydride was quenched by addition of glacial acetic acid (500 Î¼L), and the volatile components were evaporated under vacuum. The dark gummy residue was triturated with dichloromethaneâmethanol (10:1, v/v), and the resulting suspension was filtered through a pad of silica gel. The yellow filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography on silica gel using dichloromethaneâmethanol (20:1 â 10:1, v/v) as eluent, yielding <b>6</b> (153 mg, 64%) as light-yellow syrup, which solidifies upon standing. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) Î´ 12.08â10.36 (br s, 1H), 7.61 (dt, 1H, <i>J</i> = 1.7, 7.5 Hz), 7.55 (m, 1H), 7.43 (m, 1H), 7.35 (d, 1H, <i>J</i> = 8.2 Hz), 7.22 (m, 2H), 7.16 (t, 1H, <i>J</i> = 7.5 Hz), 7.03 (m, 1H), 3.69 (dd, 1H, <i>J</i> = 5.5, 7.6 Hz), 3.45 (s, 3H), 2.81 (m, 1H), 2.70 (m, 2H), 2.60 (ddd, 1H, <i>J</i> = 6.6, 14.0 Hz), 2.41 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz) Î´ 178.1, 169.9, 166.3, 161.5, 159.5, 142.4, 132.2*, 132.2*, 131.8*, 131.4*, 131.4*, 129.9, 129.0*, 126.9, 126.8, 124.4*, 124.3*, 124.3*, 121.4*, 116.2*, 116.0*, 61.9*, 35.3*, 30.7, 26.1. FTMS calcd for C<sub>19</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>F [M + H]<sup>+</sup>: 341.1301, found 341.1311.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 3-(5-(2-Fluorophenyl)-1-methyl-7-nitro-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>e</i>][1,4]diazepin-3-yl)propanoic Acid (<b>7</b>)</h3><div class="NLM_p last">KNO<sub>3</sub> (59 mg, 0.58 mmol) was added to a stirred solution of <b>6</b> (99 mg, 0.29 mmol) in fuming H<sub>2</sub>SO<sub>4</sub> (2 mL), and the mixture was allowed to stir at ambient temperature (4 h). Small (â¼20 Î¼L) aliquots were taken after 2 h of stirring and partitioned between dichloromethane and water (â¼200 Î¼L each). The organic layer was carefully separated off with a pipet, dried over Na<sub>2</sub>SO<sub>4</sub>, passed through a small pad of silica gel, and evaporated. The residue was dissolved in 100 Î¼L of methanol and analyzed by ESI-Q MS. When the reaction was judged as complete, the mixture was transferred to an ice-cold mixture of dichloromethane and water. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and used toward the next step without further purification.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 4-(3-(5-(2-Fluorophenyl)-1-methyl-7-nitro-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>e</i>][1,4]diazepin-3-yl)propanamido)butanoic Acid (Hapten RCA)</h3><div class="NLM_p last">A solution of the crude <b>7</b>, PyBOP (170 mg, 0.33 mmol), and diisopropylethylamine (130 Î¼L, 0.75 mmol) in dichloromethane (3 mL) was stirred under an atmosphere of argon for 15 min. <i>tert</i>-Butyl aminobutyrate hydrochloride (65 mg, 0.33 mmol) was added, and the reaction mixture was allowed to stir for 3 h. The mixture was partitioned between EtOAc and water, and the organic layer was washed consecutively with saturated aqueous sodium bicarbonate (3Ã) and 10% aqueous citric acid (2Ã), then dried over anhydrous sodium sulfate and evaporated. The residue was purified by flash chromatography on silica gel with dichloromethaneâacetone (3:1) as the eluent to give the <i>tert</i>-butyl protected intermediate, which was treated with 50% TFA/CH<sub>2</sub>Cl<sub>2</sub> (2 mL) for 1 h. The volatile components were evaporated, and the syrupy residue was purified by preparative reverse-phase HPLC using a linear gradient of 15% acetonitrile/0.09% TFA to 40% acetonitrile/0.09% TFA in 0.1% TFA/water over 30 min while monitoring at 254 and 280 nm. The fractions containing the target material were pooled and lyophilized to give RCA hapten (46 mg, 30% over three steps from <b>6</b>). The purity of the product was checked by analytical HPLC and found to be greater than 95%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) Î´ 10.12 (br s, 1H), 8.50 (dd, 1H, <i>J</i> = 2.6, 5.8 Hz), 8.36 (m, 1H), 7.64 (t, 1H, <i>J</i> = 7.5 Hz), 7.43 (d, 1H, <i>J</i> = 8.3 Hz), 7.16â7.29 (m, 3H), 6.97 (m, 1H), 3.74 (m, 1H), 3.48 (s, 3H), 3.32 (m, 2H), 2.55 (m, 4H), 2.35 (t, 2H, <i>J</i> = 6.8 Hz), 1.82 (p, 2H, <i>J</i> = 6.7 Hz). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz) Î´ 176.7, 175.1, 169.5, 164.6, 162.8, 157.2, 144.3, 142.7, 132.9*, 128.8*, 128.4, 127.9*, 127.8*, 127.6*, 127.6*, 127.4, 125.0*, 122.0*, 117.7*, 117.5*, 62.7*, 39.3, 35.7*, 32.5, 31.2, 27.3, 24.2. FTMS calcd for C<sub>23</sub>H<sub>23</sub>N<sub>4</sub>O<sub>6</sub>F [M + H]<sup>+</sup>: 471.1680, found 471.1685.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Preparation of Immunoconjugates</h3><div class="NLM_p last">The RCA hapten (5 mg) was treated with 1.3 equiv of 3-sulfo-<i>N</i>-hydroxysuccinimide and 1.2 equiv of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride for 24 h in DMF. This mixture was then added to solutions (5 mg/mL) of keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA) in PBS (50 mM, pH 7.4) and allowed to react for 24 h at 4 Â°C. The resulting conjugate was used without further purification.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Hydridoma Production</h3><div class="NLM_p last">Hybridoma production followed standard protocols.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Flunitrazepam Competition ELISA</h3><div class="NLM_p last">An ELISA plate (Costar, 96-well) was coated uncovered overnight at 37 Â°C with 25 Î¼L of the RCAâKLH conjugate. To this, methanol (50 Î¼L/well) was added and allowed to sit for 5 min at room temperature. The methanol was then removed from the wells, and the plates were allowed to dry. Wells were then blocked with 50 Î¼L of Blotto (5% skim milk powder in PBS) for 5 min at 37 Â°C. Typically, 25 Î¼L of a solution containing a 1:100 dilution of mAb in Blotto along with varied serial dilutions of flunitrazepam (24 Î¼M to 24 nM) was then added and incubated for 1 h at 37 Â°C. After the mixture was washed, 25 Î¼L of a 1:1000 dilution of a goat anti-mouse/horseradish peroxidase conjugate in Blotto was added and incubated for 30 min. The plate was developed with the colorimetric reagent 2,2â²-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) for 30 min and the absorbance measured on an ELISA plate reader at Î» = 405 nm. Binding constants were determined by analysis of plots of <i>A</i><sub>405</sub> versus flunitrazepam concentration. The <i>K</i><sub>d,app</sub> was defined as the concentration at which <i>A</i><sub>405</sub> was half-maximal.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> In Vivo Testing of RCA3A3. Subjects</h3><div class="NLM_p last">Female CD-1 mice (20â40 g; dose determination, <i>N</i> = 24 mice; passive immunization, <i>N</i> = 110 mice) were purchased from a breeding colony at The Scripps Research Institute at 6 weeks of age. Animals were housed four per cage in a temperature-controlled vivarium under a reversed 12 h/12 h light/dark cycle (lights off at 06:00 h). Food and water were available ad libitum throughout the study. All experiments were approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute and conducted in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. Every effort was made to reduce the number of animals used.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Flunitrazepam</h3><div class="NLM_p last">In all cases, flunitrazepam [5-(2-fluorophenyl)-1,3,dihydro-1-methyl-7-nitro-2<i>H</i>-1,4-benzodiazepin-2-one)] (Sigma) was prepared in 0.5% Tween-80 in sterile 0.9% saline and administered by intraperitoneal injection.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Determination of Flunitrazepam Dose</h3><div class="NLM_p last">One week after arrival, animals were weighed and randomly divided into four experimental groups (<i>n</i> = 6) based on drug dose, administered by intraperitoneal injection: vehicle with 0.5% Tween-80 in isotonic saline, 0.03 mg/kg flunitrazepam in 0.5% Tween-80 in isotonic saline, 0.06 mg/kg flunitrazepam in 0.5% Tween-80 in isotonic saline, and 0.09 mg/kg flunitrazepam in 0.5% Tween-80 in isotonic saline. The motor impairment conveyed by a particular drug dose was assessed via the rotarod test. Mice were trained on the rotarod 3 consecutive days prior to drug administration. On the fourth test day, subjects were injected with drug (or saline) and then returned to their home cages for 20 min before rotarod testing. Rotarod testing was repeated 24 h after drug administration to ensure motor activity had returned to baseline ability.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Effect of Passive Immunization against Flunitrazepam</h3><div class="NLM_p">One week after arrival, animals were labeled, weighed, and subjected to intravenous catheterization. Detailed methods on surgery and apparatus are described elsewhere.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> After a 5 day recovery period, mice were randomly assigned to the following experimental groups (<i>n</i> = 22, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>): VS, vehicle control, saline (ip); VF, vehicle control, saline (iv), flunitrazepam (i.p.); GS, GNC92H2 (iv), saline (ip); RS, RCA3A3 (iv), saline (ip); and RF, RCA3A3 (iv), flunitrazepam (ip). The GS test group, in which mice were immunized with the anti-cocaine mAb GNC92H2, was included as a control for effects of antibody administration. The animals were treated and tested in Latin square fashion. Flunitrazepam solution, prepared in 0.5% Tween-80 in isotonic saline (at a dose appropriate for ip administration, about 0.01 mg/mL) was injected 3 days after passive immunization or saline iv infusion. Passive immunization involved attaching a 4-in. polyethylene tube to the in-dwelling catheter on the animalâs back and then slowly delivering the bolus infusion of antibody or saline through the tube over the course of â¼1 min.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Experimental Design for Mouse Group and Treatment Assignments<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead valign="middle"><tr valign="top"><th align="center" valign="middle">Â </th><th colspan="2" align="center" valign="middle">treatment</th></tr><tr valign="top"><th align="center" valign="bottom">group</th><th align="center" valign="bottom">0.5% Tween-80 in isotonic saline</th><th align="center" valign="bottom">flunitrazepam in 0.5% Tween-80 in isotonic saline</th></tr></thead><tbody><tr valign="top"><td align="left">vehicle</td><td align="left">VS</td><td align="left">VF</td></tr><tr valign="top"><td align="left">RCA3A3</td><td align="left">RS</td><td align="left">RF</td></tr><tr valign="top"><td align="left">GNC92H2</td><td align="left">GS</td><td align="left">notâincluded</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">Of the three grouping categories, vehicle, RCA3A3, and GNC92H2, only vehicle and RCA3A3-immunized mice were subsequently challenged with flunitrazepam treatment.</p></div></div></div><div class="NLM_p last">Of the original test groups (VS, VF, RF, RS, GS; <i>n</i> = 22 per test group) half of the mice were trained on the rotarod assay before receiving drug or saline injection and subsequent rotarod testing. The remaining mice were habituated to the locomotor activity cages and conditioned fear setup. Upon drug or saline injection, these mice were then tested using the locomotor activity and conditioned fear behavioral assays to examine the ability of RCA3A3 to prevent flunitrazepam-induced cognitive impairment.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Immunization</h3><div class="NLM_p last">Passive immunization was conducted by a bolus infusion of mAb (10.2 mg/kg, iv in a volume of 1 mL/kg) before onset of behavioral testing or 3 days before flunitrazepam treatment or control saline injection. Animals in test groups receiving the nonspecific antibody (iv) were infused with the anti-cocaine mAb GNC92H2<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> at the same dose and volume. Control groups were infused with isotonic saline (1 mL/kg, iv). The infusion was delivered at a slow flow over 1 min, and antibody infusions were followed by a small amount of saline to clear the catheter of any antibody and to ensure that the entire amount reached the jugular vein. Animals were then returned to their home cages.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Rotarod Testing</h3><div class="NLM_p last">The rotarod (IITC, Inc., Life Sciences, Woodland Hills, CA) consisted of a rubber-matting-covered 3.8 cm diameter rod suspended in a test box and divided into five lanes for simultaneous testing of mice. The rotarod treadmill was programmed to reach a top speed of 30 rpm via a constant acceleration of 10 rpm per minute. The chamber and rotarod were cleaned between mice. All test groups of mice were randomly subdivided into five and sequentially placed on the rotarod (one mouse per lane). Once all five mice in a subgroup were situated on and acclimated to balancing on the rod, the rod was set to accelerate at a constant rate of 10 rotations/min<sup>2</sup> over the course of 3 min to a maximum speed of 30 rpm. Upon falling from the rod, mice crossed through a light beam sensor located just below the rod, and the resulting beam break was recorded by the computer. After all five mice had fallen, they were immediately placed back on the rod for another attempt. One session consisted of three consecutive balance attempts before proceeding to the next set of five mice. Recordings were measured in terms of rod speed at fall, and a speed of 30 rpm was recorded for mice remaining on the rotarod for the entire 3 min. The training process was repeated for a total of three sessions per day over 3 consecutive days. The data from the last day (three sessions of three balance attempts per session) were averaged for each mouse to calculate individual peak baseline performance. On the fourth day, mice underwent one session of rotarod testing 15â20 min after administration of flunitrazepam or saline. The rotarod balance test was repeated in the same manner (i.e., one session, with saline injections substituting for drug injections) 24 h after drug administration. This last session on the fifth day was implemented to verify that rotarod performance returned to baseline levels. For data analysis, the speed of the rotarod at fall for each balance attempt of the test day was divided by the average peak baseline performance of the individual mouse (calculated from the last day of rotarod training). These normalized data for each mouse were then averaged across test group (Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Locomotor Activity Testing</h3><div class="NLM_p last">Locomotor activity was measured in Plexiglas cages (42 cm Ã 22 cm Ã 20 cm) placed into frames (25.5 cm Ã 47 cm) mounted with two levels of photocell beams at 2 and 7 cm above the bottom of the cage (San Diego Instruments, San Diego, CA). These two sets of beams allowed for the recording of both horizontal (locomotion) and vertical (rearing) behavior. A thin layer of bedding material was scattered across the bottom of the cage. On the 2 days preceding drug administration, mice received daily locomotor box habituation sessions to minimize transient arousal during the test session produced by exposure to the novel environment. Mice were placed singly in the activity boxes for 15 min of monitoring directly following saline or drug injection, and then subjects were either returned to their home cages (locomotor activity habituation days) or transferred to the conditioned fear apparatus (test days). All mice received ip injections of isotonic saline (10 mL/kg) immediately prior to all habituation sessions as well as before the locomotor activity retest session in order to reproduce the environment of drug administration.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Cued and Contextual Conditioned Fear Testing</h3><div class="NLM_p last">The conditioning system consisted of a sound-proofed box of white interior housing a Freeze Monitor chamber (San Diego Instruments). The Plexiglas conditioning chamber (26 cm Ã 26 cm Ã 17 cm) was equipped with a speaker, a light, and a shockable grid floor under which orange oil-scented cedar chips were scattered. The stainless steel rod grid was connected to a shocker-scrambler unit delivering shocks of defined duration and intensity (1.0 mA). On the first day of the conditioned fear assay, mice were individually acclimated to the chamber via a 5 min habituation session. On the second day, mice were trained to associate an aversive foot shock with the conditioned stimuli, or cage context and an auditory cue, during a 5.5 min conditioning session. Specifically, a tone (3000 Hz, 80 dB) lasting 30 s was emitted 120 and 270 s into the session, and upon termination of each tone, the unconditioned stimulus (a 2 s continuous foot shock at 1.0 mA) was delivered. Testing of contextual memory was conducted on the third day by placing the subject in the conditioning chamber for a 5 min test session and monitoring freezing behavior. Neither a tone nor a shock was administered as this session examined recognition of the association between the shock and the context. The mice were then analyzed for cued conditioning on the fourth day via the 6-min CS+ test. Here, the context of the conditioning chamber was disguised by the addition of a floormat over the metal grid floor, the insertion of patterned walls, and the replacement of orange oil soaked cedar chips with vanilla oil soaked chips in the bedding tray beneath the flooring. After exposure to this novel context for the first 3 min, the association between the foot shock and the tonal cue was assessed by sounding the tone for the last 3 min of the test session. Mice were tested during their active (dark) cycle and were returned to their home cages after each day of testing. Freezing behavior, or the absence of all voluntary movements except breathing, was measured in all four sessions (habituation, conditioning, context test, and CS+ test) by a validated computer-controlled recording of photocell beam interruptions. Scoring of the freezing response entailed summing time spent freezing (the absence of laser beam breaks for â¥2 s) across 5 s intervals for the entire test session duration.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Statistical Analyses</h3><div class="NLM_p last">All values were expressed as the mean Â± SEM. For mean freezing times within the conditioned fear assay sessions, values differing by more than 2 standard deviations from the mean were excluded (approximately one mouse per test group). Test scores of rotarod, locomotor, and fear conditioning behavioral assays were analyzed for homogeneity of variance. Assuming scores met this criterion, appropriate analyses of variance (ANOVA) were performed with group (vehicle or immunized) and/or treatment (saline or flunitrazepam injection) as the between subject factors and, where appropriate, time interval within a session as the within subject factor. Differences were considered statistically significant at <i>p</i> < 0.05. Subsequently, individual means were compared using the Studentâs <i>t</i> test for comparison between two groups, Fisherâs PLSD, or the Scheffeâs test in the case of unequal group size. Data from the GS, VS, and RS groups were compared by one-way ANOVA for all behavioral tests, and given no statistically detectable difference between groups, the GS data were eliminated from further analysis. The GS group was originally included to confirm the lack of adverse effects of passive immunization, and its subsequent exclusion from analysis allowed the 2 Ã 2 structure of ANOVA tests on VS, VF, RS, and RF group data to be upheld (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="si1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35"><a href="/doi/suppl/10.1021/jm800506v">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last"><sup>1</sup>H and <sup>13</sup>C NMR spectra and HPLC traces of compounds <b>4</b>â<b>6</b> and the RCA hapten. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm800506v/suppl_file/jm800506v_si_001.pdf">jm800506v_si_001.pdf (1.23 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm800506v" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02107" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02107" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tobin J. Dickerson</span> - <span class="hlFld-Affiliation affiliation">Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Molecular and Integrative Neurosciences Department (MIND), and Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dda9b2bfb4b39daebeafb4adadaef3b8b9a8fdb6b9b7bcb3b9bc9daebeafb4adadaef3b8b9a8"><span class="__cf_email__" data-cfemail="ec98838e8582ac9f8f9e859c9c9fc2898899">[emailÂ protected]</span> <span class="__cf_email__" data-cfemail="3c5758565d52585d7c4f5f4e554c4c4f12595849">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kim D. Janda</span> - <span class="hlFld-Affiliation affiliation">Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Molecular and Integrative Neurosciences Department (MIND), and Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#42362d202b2c023121302b3232316c27263762292628232c2623023121302b3232316c272637"><span class="__cf_email__" data-cfemail="a7d3c8c5cec9e7d4c4d5ced7d7d489c2c3d2">[emailÂ protected]</span> <span class="__cf_email__" data-cfemail="ddb6b9b7bcb3b9bc9daebeafb4adadaef3b8b9a8">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer B. Treweek</span> - <span class="hlFld-Affiliation affiliation">Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Molecular and Integrative Neurosciences Department (MIND), and Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chengzao Sun</span> - <span class="hlFld-Affiliation affiliation">Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Molecular and Integrative Neurosciences Department (MIND), and Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Longwu Qi</span> - <span class="hlFld-Affiliation affiliation">Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Molecular and Integrative Neurosciences Department (MIND), and Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Coree L. Levy</span> - <span class="hlFld-Affiliation affiliation">Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Molecular and Integrative Neurosciences Department (MIND), and Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amanda J. Roberts</span> - <span class="hlFld-Affiliation affiliation">Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Molecular and Integrative Neurosciences Department (MIND), and Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16003" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16003" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge the financial support of the Skaggs Institute for Chemical Biology and the National Institute on Drug Abuse (Grant DA 21939 to J.B.T., Grant DA 98590 to K.D.J.).</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64864" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64864" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 44 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Meijler, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirsching, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Development of immunopharmacotherapy against drugs of abuse</span> <span class="citation_source-journal">Curr. Drug Discovery Technol.</span><span class="NLM_year" style="font-weight: bold;">2004</span> <span class="NLM_volume">1</span><span class="NLM_issue">1</span> <span class="NLM_fpage">77</span> <span class="NLM_lpage">89</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.2174%2F1570163043484851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16472221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVKjuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=77-89&issue=1&author=M.+M.+Meijlerauthor=M.+Matsushitaauthor=P.+Wirschingauthor=K.+D.+Janda&title=Development+of+immunopharmacotherapy+against+drugs+of+abuse"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Development of immunopharmacotherapy against drugs of abuse</span></div><div class="casAuthors">Meijler, Michael M.; Matsushita, Masayuki; Wirsching, Peter; Janda, Kim D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Discovery Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-89</span>CODEN:
                <span class="NLM_cas:coden">CDDTAF</span>;
        ISSN:<span class="NLM_cas:issn">1570-1638</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug addiction is a major worldwide medical and social problem that continues to escalate.  The addiction syndrome is remarkably similar between different drugs of abuse, and can be characterized as a chronic relapsing brain disorder with neurobiol. changes that lead to a compulsion to take a drug with loss of control over drug intake.  Presently used medications for the treatment of dependence disorders are based on drugs that are either agonists or antagonists of drugs of abuse, and have yielded only limited success.  Immunopharmacotherapy is based on the generation or administration of antibodies that are capable of binding the targeted drug before it can reach the brain, whereas replacement strategies based on agonists or antagonists of these drugs generally cause many undesired side effects.  A large amt. of data has been gathered in recent years on the effects of active and passive immunization against cocaine, nicotine, PCP and methamphetamine in animal models, suggesting potential efficacy of these treatments in humans; and clin. trials are currently underway for vaccines against cocaine and nicotine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqebJXLnhegrLVg90H21EOLACvtfcHk0lhNFunm65f54Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVKjuro%253D&md5=cc97cd7866258e9ce5345eff69788a17</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F1570163043484851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570163043484851%26sid%3Dliteratum%253Aachs%26aulast%3DMeijler%26aufirst%3DM.%2BM.%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DWirsching%26aufirst%3DP.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DDevelopment%2520of%2520immunopharmacotherapy%2520against%2520drugs%2520of%2520abuse%26jtitle%3DCurr.%2520Drug%2520Discovery%2520Technol.%26date%3D2004%26volume%3D1%26issue%3D1%26spage%3D77%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Kosten, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, S. M.</span><span> </span><span class="NLM_article-title">Immunotherapy for the treatment of drug abuse</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_year" style="font-weight: bold;">2005</span> <span class="NLM_volume">108</span><span class="NLM_issue">1</span> <span class="NLM_fpage">76</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2Fj.pharmthera.2005.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16023218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVartr3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2005&pages=76-85&issue=1&author=T.+Kostenauthor=S.+M.+Owens&title=Immunotherapy+for+the+treatment+of+drug+abuse"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy for the treatment of drug abuse</span></div><div class="casAuthors">Kosten, Thomas; Owens, S. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-85</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Antibody therapy (as either active or passive immunization) is designed primarily to prevent drugs of abuse from entering the central nervous system (CNS).  Antidrug antibodies reduce rush, euphoria, and drug distribution to the brain at doses that exceed the apparent binding capacity of the antibody.  This is accomplished through a pharmacokinetic antagonism, which reduces the amt. of drug in the brain, the rate of clearance across the blood-brain barrier, and the vol. of drug distribution.  Because the antibodies remain primarily in the circulatory system, they have no apparent central nervous system side effects.  Active immunization with drug-protein conjugate vaccines has been tested for cocaine, heroin, methamphetamine, and nicotine in animal, with 1 cocaine and 3 nicotine vaccines in Phase 2 human trials.  Passive immunization with high affinity monoclonal antibodies has been tested for cocaine, methamphetamine, nicotine, and phencyclidine (PCP) in preclin. animal models.  Antibodies have 2 immediate clin. applications in drug abuse treatment: to treat drug overdose and to reduce relapse to drug use in addicted patients.  The specificity of the therapies, the lack of addiction liability, minimal side effects, and long-lasting protection against drug use offer major therapeutic benefit over conventional small mol. agonists and antagonists.  Immunotherapies can also be combined with other antiaddiction medications and enhance behavioral therapies.  Current immunotherapies already show efficacy, but improved antigen design and antibody engineering promise highly specific and rapidly developed treatments for both existing and future addictions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrzCobv3_CXbVg90H21EOLACvtfcHk0lhNFunm65f54Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVartr3K&md5=3423b1e9cfe928ce5ecd9ede4632dfd2</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DKosten%26aufirst%3DT.%26aulast%3DOwens%26aufirst%3DS.%2BM.%26atitle%3DImmunotherapy%2520for%2520the%2520treatment%2520of%2520drug%2520abuse%26jtitle%3DPharmacol.%2520Ther.%26date%3D2005%26volume%3D108%26issue%3D1%26spage%3D76%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Pentel, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufek, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roiko, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesage, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keyler, D. E.</span><span> </span><span class="NLM_article-title">Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_year" style="font-weight: bold;">2006</span> <span class="NLM_volume">317</span><span class="NLM_issue">2</span> <span class="NLM_fpage">660</span> <span class="NLM_lpage">666</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1124%2Fjpet.105.097873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16407464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFamur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2006&pages=660-666&issue=2&author=P.+R.+Pentelauthor=M.+B.+Dufekauthor=S.+A.+Roikoauthor=M.+G.+Lesageauthor=D.+E.+Keyler&title=Differential+effects+of+passive+immunization+with+nicotine-specific+antibodies+on+the+acute+and+chronic+distribution+of+nicotine+to+brain+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats</span></div><div class="casAuthors">Pentel, P. R.; Dufek, M. B.; Roiko, S. A.; LeSage, M. G.; Keyler, D. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">660-666</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Vaccination against nicotine blocks or attenuates nicotine-related behaviors relevant to addiction in rats.  Passive immunization with nicotine-specific antibodies is an alternative to vaccination with the potential advantages of allowing control of antibody dose and affinity.  Here, the effects of 2 antibodies on the distribution of nicotine to brain were evaluated during chronic nicotine administration in rats; the monoclonal antibody Nic311 (Kd = 60 nM) and nicotine-specific antiserum (Kd = 1.6 nM).  Nicotine was administered via repeated i.v. bolus doses over 2 days and antibody was administered during the first day.  Neither antibody appreciably reduced the chronic accumulation of nicotine in brain, despite high protein binding of nicotine in serum (98.9%) and a 73% redn. in the unbound serum nicotine concn. with the highest Nic311 dose.  However, both antibodies substantially reduced the early distribution of nicotine to brain 5 min after a dose.  The higher affinity antibody was no more effective than Nic311.  The highest Nic311 dose produced serum antibody levels 10 times higher than those reported with vaccination.  The efficacy of Nic311 was dose-related, with the highest dose producing a 76% decrease in the early distribution of nicotine to brain.  These findings, along with previous data, suggest that the primary effect of passive immunization is to slow, rather than prevent, the distribution of nicotine to brain.  In the setting of chronic nicotine dosing, antibodies with a moderate affinity for nicotine produced substantial effects on the early distribution of nicotine to brain and were as effective as higher affinity antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnmMHR7aJ7cLVg90H21EOLACvtfcHk0lgk3bIqdNM3CQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFamur8%253D&md5=82178544c9a0347f5d64ffb2b5d5ee5d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.097873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.097873%26sid%3Dliteratum%253Aachs%26aulast%3DPentel%26aufirst%3DP.%2BR.%26aulast%3DDufek%26aufirst%3DM.%2BB.%26aulast%3DRoiko%26aufirst%3DS.%2BA.%26aulast%3DLesage%26aufirst%3DM.%2BG.%26aulast%3DKeyler%26aufirst%3DD.%2BE.%26atitle%3DDifferential%2520effects%2520of%2520passive%2520immunization%2520with%2520nicotine-specific%2520antibodies%2520on%2520the%2520acute%2520and%2520chronic%2520distribution%2520of%2520nicotine%2520to%2520brain%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D317%26issue%3D2%26spage%3D660%26epage%3D666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Utzinger, R.</span><span> </span><span class="NLM_article-title">Hapten-immunological studies on mescaline</span> <span class="citation_source-journal">Psychopharmacologia</span><span class="NLM_year" style="font-weight: bold;">1975</span> <span class="NLM_volume">41</span><span class="NLM_issue">3</span> <span class="NLM_fpage">301</span> <span class="NLM_lpage">304</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1007%2FBF00428941" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=807928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADyaE2MXhs1ykt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1975&pages=301-304&issue=3&author=R.+Utzinger&title=Hapten-immunological+studies+on+mescaline"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Hapten-immunological studies on mescaline</span></div><div class="casAuthors">Utzinger, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacologia</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-4</span>CODEN:
                <span class="NLM_cas:coden">PSYPAG</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">Antibodies with mescaline binding specificity were raised in rabbits by immunization with conjugates of bovine serum albumin with mescaline or its analog 3,4,5-trimethoxyphenylacetic acid.  Immunized rats were given mescaline and their behavior was compared with that of nonimmunized controls.  In immunized rats, the effects of mescaline (breathing frequency and crawling were milder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTqDUwUppdW7Vg90H21EOLACvtfcHk0lgk3bIqdNM3CQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXhs1ykt74%253D&md5=be7bee90f7340dc1e3455251b57bf7df</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2FBF00428941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00428941%26sid%3Dliteratum%253Aachs%26aulast%3DUtzinger%26aufirst%3DR.%26atitle%3DHapten-immunological%2520studies%2520on%2520mescaline%26jtitle%3DPsychopharmacologia%26date%3D1975%26volume%3D41%26issue%3D3%26spage%3D301%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Fox, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantak, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollinger, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botka, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schad, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenstein, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gefter, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Exley, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swain, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briner, T. J.</span><span> </span><span class="NLM_article-title">Efficacy of a therapeutic cocaine vaccine in rodent models</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_year" style="font-weight: bold;">1996</span> <span class="NLM_volume">2</span> <span class="NLM_fpage">1129</span> <span class="NLM_lpage">1132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1038%2Fnm1096-1129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=8837612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADyaK28Xmt1Wmsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=1129-1132&author=B.+S.+Foxauthor=K.+M.+Kantakauthor=M.+A.+Edwardsauthor=K.+M.+Blackauthor=B.+K.+Bollingerauthor=A.+J.+Botkaauthor=T.+L.+Frenchauthor=T.+L.+Thompsonauthor=V.+C.+Schadauthor=J.+L.+Greensteinauthor=M.+L.+Gefterauthor=M.+A.+Exleyauthor=P.+A.+Swainauthor=T.+J.+Briner&title=Efficacy+of+a+therapeutic+cocaine+vaccine+in+rodent+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a therapeutic cocaine vaccine in rodent models</span></div><div class="casAuthors">Fox, Barbara S.; Kantak, Kathleen M.; Edwards, Melissa A.; Black, Kerry M.; Bollinger, Brenda K.; Botka, Alison J.; French, Tammy L.; Thompson, Terry L.; Schad, Victoria C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1129-1132</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Cocaine abuse is a major medical and public health concern in the United States, with approx. 2.1 million people dependent on cocaine.  Pharmacol. approaches to the treatment of cocaine addiction have thus far been disappointing, and new therapies are urgently needed.  This paper describes an immunol. approach to cocaine addiction.  Antibody therapy for neutralization of abused drugs has been described previously, including a recent paper demonstrating the induction of anti-cocaine antibodies.  However, both the rapidity of entry of cocaine into the brain and the high doses of cocaine frequently encountered have created challenges for an antibody-based therapy.  Here the authors demonstrate that antibodies are efficacious in an animal model of addn.  I.v. cocaine self-administration in rats was inhibited by passive transfer of an anti-cocaine monoclonal antibody.  To actively induce anti-cocaine antibodies, a cocaine vaccine was developed that generated a high-titer, long-lasting antibody response in mice.  Immunized mice displayed a significant change in cocaine pharmacokinetics, with decreased levels of cocaine measured in the brain of immunized mice only 30 s after i.v. administration of cocaine.  These data establish the feasibility of a therapeutic cocaine vaccine for the treatment of cocaine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4daqGudoVAbVg90H21EOLACvtfcHk0lgk3bIqdNM3CQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmt1Wmsr8%253D&md5=eab16288d4ed29af066f5c0d449092a4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnm1096-1129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1096-1129%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DB.%2BS.%26aulast%3DKantak%26aufirst%3DK.%2BM.%26aulast%3DEdwards%26aufirst%3DM.%2BA.%26aulast%3DBlack%26aufirst%3DK.%2BM.%26aulast%3DBollinger%26aufirst%3DB.%2BK.%26aulast%3DBotka%26aufirst%3DA.%2BJ.%26aulast%3DFrench%26aufirst%3DT.%2BL.%26aulast%3DThompson%26aufirst%3DT.%2BL.%26aulast%3DSchad%26aufirst%3DV.%2BC.%26aulast%3DGreenstein%26aufirst%3DJ.%2BL.%26aulast%3DGefter%26aufirst%3DM.%2BL.%26aulast%3DExley%26aufirst%3DM.%2BA.%26aulast%3DSwain%26aufirst%3DP.%2BA.%26aulast%3DBriner%26aufirst%3DT.%2BJ.%26atitle%3DEfficacy%2520of%2520a%2520therapeutic%2520cocaine%2520vaccine%2520in%2520rodent%2520models%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D1129%26epage%3D1132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Valentine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayersohn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessinger, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, S. M.</span><span> </span><span class="NLM_article-title">Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_year" style="font-weight: bold;">1996</span> <span class="NLM_volume">278</span><span class="NLM_issue">2</span> <span class="NLM_fpage">709</span> <span class="NLM_lpage">716</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=8768722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADyaK28XkvFKjt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=1996&pages=709-716&issue=2&author=J.+L.+Valentineauthor=M.+Mayersohnauthor=W.+D.+Wessingerauthor=L.+W.+Arnoldauthor=S.+M.+Owens&title=Antiphencyclidine+monoclonal+Fab+fragments+reverse+phencyclidine-induced+behavioral+effects+and+ataxia+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats</span></div><div class="casAuthors">Valentine, John L.; Mayersohn, Michael; Wessinger, William D.; Arnold, Larry W.; Owens, S. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">709-716</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Antiphencyclidine monoclonal antibody binding fragments (anti-PCP Fab) were studied in rats as a possible treatment for phencyclidine (PCP) overdose.  Each male Sprague-Dawley rat (n = 4 per group) received an i.v. dose of 1 mg/kg of PCP followed 5 min later (as toxicity maximized) by the one of three treatments in a random cross-over design.  The treatments were 1 mL of saline, a nonspecific polyclonal human FAb, or a high affinity (Kd - 1.8 nM) anti-PCP monoclonal Fab.  The doses of the nonspecific and anti-PCP Fab were 0.3, 1.0 and 3.0 times the mole equiv. (mol-eq) dose of PCP.  Changes in locomotor activity and ataxia were the best indicators of PCP-induced behaviors among several time-dependent behavioral changes that were evaluated.  PCP administration followed by saline treatment resulted in increases in locomotor activity and ataxia that declined to base line after 35 to 40 min.  Anti-PCP FAb at 1.0 and 3.0 times the mol-eq dose of PCP significantly (P < 0.5) and rapidly reversed PCP-induced behaviors to base-line values.  Although the 0.3 mol-eq dose of Fab appeared to slightly decrease the behavioral toxicity, the effects were not statistically different from controls in most cases.  No significant effects on PCP-induced behaviors were obsd. after any dose of nonspecific Fab.  In addn., pharmacol. and immunol. specificity were tested further by treatment of MK-801 {(+)-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine-}-induced behavioral effects.  MK-801 is a PCP-like, noncompetitive N-methyl-D-aspartate receptor antagonist which is structurally unrelated to PCP.  The anti-PCP Fab treatment had no effect on MK-801-induced locomotor activity.  These data clearly show that the anti-PCP FAb is a specific PCP antagonist that can rapidly reverse PCP-induced behavioral toxicity in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkvIqzC3hawbVg90H21EOLACvtfcHk0lhCIoFhfE7j2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XkvFKjt7o%253D&md5=ce6973d0c2f60ed1d2156caad2a276d6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DValentine%26aufirst%3DJ.%2BL.%26aulast%3DMayersohn%26aufirst%3DM.%26aulast%3DWessinger%26aufirst%3DW.%2BD.%26aulast%3DArnold%26aufirst%3DL.%2BW.%26aulast%3DOwens%26aufirst%3DS.%2BM.%26atitle%3DAntiphencyclidine%2520monoclonal%2520Fab%2520fragments%2520reverse%2520phencyclidine-induced%2520behavioral%2520effects%2520and%2520ataxia%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1996%26volume%3D278%26issue%3D2%26spage%3D709%26epage%3D716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Kantak, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipman, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovanoni, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, B. S.</span><span> </span><span class="NLM_article-title">Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_year" style="font-weight: bold;">2000</span> <span class="NLM_volume">148</span><span class="NLM_issue">3</span> <span class="NLM_fpage">251</span> <span class="NLM_lpage">262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2000&pages=251-262&issue=3&author=K.+M.+Kantakauthor=S.+L.+Collinsauthor=E.+G.+Lipmanauthor=J.+Bondauthor=K.+Giovanoniauthor=B.+S.+Fox&title=Evaluation+of+anti-cocaine+antibodies+and+a+cocaine+vaccine+in+a+rat+self-administration+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKantak%26aufirst%3DK.%2BM.%26aulast%3DCollins%26aufirst%3DS.%2BL.%26aulast%3DLipman%26aufirst%3DE.%2BG.%26aulast%3DBond%26aufirst%3DJ.%26aulast%3DGiovanoni%26aufirst%3DK.%26aulast%3DFox%26aufirst%3DB.%2BS.%26atitle%3DEvaluation%2520of%2520anti-cocaine%2520antibodies%2520and%2520a%2520cocaine%2520vaccine%2520in%2520a%2520rat%2520self-administration%2520model%26jtitle%3DPsychopharmacology%26date%3D2000%26volume%3D148%26issue%3D3%26spage%3D251%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hardin, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessinger, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenger, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proksch, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurenzana, E., M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, S. M.</span><span> </span><span class="NLM_article-title">A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_year" style="font-weight: bold;">2002</span> <span class="NLM_volume">302</span> <span class="NLM_fpage">119</span> <span class="NLM_lpage">126</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1124%2Fjpet.302.1.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=12065708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1Sgu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2002&pages=119-126&author=J.+S.+Hardinauthor=W.+D.+Wessingerauthor=G.+R.+Wengerauthor=J.+W.+Prokschauthor=E.%2C+M.+Laurenzanaauthor=S.+M.+Owens&title=A+single+dose+of+monoclonal+anti-phencyclidine+IgG+offers+long-term+reductions+in+phencyclidine+behavioral+effects+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats</span></div><div class="casAuthors">Hardin, J. Shane; Wessinger, William D.; Wenger, Galen R.; Proksch, Joel W.; Laurenzana, Elizabeth M.; Owens, S. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-126</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">These studies tested the hypothesis that a single dose of high-affinity anti-phencyclidine monoclonal antibody (anti-PCP mAb) provides long-term protection against behavioral effects of repeated PCP administration in rats.  Rats were treated with saline, nonspecific bovine IgG (NS-IgG), or anti-PCP mAb (1.0 g/kg).  The next morning, the rats were challenged with escalating i.v. doses of PCP (0.32, 0.56, and 1.0 mg/kg) at 90-min intervals.  This regimen was repeated every 3 days for 2 wk.  In the saline and NS-IgG control groups, PCP yielded reproducible and linear dose-dependent effects that remained const. during the expt.  In contrast, the anti-PCP mAb treatment blocked PCP effects on day 1, and sustained significant redns. in drug effects for the entire 2-wk expt.  Brain PCP concns. (detd. at study termination) were reduced by â¼55%, whereas serum concns. were increased over 4000% compared with controls.  Thus, a single dose of antibody medication provided long-term redns. in drug effects and brain concns., beyond the expected capacity of the drug-antibody interaction.  These data challenge current concepts about in vivo dose dependence and unimol. interaction between antibody binding sites and small mols. and establish that neuroprotection by mAbs may have an unique mechanism of action.  Because PCP is a prototype for drugs that have been difficult to treat due to complex actions at multiple sites within the brain, these studies may provide a new approach for treating a wide range of CNS acting drugs or chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv_5d1wtsHPbVg90H21EOLACvtfcHk0ljs6np7xpUXAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1Sgu7s%253D&md5=8069f38dccaf07afecc4add7e5547817</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1124%2Fjpet.302.1.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.302.1.119%26sid%3Dliteratum%253Aachs%26aulast%3DHardin%26aufirst%3DJ.%2BS.%26aulast%3DWessinger%26aufirst%3DW.%2BD.%26aulast%3DWenger%26aufirst%3DG.%2BR.%26aulast%3DProksch%26aufirst%3DJ.%2BW.%26aulast%3DLaurenzana%26aufirst%3DE.%252C%2BM.%26aulast%3DOwens%26aufirst%3DS.%2BM.%26atitle%3DA%2520single%2520dose%2520of%2520monoclonal%2520anti-phencyclidine%2520IgG%2520offers%2520long-term%2520reductions%2520in%2520phencyclidine%2520behavioral%2520effects%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D302%26spage%3D119%26epage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gentry, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurenzana, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terlea, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, S. M.</span><span> </span><span class="NLM_article-title">Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_year" style="font-weight: bold;">2006</span> <span class="NLM_volume">6</span> <span class="NLM_fpage">968</span> <span class="NLM_lpage">977</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2Fj.intimp.2006.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16644483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvV2qtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=968-977&author=W.+B.+Gentryauthor=E.+M.+Laurenzanaauthor=D.+K.+Williamsauthor=J.+R.+Westauthor=R.+J.+Bergauthor=T.+Terleaauthor=S.+M.+Owens&title=Safety+and+efficiency+of+an+anti-%28%2B%29-methamphetamine+monoclonal+antibody+in+the+protection+against+cardiovascular+and+central+nervous+system+effects+of+%28%2B%29-methamphetamine+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats</span></div><div class="casAuthors">Gentry, W. Brooks; Laurenzana, Elizabeth M.; Williams, D. Keith; West, Jeremy R.; Berg, Renata J.; Terlea, Teodora; Owens, S. Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">968-977</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The purpose of these studies was to det. if a high-affinity, anti-(+)-methamphetamine (METH) monoclonal antibody (mAb6H4; K D = 11 nM) protects against METH-induced central nervous and cardiovascular system effects in rats.  Rats (n = 5 per group) received one of three anti-METH mAb6H4 doses, equal to 0.32, 0.56 or 1 times the mole equiv. (mol-eq) amt. of METH in the body following a 1 mg/kg iv METH dose.  Each rat was challenged with METH (1 mg/kg, iv) 1 and 4 days after the anti-METH mAb dose.  The 1 mol-eq anti-METH mAb dose significantly reduced the duration of METH-induced locomotor activity (horizontal locomotion and rearing events), heart rate and blood pressure effects from 2 to 3 h to about an hour.  This resulted in a significant redn. in total locomotor activity and the area under the hemodynamic effect vs. time curve for heart rate and blood pressure.  In addn., the time to peak locomotor activity was decreased after the 1 mol-eq mAb dose vs. the lower doses.  These changes were limited to the first METH challenge.  The responses to the second METH challenge were not different from baseline.  The peak hemodynamic and locomotor activity values were unchanged after both challenges.  These results indicate anti-METH mAb6H4 can safely reduce the hemodynamic and locomotor effects of METH given one day after anti-METH IgG, and that the mAb is safe when administered in the absence of METH.  These results are important because they indicate these antibody medications have simultaneous beneficial effects in multiple organ systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo81fIrakWfMbVg90H21EOLACvtfcHk0ljs6np7xpUXAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvV2qtLo%253D&md5=fcf02027c48c7e871c3f8ffa69d8c141</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2006.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2006.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DGentry%26aufirst%3DW.%2BB.%26aulast%3DLaurenzana%26aufirst%3DE.%2BM.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DWest%26aufirst%3DJ.%2BR.%26aulast%3DBerg%26aufirst%3DR.%2BJ.%26aulast%3DTerlea%26aufirst%3DT.%26aulast%3DOwens%26aufirst%3DS.%2BM.%26atitle%3DSafety%2520and%2520efficiency%2520of%2520an%2520anti-%2528%252B%2529-methamphetamine%2520monoclonal%2520antibody%2520in%2520the%2520protection%2520against%2520cardiovascular%2520and%2520central%2520nervous%2520system%2520effects%2520of%2520%2528%252B%2529-methamphetamine%2520in%2520rats%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2006%26volume%3D6%26spage%3D968%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Carrera, M. R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trigo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirshing, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_year" style="font-weight: bold;">2005</span> <span class="NLM_volume">81</span> <span class="NLM_fpage">709</span> <span class="NLM_lpage">714</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2Fj.pbb.2005.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16005948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1Wrt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2005&pages=709-714&author=M.+R.+A.+Carreraauthor=J.+M.+Trigoauthor=P.+Wirshingauthor=A.+J.+Robertsauthor=K.+D.+Janda&title=Evaluation+of+the+anticocaine+monoclonal+antibody+GNC92H2+as+an+immunotherapy+for+cocaine+overdose"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose</span></div><div class="casAuthors">Carrera, M. Rocio A.; Trigo, Jose Manuel; Wirsching, Peter; Roberts, Amanda J.; Janda, Kim D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">709-714</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.  Current protein-based technol. offers a new therapeutic venue by which antibodies bind the drug in the blood stream, inactivating its toxic effects.  The therapeutic potential of the anticocaine antibody GNC92H2 was examd. using a model of cocaine overdose.  Swiss albino mice prepd. with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg.  GNC92H2 was delivered 30 min before, concomitantly or 3 min after cocaine treatment.  Significant blockade of cocaine toxicity was obsd. with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.  Importantly, GNC92H2 prevented death even post-cocaine injection.  The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIzIqClQiCRbVg90H21EOLACvtfcHk0ljs6np7xpUXAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1Wrt7k%253D&md5=59b8d1333b75c98a762fa2cb70f498f1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2005.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2005.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DCarrera%26aufirst%3DM.%2BR.%2BA.%26aulast%3DTrigo%26aufirst%3DJ.%2BM.%26aulast%3DWirshing%26aufirst%3DP.%26aulast%3DRoberts%26aufirst%3DA.%2BJ.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DEvaluation%2520of%2520the%2520anticocaine%2520monoclonal%2520antibody%2520GNC92H2%2520as%2520an%2520immunotherapy%2520for%2520cocaine%2520overdose%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2005%26volume%3D81%26spage%3D709%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Malin, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lake, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saldana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvin, M. L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keyler, D. E.</span><span> </span><span class="NLM_article-title">Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_year" style="font-weight: bold;">2001</span> <span class="NLM_volume">68</span><span class="NLM_issue">1</span> <span class="NLM_fpage">87</span> <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2FS0091-3057%2800%2900436-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=11274712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD3MXit1Sis7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2001&pages=87-92&issue=1&author=D.+H.+Malinauthor=J.+R.+Lakeauthor=A.+Linauthor=M.+Saldanaauthor=L.+Balchauthor=M.+L.+L.+Irvinauthor=H.+Chandrasekaraauthor=C.+L.+Alvaradoauthor=Y.+Hiedaauthor=D.+E.+Keyler&title=Passive+immunization+against+nicotine+prevents+nicotine+alleviation+of+nicotine+abstinence+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome</span></div><div class="casAuthors">Malin, D. H.; Lake, J. R.; Lin, A.; Saldana, M.; Balch, L.; Irvin, M. L. L.; Chandrasekara, H.; Alvarado, C. L.; Hieda, Y.; Keyler, D. E.; Pentel, P. R.; Ennifar, S.; Basham, L. E.; Naso, R.; Fattom, A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-92</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Passive immunization against nicotine interferes with its locomotor and pressor effects.  The current study detd. whether immunization could prevent another nicotine action: the reversal of nicotine abstinence syndrome.  IgG contg. 4.4-5.6% nicotine-specific antibody was isolated from rabbits immunized with 3'-amino-methyl-nicotine conjugated to a carrier protein.  Twenty rats were rendered dependent by 7 days of s.c. infusion of 3.15 mg/kg/day nicotine (expressed as the base).  Upon termination of nicotine infusion, each rat was injected i.p. with 150 mg of IgG from normal serum (n=13) or from nicotine antiserum (n=7).  Twenty-two and one-half hours later, all rats were obsd. over 15 min for baseline nicotine abstinence signs.  Two and one-half hours after baseline observations, seven of the 13 rats pretreated with control IgG and all seven rats pretreated with nicotine-specific IgG were then challenged by 0.12 mg/kg (s.c.) nicotine.  The remaining six rats pretreated with control IgG were challenged with saline alone.  All rats were then obsd. again for abstinence signs.  Nicotine injection caused significantly less redn. of abstinence signs in the immunized rats.  The nicotine effect in immunized rats was comparable to the saline effect in nonimmunized rats.  Immunization also significantly reduced free serum nicotine concn. and nicotine distribution to the brain.  These results raise the possibility that immunization might prevent nicotine consumption from relieving the discomforts of smoking cessation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyJdeu6txRYLVg90H21EOLACvtfcHk0ljpqCXp5HL2kQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXit1Sis7o%253D&md5=c1029cddbbb9c71066a67366d932a6d0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2800%2900436-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252800%252900436-6%26sid%3Dliteratum%253Aachs%26aulast%3DMalin%26aufirst%3DD.%2BH.%26aulast%3DLake%26aufirst%3DJ.%2BR.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DSaldana%26aufirst%3DM.%26aulast%3DBalch%26aufirst%3DL.%26aulast%3DIrvin%26aufirst%3DM.%2BL.%2BL.%26aulast%3DChandrasekara%26aufirst%3DH.%26aulast%3DAlvarado%26aufirst%3DC.%2BL.%26aulast%3DHieda%26aufirst%3DY.%26aulast%3DKeyler%26aufirst%3DD.%2BE.%26atitle%3DPassive%2520immunization%2520against%2520nicotine%2520prevents%2520nicotine%2520alleviation%2520of%2520nicotine%2520abstinence%2520syndrome%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2001%26volume%3D68%26issue%3D1%26spage%3D87%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Mattila, M. A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larni, H. M.</span><span> </span><span class="NLM_article-title">Flunitrazepam: a review of its pharmacological properties and therapeutic use</span> <span class="citation_source-journal">Drugs</span><span class="NLM_year" style="font-weight: bold;">1980</span> <span class="NLM_volume">20</span><span class="NLM_issue">5</span> <span class="NLM_fpage">353</span> <span class="NLM_lpage">374</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1980&pages=353-374&issue=5&author=M.+A.+K.+Mattilaauthor=H.+M.+Larni&title=Flunitrazepam%3A+a+review+of+its+pharmacological+properties+and+therapeutic+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMattila%26aufirst%3DM.%2BA.%2BK.%26aulast%3DLarni%26aufirst%3DH.%2BM.%26atitle%3DFlunitrazepam%253A%2520a%2520review%2520of%2520its%2520pharmacological%2520properties%2520and%2520therapeutic%2520use%26jtitle%3DDrugs%26date%3D1980%26volume%3D20%26issue%3D5%26spage%3D353%26epage%3D374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Berezhnoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyfeler, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonthier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwob, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goeldner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigel, E.</span><span> </span><span class="NLM_article-title">On the benzodiazepine binding pocket in GABAA receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_year" style="font-weight: bold;">2004</span> <span class="NLM_volume">279</span><span class="NLM_issue">5</span> <span class="NLM_fpage">3160</span> <span class="NLM_lpage">3168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=3160-3168&issue=5&author=D.+Berezhnoyauthor=Y.+Nyfelerauthor=A.+Gonthierauthor=H.+Schwobauthor=M.+Goeldnerauthor=E.+Sigel&title=On+the+benzodiazepine+binding+pocket+in+GABAA+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerezhnoy%26aufirst%3DD.%26aulast%3DNyfeler%26aufirst%3DY.%26aulast%3DGonthier%26aufirst%3DA.%26aulast%3DSchwob%26aufirst%3DH.%26aulast%3DGoeldner%26aufirst%3DM.%26aulast%3DSigel%26aufirst%3DE.%26atitle%3DOn%2520the%2520benzodiazepine%2520binding%2520pocket%2520in%2520GABAA%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26issue%3D5%26spage%3D3160%26epage%3D3168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Drummer, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syrjanen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordner, S. M.</span><span> </span><span class="NLM_article-title">Deaths involving the benzodiazepine flunitrazepam</span> <span class="citation_source-journal">Am. J. Forensic Med. Pathol.</span><span class="NLM_year" style="font-weight: bold;">1993</span> <span class="NLM_volume">14</span><span class="NLM_issue">3</span> <span class="NLM_fpage">238</span> <span class="NLM_lpage">243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=8311057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A280%3ADyaK2c7ksVKiug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1993&pages=238-243&issue=3&author=O.+H.+Drummerauthor=M.+L.+Syrjanenauthor=S.+M.+Cordner&title=Deaths+involving+the+benzodiazepine+flunitrazepam"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Deaths involving the benzodiazepine flunitrazepam</span></div><div class="casAuthors">Drummer O H; Syrjanen M L; Cordner S M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of forensic medicine and pathology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">238-43</span>
        ISSN:<span class="NLM_cas:issn">0195-7910</span>.
    </div><div class="casAbstract">A study of eight deaths involving the benzodiazepine flunitrazepam was performed to assess the contribution of this drug to the fatalities.  Coronial deaths in Victoria in the 2-year period to mid-1991 were selected in which either flunitrazepam or flunitrazepam and ethanol were the principal toxicological findings.  All bodies were subject to a full autopsy by forensic pathologists, and a full toxicological examination.  No significant pathology was found at autopsy in any case.  Very high concentrations of 7-aminoflunitrazepam, a metabolite of flunitrazepam, were present in all cases.  In four cases no other significant drug was detected, whereas in the other four cases there were significant concentrations of ethanol (mean 1.6 g/L).  In these two groups of cases the concentrations of 7-aminoflunitrazepam were 0.45 mg/L and 0.16 mg/L, respectively.  Only moderate levels of flunitrazepam were detected, suggesting that 7-aminoflunitrazepam is produced postmortem and may be an important marker of flunitrazepam usage.  The causes of death in these eight cases were probably either flunitrazepam toxicity or a combination of flunitrazepam and ethanol toxicity.  Only one case appeared likely to have been a suicide.  Our observations in these cases suggest that flunitrazepam may cause death in the absence of other drugs or significant disease.  The presence of ethanol reduces the amount of flunitrazepam needed to cause death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmLnoI-iZ4iFUIs6wFK5xJfW6udTcc2eZ4hUTt_GT2ubntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c7ksVKiug%253D%253D&md5=e4c91e6381713c754188095c15634179</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrummer%26aufirst%3DO.%2BH.%26aulast%3DSyrjanen%26aufirst%3DM.%2BL.%26aulast%3DCordner%26aufirst%3DS.%2BM.%26atitle%3DDeaths%2520involving%2520the%2520benzodiazepine%2520flunitrazepam%26jtitle%3DAm.%2520J.%2520Forensic%2520Med.%2520Pathol.%26date%3D1993%26volume%3D14%26issue%3D3%26spage%3D238%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Farre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teran, M.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roset, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torrens, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cami, J.</span><span> </span><span class="NLM_article-title">Abuse liability of flunitrazepam among methadone-maintained patients</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_year" style="font-weight: bold;">1998</span> <span class="NLM_volume">140</span> <span class="NLM_fpage">486</span> <span class="NLM_lpage">495</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=1998&pages=486-495&author=M.+Farreauthor=M.-T.+Teranauthor=P.+N.+Rosetauthor=M.+Masauthor=M.+Torrensauthor=J.+Cami&title=Abuse+liability+of+flunitrazepam+among+methadone-maintained+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFarre%26aufirst%3DM.%26aulast%3DTeran%26aufirst%3DM.-T.%26aulast%3DRoset%26aufirst%3DP.%2BN.%26aulast%3DMas%26aufirst%3DM.%26aulast%3DTorrens%26aufirst%3DM.%26aulast%3DCami%26aufirst%3DJ.%26atitle%3DAbuse%2520liability%2520of%2520flunitrazepam%2520among%2520methadone-maintained%2520patients%26jtitle%3DPsychopharmacology%26date%3D1998%26volume%3D140%26spage%3D486%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Gambi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimaldi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giampietro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Bernardis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferro, F. M.</span><span> </span><span class="NLM_article-title">Flunitrazepam a benzodiazepine most used among drug abusers</span> <span class="citation_source-journal">Int. J. Immunopathol. Pharmacol.</span><span class="NLM_year" style="font-weight: bold;">1999</span> <span class="NLM_volume">12</span><span class="NLM_issue">3</span> <span class="NLM_fpage">157</span> <span class="NLM_lpage">159</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=12783645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktFWm" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1999&pages=157-159&issue=3&author=F.+Gambiauthor=C.+M.+Contiauthor=M.+R.+Grimaldiauthor=L.+Giampietroauthor=B.+De+Bernardisauthor=F.+M.+Ferro&title=Flunitrazepam+a+benzodiazepine+most+used+among+drug+abusers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Flunitrazepam a benzodiazepine most used among drug abusers</span></div><div class="casAuthors">Gambi, F.; Conti, C. M. V.; Grimaldi, M. R.; Giampietro, L.; De Berardis, D.; Ferro, F. M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Immunopathology and Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-159</span>CODEN:
                <span class="NLM_cas:coden">IJIPE4</span>;
        ISSN:<span class="NLM_cas:issn">0394-6320</span>.
    
            (<span class="NLM_cas:orgname">Biomedical Research Press</span>)
        </div><div class="casAbstract">A review with 19 refs.  Flunitrazepam (FZ) is a sedative/hypnotic nitro-benzodiazepine.  This drug has been accepted by both patients and physicians and in the last 20 yr flunitrazepam has been included and studied in many clin. trials so, in many countries, flunitrazepam is one of the most prescribed hypnotic.  Since 1980 it has been found that FZ began to be a popular drug among drug abusers all over the word.  However, little is known about the difference between Fz and other Benzodiazepines in capacity to produce physiol. dependence or in ability to produce drug taking or drug seeking behavior.  Flunitrazepam has little risk of abuse by the vast majority of patients; however when the drug is taken i. v. or intranasally, its effect is much faster and risk of abuse is much greater.  In this report we examine the reasons why some populations of drug abusers prefer flunitrazepam over the other benzodiazepines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVKySlI7xe2bVg90H21EOLACvtfcHk0lgLz4E9hT2MFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktFWm&md5=1bc3bf12775100898fca7dd2795815f6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGambi%26aufirst%3DF.%26aulast%3DConti%26aufirst%3DC.%2BM.%26aulast%3DGrimaldi%26aufirst%3DM.%2BR.%26aulast%3DGiampietro%26aufirst%3DL.%26aulast%3DDe%2BBernardis%26aufirst%3DB.%26aulast%3DFerro%26aufirst%3DF.%2BM.%26atitle%3DFlunitrazepam%2520a%2520benzodiazepine%2520most%2520used%2520among%2520drug%2520abusers%26jtitle%3DInt.%2520J.%2520Immunopathol.%2520Pharmacol.%26date%3D1999%26volume%3D12%26issue%3D3%26spage%3D157%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Mintzer, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, R. R.</span><span> </span><span class="NLM_article-title">An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers</span> <span class="citation_source-journal">Behav. Pharmacol.</span><span class="NLM_year" style="font-weight: bold;">2005</span> <span class="NLM_volume">16</span><span class="NLM_issue">7</span> <span class="NLM_fpage">579</span> <span class="NLM_lpage">584</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1097%2F01.fbp.0000172736.11994.3c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16170235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWntrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=579-584&issue=7&author=M.+Z.+Mintzerauthor=R.+R.+Griffiths&title=An+abuse+liability+comparison+of+flunitrazepam+and+triazolam+in+sedative+drug+abusers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers</span></div><div class="casAuthors">Mintzer, M. Z.; Griffiths, R. R.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">579-584</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The present double-blind, placebo-controlled study compared the acute effects of oral administration of the benzodiazepine hypnotics flunitrazepam (6 mg/70 kg) and triazolam (1 and 2 mg/70 kg) on measures relevant to abuse liability as well as on psychomotor performance and observer- and participant-rated measures of drug effects in nine sedative drug abusers.  Anal. of participant-rated measures collected 24 h after drug administration (next-day; assessing the overall effects of the drug received 24 h earlier) indicated that flunitrazepam, but neither triazolam dose, produced significant increases relative to placebo in next-day ratings of drug liking, the amt. of money the drug would be worth on the street, and the amt. of money the participant would be willing to pay for the drug on the street.  Importantly, these abuse liability differences between flunitrazepam and triazolam were present at a dose of flunitrazepam (6 mg/70 kg) that produced overall drug effects that were comparable to, or significantly less than, those of a high triazolam dose (2 mg/70 kg).  Consistent with results of a previous study in our lab., these results suggest that flunitrazepam may have a greater abuse liability than triazolam, and that this abuse liability difference emerges on measures taken 24 h after drug administration but not on same-day measures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs__K4IOyKwbVg90H21EOLACvtfcHk0lgLz4E9hT2MFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWntrrM&md5=0e220335b07bb56be33783ad289c9f71</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2F01.fbp.0000172736.11994.3c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.fbp.0000172736.11994.3c%26sid%3Dliteratum%253Aachs%26aulast%3DMintzer%26aufirst%3DM.%2BZ.%26aulast%3DGriffiths%26aufirst%3DR.%2BR.%26atitle%3DAn%2520abuse%2520liability%2520comparison%2520of%2520flunitrazepam%2520and%2520triazolam%2520in%2520sedative%2520drug%2520abusers%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2005%26volume%3D16%26issue%3D7%26spage%3D579%26epage%3D584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Schwartz, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, A. B.</span><span> </span><span class="NLM_article-title">Rohypnol, the date rape drug</span> <span class="citation_source-journal">Clin. Pediatr.</span><span class="NLM_year" style="font-weight: bold;">1998</span> <span class="NLM_volume">37</span> <span class="NLM_fpage">321</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1177%2F000992289803700508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=9597300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A280%3ADyaK1c3lvFGrug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=321&author=R.+H.+Schwartzauthor=A.+B.+Weaver&title=Rohypnol%2C+the+date+rape+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Rohypnol, the date rape drug</span></div><div class="casAuthors">Schwartz R H; Weaver A B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pediatrics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">321</span>
        ISSN:<span class="NLM_cas:issn">0009-9228</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzRK5dUlcSBWlSCSgBhwJFfW6udTcc2eZJvtXoRMUh8Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3lvFGrug%253D%253D&md5=410e1379c7fb79c26d34e84b85c013ac</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1177%2F000992289803700508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F000992289803700508%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DR.%2BH.%26aulast%3DWeaver%26aufirst%3DA.%2BB.%26atitle%3DRohypnol%252C%2520the%2520date%2520rape%2520drug%26jtitle%3DClin.%2520Pediatr.%26date%3D1998%26volume%3D37%26spage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Smith, K. M.</span><span> </span><span class="NLM_article-title">Drugs used in acquaintance rape</span> <span class="citation_source-journal">J. Am. Pharm. Assoc.</span><span class="NLM_year" style="font-weight: bold;">1999</span> <span class="NLM_volume">39</span> <span class="NLM_fpage">519</span> <span class="NLM_lpage">583</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1999&pages=519-583&author=K.+M.+Smith&title=Drugs+used+in+acquaintance+rape"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DK.%2BM.%26atitle%3DDrugs%2520used%2520in%2520acquaintance%2520rape%26jtitle%3DJ.%2520Am.%2520Pharm.%2520Assoc.%26date%3D1999%26volume%3D39%26spage%3D519%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span> <span class="citation_source-book">DEA Congressional Testimony</span>, House Commerce Committee Subcommittee on Oversight and Investigations, 106th Congress, 1st Session; <span class="NLM_publisher-name">U.S. Drug Enforcement Administration</span>: <span class="NLM_publisher-loc">Springfield, VA</span>, <span class="NLM_year">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DEA+Congressional+Testimony%2C+House+Commerce+Committee+Subcommittee+on+Oversight+and+Investigations%2C+106th+Congress%2C+1st+Session%3B+U.S.+Drug+Enforcement+Administration%3A+Springfield%2C+VA%2C+1999."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DDEA%2520Congressional%2520Testimony%26pub%3DU.S.%2520Drug%2520Enforcement%2520Administration%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valvano, N. L.</span><span> </span><span class="NLM_article-title">Synthesis of 2-aminobenzophenones via rapid halogenâlithium exchange in the presence of a 2-amino-<i>N</i>-methoxy-<i>N</i>-methylbenzamide</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_year" style="font-weight: bold;">1991</span> <span class="NLM_volume">56</span> <span class="NLM_fpage">3750</span> <span class="NLM_lpage">3752</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00011a066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1991&pages=3750-3752&author=S.+V.+Fryeauthor=M.+C.+Johnsonauthor=N.+L.+Valvano&title=Synthesis+of+2-aminobenzophenones+via+rapid+halogen%E2%88%92lithium+exchange+in+the+presence+of+a+2-amino-N-methoxy-N-methylbenzamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjo00011a066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00011a066%26sid%3Dliteratum%253Aachs%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DJohnson%26aufirst%3DM.%2BC.%26aulast%3DValvano%26aufirst%3DN.%2BL.%26atitle%3DSynthesis%2520of%25202-aminobenzophenones%2520via%2520rapid%2520halogen%25E2%2588%2592lithium%2520exchange%2520in%2520the%2520presence%2520of%2520a%25202-amino-N-methoxy-N-methylbenzamide%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1991%26volume%3D56%26spage%3D3750%26epage%3D3752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Carpino, L. A.</span><span> </span><span class="NLM_article-title">1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_year" style="font-weight: bold;">1993</span> <span class="NLM_volume">115</span> <span class="NLM_fpage">4397</span> <span class="NLM_lpage">4398</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00063a082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1993&pages=4397-4398&author=L.+A.+Carpino&title=1-Hydroxy-7-azabenzotriazole.+An+efficient+peptide+coupling+additive"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fja00063a082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00063a082%26sid%3Dliteratum%253Aachs%26aulast%3DCarpino%26aufirst%3DL.%2BA.%26atitle%3D1-Hydroxy-7-azabenzotriazole.%2520An%2520efficient%2520peptide%2520coupling%2520additive%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1993%26volume%3D115%26spage%3D4397%26epage%3D4398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Sternbach, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fryer, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metlesics, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stempel, A.</span><span> </span><span class="NLM_article-title">Quinazolines and 1,4-benzodiazepines. V. <i>o</i>-Aminobenzophenones</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_year" style="font-weight: bold;">1962</span> <span class="NLM_volume">27</span><span class="NLM_issue">11</span> <span class="NLM_fpage">3781</span> <span class="NLM_lpage">3788</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo01058a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1962&pages=3781-3788&issue=11&author=L.+H.+Sternbachauthor=R.+I.+Fryerauthor=W.+Metlesicsauthor=G.+Sachauthor=A.+Stempel&title=Quinazolines+and+1%2C4-benzodiazepines.+V.+o-Aminobenzophenones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjo01058a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01058a009%26sid%3Dliteratum%253Aachs%26aulast%3DSternbach%26aufirst%3DL.%2BH.%26aulast%3DFryer%26aufirst%3DR.%2BI.%26aulast%3DMetlesics%26aufirst%3DW.%26aulast%3DSach%26aufirst%3DG.%26aulast%3DStempel%26aufirst%3DA.%26atitle%3DQuinazolines%2520and%25201%252C4-benzodiazepines.%2520V.%2520o-Aminobenzophenones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1962%26volume%3D27%26issue%3D11%26spage%3D3781%26epage%3D3788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Sternbach, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fryer, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metlesics, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiger, N.</span><span> </span><span class="NLM_article-title">Quinazolinesand 1,4-benzodiazepines. X. Nitro-substituted 5-phenyl-1,4-benzodiazepine derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_year" style="font-weight: bold;">1963</span> <span class="NLM_volume">6</span> <span class="NLM_fpage">261</span> <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00339a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1963&pages=261-265&author=L.+H.+Sternbachauthor=R.+I.+Fryerauthor=O.+Kellerauthor=W.+Metlesicsauthor=G.+Sachauthor=N.+Steiger&title=Quinazolinesand+1%2C4-benzodiazepines.+X.+Nitro-substituted+5-phenyl-1%2C4-benzodiazepine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm00339a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00339a010%26sid%3Dliteratum%253Aachs%26aulast%3DSternbach%26aufirst%3DL.%2BH.%26aulast%3DFryer%26aufirst%3DR.%2BI.%26aulast%3DKeller%26aufirst%3DO.%26aulast%3DMetlesics%26aufirst%3DW.%26aulast%3DSach%26aufirst%3DG.%26aulast%3DSteiger%26aufirst%3DN.%26atitle%3DQuinazolinesand%25201%252C4-benzodiazepines.%2520X.%2520Nitro-substituted%25205-phenyl-1%252C4-benzodiazepine%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1963%26volume%3D6%26spage%3D261%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Carrera, M. R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirshing, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koob, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Suppression of psychoactive effects of cocaine by active immunization</span> <span class="citation_source-journal">Nature</span><span class="NLM_year" style="font-weight: bold;">1995</span> <span class="NLM_volume">378</span><span class="NLM_issue">6558</span> <span class="NLM_fpage">727</span> <span class="NLM_lpage">730</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=1995&pages=727-730&issue=6558&author=M.+R.+A.+Carreraauthor=J.+A.+Ashleyauthor=L.+H.+Parsonsauthor=P.+Wirshingauthor=G.+F.+Koobauthor=K.+D.+Janda&title=Suppression+of+psychoactive+effects+of+cocaine+by+active+immunization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarrera%26aufirst%3DM.%2BR.%2BA.%26aulast%3DAshley%26aufirst%3DJ.%2BA.%26aulast%3DParsons%26aufirst%3DL.%2BH.%26aulast%3DWirshing%26aufirst%3DP.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DSuppression%2520of%2520psychoactive%2520effects%2520of%2520cocaine%2520by%2520active%2520immunization%26jtitle%3DNature%26date%3D1995%26volume%3D378%26issue%3D6558%26spage%3D727%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Carrera, M. R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirsching, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koob, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Cocaine vaccines: antibody protection against relapse in a rat model</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_year" style="font-weight: bold;">2000</span> <span class="NLM_volume">97</span><span class="NLM_issue">11</span> <span class="NLM_fpage">6202</span> <span class="NLM_lpage">6206</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=6202-6206&issue=11&author=M.+R.+A.+Carreraauthor=J.+A.+Ashleyauthor=B.+Zhouauthor=P.+Wirschingauthor=G.+F.+Koobauthor=K.+D.+Janda&title=Cocaine+vaccines%3A+antibody+protection+against+relapse+in+a+rat+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarrera%26aufirst%3DM.%2BR.%2BA.%26aulast%3DAshley%26aufirst%3DJ.%2BA.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DWirsching%26aufirst%3DP.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DCocaine%2520vaccines%253A%2520antibody%2520protection%2520against%2520relapse%2520in%2520a%2520rat%2520model%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2000%26volume%3D97%26issue%3D11%26spage%3D6202%26epage%3D6206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Deroche, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caine, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyser, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koob, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gold, L. H.</span><span> </span><span class="NLM_article-title">Differences in the liability to self-administer intravenous cocaine between C57BL/6 Ã SJL and BALB/cByJ mice</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_year" style="font-weight: bold;">1997</span> <span class="NLM_volume">57</span><span class="NLM_issue">3</span> <span class="NLM_fpage">429</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2FS0091-3057%2896%2900439-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=9218267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADyaK2sXkt1yiu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=429-440&issue=3&author=V.+Derocheauthor=S.+B.+Caineauthor=C.+J.+Heyserauthor=I.+Polisauthor=G.+F.+Koobauthor=L.+H.+Gold&title=Differences+in+the+liability+to+self-administer+intravenous+cocaine+between+C57BL%2F6+%C3%97+SJL+and+BALB%2FcByJ+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Differences in the liability to self-administer intravenous cocaine between C57BL/6 Ã SJL and BALB/cByJ mice</span></div><div class="casAuthors">Deroche, V.; Caine, S. B.; Heyser, C. J.; Polis, I.; Koob, G. F.; Gold, L. H.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-440</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Application of animal models of psychostimulant abuse for experimentation in mice is becoming increasingly important for studying the contribution of genetic differences, as well as the roles of selected (targeted) genes, in specific behaviors.  The purpose of this study was to investigate strain differences in cocaine self-administration behavior between C57BL/6 Ã SJL hybrid mice and BALB/cByJ mice.  These two strains were chosen because BALB/cByJ mice have a well-developed behavioral pharmacol. profile, and hybrid strains on a C57BL/6 background are commonly used for generating transgenic expressing and knockout mutant mice.  C57BL/6 Ã SJL mice dose-dependently acquired cocaine self-administration (1.0 mg/kg/injection but not 0.25 mg/kg/injection) by responding selectively in the active nose-poke hole and maintaining stable levels of daily drug intake; they also exhibited a characteristic inverted-U-shaped cocaine dose-effect function.  BALB/cByJ mice failed to acquire cocaine self-administration at either dose under the same test conditions.  The strain differences obsd. in self-administration did not seem to be attributed to other behavioral differences because the two strains exhibited similar amts. of spontaneous nose-poking in the absence of reinforcers, and BALB/cByJ mice responded more than C57BL/6 Ã SJL mice in a food-reinforced nose-poke operant task.  Importantly, the dose-effect function for the motor stimulating effects of cocaine (3.8-30 mg/kg i.p.) suggests enhanced sensitivity but reduced efficacy of cocaine in stimulating motor activity in BALB/cByJ mice relative to the C57BL/6 Ã SJL hybrid mice.  These results indicate that the decreased liability of BALB/cByJ mice to acquire cocaine self-administration is not the result of differences in spontaneous activity or performance, but may reflect different sensitivities to the reinforcing, or rate-disrupting, properties of cocaine.  The data support an influence of genetic background in the liability to self-administer cocaine.  Thus, a hypothesis is proposed that the decreased liability of BALB/cByJ mice to acquire cocaine self-administration is related to differences in brain monoamine systems linked to the high "emotionality" profile of BALB/c mice in novel or fearful situations, including perhaps cocaine administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJeNeEDGg_47Vg90H21EOLACvtfcHk0liF0h30dR65iw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt1yiu7w%253D&md5=fbce8f49a6078cf2ac97c1d07b5d4e60</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2896%2900439-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252896%252900439-X%26sid%3Dliteratum%253Aachs%26aulast%3DDeroche%26aufirst%3DV.%26aulast%3DCaine%26aufirst%3DS.%2BB.%26aulast%3DHeyser%26aufirst%3DC.%2BJ.%26aulast%3DPolis%26aufirst%3DI.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26aulast%3DGold%26aufirst%3DL.%2BH.%26atitle%3DDifferences%2520in%2520the%2520liability%2520to%2520self-administer%2520intravenous%2520cocaine%2520between%2520C57BL%252F6%2520%25C3%2597%2520SJL%2520and%2520BALB%252FcByJ%2520mice%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D1997%26volume%3D57%26issue%3D3%26spage%3D429%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Isomura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirsching, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_year" style="font-weight: bold;">2001</span> <span class="NLM_volume">66</span><span class="NLM_issue">12</span> <span class="NLM_fpage">4115</span> <span class="NLM_lpage">4121</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo001442w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=4115-4121&issue=12&author=S.+Isomuraauthor=P.+Wirschingauthor=K.+D.+Janda&title=An+immunotherapeutic+program+for+the+treatment+of+nicotine+addiction%3A+hapten+design+and+synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjo001442w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo001442w%26sid%3Dliteratum%253Aachs%26aulast%3DIsomura%26aufirst%3DS.%26aulast%3DWirsching%26aufirst%3DP.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DAn%2520immunotherapeutic%2520program%2520for%2520the%2520treatment%2520of%2520nicotine%2520addiction%253A%2520hapten%2520design%2520and%2520synthesis%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26issue%3D12%26spage%3D4115%26epage%3D4121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Matsushita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, T. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirsching, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Cocaine catalytic antibodies: the primary importance of linker effects</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_year" style="font-weight: bold;">2001</span> <span class="NLM_volume">11</span><span class="NLM_issue">2</span> <span class="NLM_fpage">87</span> <span class="NLM_lpage">90</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=87-90&issue=2&author=M.+Matsushitaauthor=T.+Z.+Hoffmanauthor=J.+A.+Ashleyauthor=B.+Zhouauthor=P.+Wirschingauthor=K.+D.+Janda&title=Cocaine+catalytic+antibodies%3A+the+primary+importance+of+linker+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DT.%2BZ.%26aulast%3DAshley%26aufirst%3DJ.%2BA.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DWirsching%26aufirst%3DP.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DCocaine%2520catalytic%2520antibodies%253A%2520the%2520primary%2520importance%2520of%2520linker%2520effects%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26issue%3D2%26spage%3D87%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Meijler, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altobell, L. J.,  III.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirsching, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">A new strategy for improved nicotine vaccines using conformationally constrained haptens</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_year" style="font-weight: bold;">2003</span> <span class="NLM_volume">125</span><span class="NLM_issue">47</span> <span class="NLM_fpage">164</span> <span class="NLM_lpage">165</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2003&pages=164-165&issue=47&author=M.+M.+Meijlerauthor=M.+Matsushitaauthor=L.+J.+Altobellauthor=P.+Wirschingauthor=K.+D.+Janda&title=A+new+strategy+for+improved+nicotine+vaccines+using+conformationally+constrained+haptens"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeijler%26aufirst%3DM.%2BM.%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DAltobell%26aufirst%3DL.%2BJ.%26aulast%3DWirsching%26aufirst%3DP.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DA%2520new%2520strategy%2520for%2520improved%2520nicotine%2520vaccines%2520using%2520conformationally%2520constrained%2520haptens%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2003%26volume%3D125%26issue%3D47%26spage%3D164%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Ino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Positional linker effects in haptens for cocaine immunopharmacotherapy</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_year" style="font-weight: bold;">2007</span> <span class="NLM_volume">17</span><span class="NLM_issue">15</span> <span class="NLM_fpage">4280</span> <span class="NLM_lpage">4283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4280-4283&issue=15&author=A.+Inoauthor=T.+J.+Dickersonauthor=K.+D.+Janda&title=Positional+linker+effects+in+haptens+for+cocaine+immunopharmacotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIno%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DT.%2BJ.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DPositional%2520linker%2520effects%2520in%2520haptens%2520for%2520cocaine%2520immunopharmacotherapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D15%26spage%3D4280%26epage%3D4283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Qi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijler, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altobell, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koob, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirsching, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Delta-9-tetrahydrocannabinol immunochemical studies: haptens, monoclonal antibodies, and a convenient synthesis of radiolabeled delta-9-tetrahydrocannabinol</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_year" style="font-weight: bold;">2005</span> <span class="NLM_volume">48</span><span class="NLM_issue">23</span> <span class="NLM_fpage">7389</span> <span class="NLM_lpage">7399</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050442r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7389-7399&issue=23&author=L.+Qiauthor=N.+Yamamotoauthor=M.+M.+Meijlerauthor=L.+J.+Altobellauthor=G.+F.+Koobauthor=P.+Wirschingauthor=K.+D.+Janda&title=Delta-9-tetrahydrocannabinol+immunochemical+studies%3A+haptens%2C+monoclonal+antibodies%2C+and+a+convenient+synthesis+of+radiolabeled+delta-9-tetrahydrocannabinol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm050442r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050442r%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DL.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DMeijler%26aufirst%3DM.%2BM.%26aulast%3DAltobell%26aufirst%3DL.%2BJ.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26aulast%3DWirsching%26aufirst%3DP.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DDelta-9-tetrahydrocannabinol%2520immunochemical%2520studies%253A%2520haptens%252C%2520monoclonal%2520antibodies%252C%2520and%2520a%2520convenient%2520synthesis%2520of%2520radiolabeled%2520delta-9-tetrahydrocannabinol%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D23%26spage%3D7389%26epage%3D7399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Fryer, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z. Q.</span><span> </span><span class="NLM_article-title">The rational design and synthesis of haptens having specific activity as full agonists or full antagonists at the benzodiazepine receptor</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_year" style="font-weight: bold;">1990</span> <span class="NLM_volume">47</span><span class="NLM_issue">10</span> <span class="NLM_fpage">833</span> <span class="NLM_lpage">840</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1990&pages=833-840&issue=10&author=R.+I.+Fryerauthor=Z.+Q.+Gu&title=The+rational+design+and+synthesis+of+haptens+having+specific+activity+as+full+agonists+or+full+antagonists+at+the+benzodiazepine+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFryer%26aufirst%3DR.%2BI.%26aulast%3DGu%26aufirst%3DZ.%2BQ.%26atitle%3DThe%2520rational%2520design%2520and%2520synthesis%2520of%2520haptens%2520having%2520specific%2520activity%2520as%2520full%2520agonists%2520or%2520full%2520antagonists%2520at%2520the%2520benzodiazepine%2520receptor%26jtitle%3DLife%2520Sci.%26date%3D1990%26volume%3D47%26issue%3D10%26spage%3D833%26epage%3D840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Peterson, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunnell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goforth, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, S. M.</span><span> </span><span class="NLM_article-title">Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_year" style="font-weight: bold;">2007</span> <span class="NLM_volume">322</span><span class="NLM_issue">1</span> <span class="NLM_fpage">30</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1124%2Fjpet.106.117150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=17452421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntl2jsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=30-39&issue=1&author=E.+C.+Petersonauthor=M.+Gunnellauthor=Y.+Cheauthor=R.+L.+Goforthauthor=F.+I.+Carrollauthor=R.+Henryauthor=H.+Liuauthor=S.+M.+Owens&title=Using+hapten+design+to+discover+therapeutic+monoclonal+antibodies+for+treating+methamphetamine+abuse"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse</span></div><div class="casAuthors">Peterson, Eric C.; Gunnell, Melinda; Che, Yingni; Goforth, Robyn L.; Carroll, F. Ivy; Henry, Ralph; Liu, Huimin; Owens, S. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">When generating monoclonal antibodies (mAb) against small mols., the chem. compn. and mol. orientation of the drug-like hapten on the antigen is a crucial determinant.  This is esp. important when attempting to discover therapeutic mAb against the drugs of abuse (+)-methamphetamine [(+)-METH], (+)-amphetamine [(+)-AMP], and the related compd. (+)-3,4-methylenedioxymethamphetamine [(+)-MDMA, the plus isomer in the racemic mixt. known as MDMA or ecstasy].  The goal of these studies was to design and synthesize (+)-METH-like haptens with structural attributes that could make them effective for generating monoclonal antibodies for treating medical problems assocd. with these stimulant drugs of abuse.  Five prototype (+)-METH-like haptens, which mimic structural aspects of these drugs, were synthesized and used to generate mAb.  After screening for anti-(+)-METH IgG antibodies in more than 25,000 potential mouse hybridoma cell lines, one prototype mAb from each of the 5 haptens was selected and studied in detail for mol. properties and preclin. efficacy.  The amino acid sequences of the IgG-variable regions, structural models, affinity, and ligand specificity of each mAb were then used to help elucidate important therapeutic characteristics.  Four of these antibodies exhibited high affinity and specificity to (+)-METH and (+)-MDMA; whereas one antibody (designated mAb4G9) exhibited high affinity and specificity to (+)-METH, (+)-MDMA, and (+)-AMP, without significant cross-reactivity against other METH-like ligands, over-the-counter medications, or endogenous neurotransmitters.  Considered together, discovery of mAb4G9 and the other antibodies in this report represent an important step in understanding the process for custom design of drug class-specific therapeutic antibodies for the treatment of drug addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKlOI-7pwFvbVg90H21EOLACvtfcHk0ljG80AKVPfauw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntl2jsbg%253D&md5=f9a28b07d1dee11337b955f4f0975032</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.117150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.117150%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DE.%2BC.%26aulast%3DGunnell%26aufirst%3DM.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DGoforth%26aufirst%3DR.%2BL.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DHenry%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DOwens%26aufirst%3DS.%2BM.%26atitle%3DUsing%2520hapten%2520design%2520to%2520discover%2520therapeutic%2520monoclonal%2520antibodies%2520for%2520treating%2520methamphetamine%2520abuse%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26issue%3D1%26spage%3D30%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Castellano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavone, F.</span><span> </span><span class="NLM_article-title">Effects of flunitrazepam on passive avoidance behaviour in mice subjected to immobilization stress or familiarized with the testing apparatus</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_year" style="font-weight: bold;">1986</span> <span class="NLM_volume">22</span><span class="NLM_issue">1</span> <span class="NLM_fpage">91</span> <span class="NLM_lpage">95</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2F0166-4328%2886%2990084-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=3024662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADyaL2sXht1OrsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1986&pages=91-95&issue=1&author=C.+Castellanoauthor=F.+Pavone&title=Effects+of+flunitrazepam+on+passive+avoidance+behaviour+in+mice+subjected+to+immobilization+stress+or+familiarized+with+the+testing+apparatus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of flunitrazepam on passive avoidance behavior in mice subjected to immobilization stress or familiarized with the testing apparatus</span></div><div class="casAuthors">Castellano, Claudio; Pavone, Flaminia</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-5</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    </div><div class="casAbstract">The effects of flunitrazepam  [1622-62-4] on passive avoidance behavior were investigated in DBA/2 mice.  In a first set of expts. retention performance impairment was obsd. in mice injected with the drug immediately but not 120 min after training.  In a second set of expts., immobilization stress enhanced, while familiarization with the app. decreased, the effects of flunitrazepam, suggesting involvement of emotional factors.  All the effects obsd. were antagonized by naltrexone, showing involvement of opioid receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3q4maGK6_7LVg90H21EOLACvtfcHk0ljG80AKVPfauw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXht1OrsA%253D%253D&md5=231f3c4d3a7371bf2770b3315932ed3e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2F0166-4328%2886%2990084-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0166-4328%252886%252990084-7%26sid%3Dliteratum%253Aachs%26aulast%3DCastellano%26aufirst%3DC.%26aulast%3DPavone%26aufirst%3DF.%26atitle%3DEffects%2520of%2520flunitrazepam%2520on%2520passive%2520avoidance%2520behaviour%2520in%2520mice%2520subjected%2520to%2520immobilization%2520stress%2520or%2520familiarized%2520with%2520the%2520testing%2520apparatus%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D1986%26volume%3D22%26issue%3D1%26spage%3D91%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Bowers, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehner, J. M.</span><span> </span><span class="NLM_article-title">Differential sensitivity to the anxiolytic effects of ethanol and flunitrazepam in PKCgamma null mutant mice</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_year" style="font-weight: bold;">2001</span> <span class="NLM_volume">69</span> <span class="NLM_fpage">99</span> <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2FS0091-3057%2801%2900510-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=11420074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksVGrt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2001&pages=99-110&author=B.+J.+Bowersauthor=K.+J.+Elliottauthor=J.+M.+Wehner&title=Differential+sensitivity+to+the+anxiolytic+effects+of+ethanol+and+flunitrazepam+in+PKCgamma+null+mutant+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Differential sensitivity to the anxiolytic effects of ethanol and flunitrazepam in PKCÎ³ null mutant mice</span></div><div class="casAuthors">Bowers, B. J.; Elliott, K. J.; Wehner, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">99-110</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Tests of ethanol effects in PKCÎ³ null mutant mice have indicated that PKCÎ³ plays a role in initial sensitivity to ethanol-induced sedation, hypothermia, and GABAA receptor function and impacts neurochem. pathways mediating anxiety.  The present study was undertaken to evaluate whether the decreased sensitivity to ethanol previously obsd. in these mice generalized to the anxiolytic effects of ethanol.  PKCÎ³ null mutant mice and wild-type controls were tested in the elevated-plus maze, the black/white box, and the mirrored chamber after ethanol (0, 1.0, 1.25, 1.5 g/kg) or flunitrazepam (FNZ) (0, 0.015, 0.03, 0.06 mg/kg).  Results indicated that although both genotypes exhibited anxiolytic responses to ethanol in the elevated plus-maze, null mutant mice were less sensitive than wild-type control mice; however, in the black/white box, PKCÎ³ null mutants were more sensitive than controls to the anxiolytic effects of FNZ.  Neither ethanol nor FNZ produced anxiolytic responses in the mirrored chamber for either genotype.  These results suggest that PKCÎ³ differentially mediates anxiolytic responses to ethanol and FNZ and that this relationship interacts with each drug's efficacy in reducing anxiety-related behaviors specific to each of the three mazes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFJN8VYuiJxbVg90H21EOLACvtfcHk0lhwtaWFFh6Nyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksVGrt7k%253D&md5=bb8dbb9744d508bd9299c873d3093ccc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2801%2900510-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252801%252900510-X%26sid%3Dliteratum%253Aachs%26aulast%3DBowers%26aufirst%3DB.%2BJ.%26aulast%3DElliott%26aufirst%3DK.%2BJ.%26aulast%3DWehner%26aufirst%3DJ.%2BM.%26atitle%3DDifferential%2520sensitivity%2520to%2520the%2520anxiolytic%2520effects%2520of%2520ethanol%2520and%2520flunitrazepam%2520in%2520PKCgamma%2520null%2520mutant%2520mice%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2001%26volume%3D69%26spage%3D99%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">SaviÄ, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ObradoviÄ, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">UgresiÄ, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Linn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BokonjiÄ, D. R.</span><span> </span><span class="NLM_article-title">Benzodiazepine site inverse agonists and locomotor activity in rats: bimodal and biphasic influence</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_year" style="font-weight: bold;">2006</span> <span class="NLM_volume">84</span><span class="NLM_issue">1</span> <span class="NLM_fpage">35</span> <span class="NLM_lpage">42</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2Fj.pbb.2006.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16725185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmslyku7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2006&pages=35-42&issue=1&author=M.+M.+Savi%C4%87author=D.+I.+Obradovi%C4%87author=N.+D.+Ugresi%C4%87author=J.+M.+Cookauthor=W.+Yinauthor=M.+Van+Linnauthor=D.+R.+Bokonji%C4%87&title=Benzodiazepine+site+inverse+agonists+and+locomotor+activity+in+rats%3A+bimodal+and+biphasic+influence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Benzodiazepine site inverse agonists and locomotor activity in rats: Bimodal and biphasic influence</span></div><div class="casAuthors">Savic, Miroslav M.; Obradovic, Dragan I.; Ugresic, Nenad D.; Cook, James M.; Yin, Wenyuan; Van Linn, Michael; Bokonjic, Dubravko R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-42</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Benzodiazepine site inverse agonists may increase or decrease locomotor activity in rodents, depending on the exptl. settings.  We have compared the behavioral responses to environmental novelty of rats treated with the non-selective inverse agonist DMCM (2 mg/kg) and the Î±1-subunit affinity-selective inverse agonist 3-EBC (15 mg/kg).  The behavior in spontaneous locomotor assay (during 45 min) and elevated plus maze (EPM) was automatically recorded.  In the EPM, general activity-related parameters were similarly decreased, whereas only DMCM inhibited open-arm activity.  In the locomotor assay, both compds. depressed locomotion in the first 15 min and activity in the central zone of the chamber.  However, the influence of 3-EBC was less pronounced.  The Î±1-subunit selective antagonist Î²-CCt (15 mg/kg) attenuated locomotor depression, but not the central-zone avoidance elicited by DMCM.  When habituated to the chamber, DMCM-treated animals emitted a plateau phase of activity, which disappeared by adding Î²-CCt.  Hence, inhibition of activity in exposed areas may be mediated by non-Î±1-subunits, whereas both Î±1 and non-Î±1-subunits may participate in suppression of activity in more protective areas of an app.  Hyperlocomotion in habituated animals may depend primarily on the Î±1-subunit.  Moreover, the bimodal influence of inverse agonists on locomotion can be biphasic, observable in the same expt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7v3lQdNdCc7Vg90H21EOLACvtfcHk0lhwtaWFFh6Nyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmslyku7k%253D&md5=0693b25f56d798a92d78c02a8ac0cbba</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2006.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2006.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%25C4%2587%26aufirst%3DM.%2BM.%26aulast%3DObradovi%25C4%2587%26aufirst%3DD.%2BI.%26aulast%3DUgresi%25C4%2587%26aufirst%3DN.%2BD.%26aulast%3DCook%26aufirst%3DJ.%2BM.%26aulast%3DYin%26aufirst%3DW.%26aulast%3DVan%2BLinn%26aufirst%3DM.%26aulast%3DBokonji%25C4%2587%26aufirst%3DD.%2BR.%26atitle%3DBenzodiazepine%2520site%2520inverse%2520agonists%2520and%2520locomotor%2520activity%2520in%2520rats%253A%2520bimodal%2520and%2520biphasic%2520influence%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2006%26volume%3D84%26issue%3D1%26spage%3D35%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">DeLorey, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBrady, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lameh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loew, G. H.</span><span> </span><span class="NLM_article-title">Influence of benzodiazepine binding site ligands on fear-conditioned contextual memory</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_year" style="font-weight: bold;">2001</span> <span class="NLM_volume">426</span><span class="NLM_issue">1â2</span> <span class="NLM_fpage">45</span> <span class="NLM_lpage">54</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2FS0014-2999%2801%2901199-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=11525770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmt1Kkurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2001&pages=45-54&issue=1%E2%88%922&author=T.+M.+DeLoreyauthor=R.+C.+Linauthor=B.+McBradyauthor=X.+Heauthor=J.+M.+Cookauthor=J.+Lamehauthor=G.+H.+Loew&title=Influence+of+benzodiazepine+binding+site+ligands+on+fear-conditioned+contextual+memory"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of benzodiazepine binding site ligands on fear-conditioned contextual memory</span></div><div class="casAuthors">DeLorey, T. M.; Lin, R. C.; McBrady, B.; He, X.; Cook, J. M.; Lameh, J.; Loew, G. H.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">45-54</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Eight compds. that bind to the benzodiazepine binding site on the Î³-amino butyric acidA (GABAA) receptor were assessed for their influence on contextual memory, an aspect of memory affected in various cognitive disorders including Alzheimer's disease.  Using a Pavlovian fear-conditioning paradigm, each ligand was evaluated in C57Bl/6 mice in regards to its direct affect on contextual memory and whether the ligand could attenuate scopolamine-induced contextual memory impairment.  Of the eight ligands tested, one impaired contextual memory (agonist), six attenuated scopolamine-induced contextual memory impairment (inverse agonists), and one antagonized the ability of an inverse agonist to attenuate scopolamine-induced contextual memory impairment.  Hence, further demonstrating the bi-directional influence benzodiazepine binding site ligands are able to exert on memory modulation.  This study serves as an initial starting point in the development of pharmacol. tools to be used in deciphering how GABAA receptors influence contextual memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLUexfDv6LGbVg90H21EOLACvtfcHk0lj6MO9kBQnFJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmt1Kkurs%253D&md5=a7c610a75448d5fe99a280cbfaeb4082</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2801%2901199-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252801%252901199-2%26sid%3Dliteratum%253Aachs%26aulast%3DDeLorey%26aufirst%3DT.%2BM.%26aulast%3DLin%26aufirst%3DR.%2BC.%26aulast%3DMcBrady%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DCook%26aufirst%3DJ.%2BM.%26aulast%3DLameh%26aufirst%3DJ.%26aulast%3DLoew%26aufirst%3DG.%2BH.%26atitle%3DInfluence%2520of%2520benzodiazepine%2520binding%2520site%2520ligands%2520on%2520fear-conditioned%2520contextual%2520memory%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D426%26issue%3D1%25E2%2588%25922%26spage%3D45%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Blanchard, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griebel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, R. J.</span><span> </span><span class="NLM_article-title">The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_year" style="font-weight: bold;">2003</span> <span class="NLM_volume">463</span><span class="NLM_issue">1â3</span> <span class="NLM_fpage">97</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2FS0014-2999%2803%2901276-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=12600704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsVanu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2003&pages=97-116&issue=1%E2%88%923&author=D.+C.+Blanchardauthor=G.+Griebelauthor=R.+J.+Blanchard&title=The+mouse+defense+test+battery%3A+pharmacological+and+behavioral+assays+for+anxiety+and+panic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic</span></div><div class="casAuthors">Blanchard, D. Caroline; Griebel, Guy; Blanchard, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">97-116</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review. The Mouse Defense Test Battery was developed from tests of defensive behaviors in rats, reflecting earlier studies of both acute and chronic responses of lab. and wild rodents to threatening stimuli and situations.  It measures flight, freezing, defensive threat and attack, and risk assessment in response to an unconditioned predator stimulus, as well as pretest activity and post-threat (conditioned) defensiveness to the test context.  Factor analyses of these indicate four factors relating to cognitive and emotional aspects of defense, flight, and defensiveness to the test context.  In the Mouse Defense Test Battery, GABAA-benzodiazepine anxiolytics produce consistent redns. in defensive threat/attack and risk assessment, while panicolytic and panicogenic drugs selectively reduce and enhance, resp., flight.  Effects of GABAA-benzodiazepine, serotonin, and neuropeptide ligands in the Mouse Defense Test Battery are reviewed.  This review suggests that the Mouse Defense Test Battery is a sensitive and appropriate tool for preclin. evaluation of drugs potentially effective against defense-related disorders such as anxiety and panic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb5XWnQLrZsbVg90H21EOLACvtfcHk0lj6MO9kBQnFJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsVanu7k%253D&md5=27c3f278e68b3cecaada05cf107ee1bd</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2803%2901276-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252803%252901276-7%26sid%3Dliteratum%253Aachs%26aulast%3DBlanchard%26aufirst%3DD.%2BC.%26aulast%3DGriebel%26aufirst%3DG.%26aulast%3DBlanchard%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520mouse%2520defense%2520test%2520battery%253A%2520pharmacological%2520and%2520behavioral%2520assays%2520for%2520anxiety%2520and%2520panic%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D463%26issue%3D1%25E2%2588%25923%26spage%3D97%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Guscott, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, L. J.</span><span> </span><span class="NLM_article-title">Contextual fear conditioning and baseline startle responses in the rat fear-potentiated startle test: a comparison of benzodiazepine/gamma-aminobutyric acid-A receptor agonists</span> <span class="citation_source-journal">Behav. Pharmacol.</span><span class="NLM_year" style="font-weight: bold;">2000</span> <span class="NLM_volume">11</span><span class="NLM_issue">6</span> <span class="NLM_fpage">495</span> <span class="NLM_lpage">504</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=11103915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1Ohurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2000&pages=495-504&issue=6&author=M.+R.+Guscottauthor=G.+P.+Cookauthor=L.+J.+Bristow&title=Contextual+fear+conditioning+and+baseline+startle+responses+in+the+rat+fear-potentiated+startle+test%3A+a+comparison+of+benzodiazepine%2Fgamma-aminobutyric+acid-A+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Contextual fear conditioning and baseline startle responses in the rat fear-potentiated startle test: a comparison of benzodiazepine/Î³-aminobutyric acid-A receptor agonists</span></div><div class="casAuthors">Guscott, M. R.; Cook, G. P.; Bristow, L. J.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">495-504</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">In the rat, fear-potentiated startle (FPS) test animals are first trained to assoc. brief light presentations with a mild elec. footshock and then tested for startle responses to acoustic stimuli, delivered either in darkness (i.e., basal startle) or after the conditioning stimulus.  Following light presentation the magnitude of the startle response is markedly increased, and the test is commonly used to distinguish anxiolytic drug effects (i.e., a redn. in FPS) from nonspecific effects such as sedation/muscle relaxation.  However, recent studies suggest that the environment in which the animal is trained may also contribute towards the acquisition of a conditioned fear response (i.e., contextual fear conditioning) and that this may elevate startle responses recorded in the dark.  The present study, therefore, compared the benzodiazepine/GABAA receptor agonist chlordiazepoxide with the partial agonists FG 8205 and bretazenil, which are known to have a reduced propensity to produce sedation/myorelaxation;, the study used two different FPS procedures: (i) conditioning and testing in stabilimeter chambers, and (ii) conditioning and testing in different environments.  FPS could be demonstrated in both procedures, and treatment with chlordiazepoxide, FG 8205 or bretazenil dose-dependently attenuated the response.  However, animals conditioned and tested in stabilimeter chambers also showed a significant increase in dark-startle amplitudes compared with nonshocked rats, suggesting that this response was elevated by contextual fear conditioning.  Furthermore, despite clear differences in side-effect liabilities, FG 8205 and bretazenil reduced dark-startle responses, suggesting that this measure is also sensitive to the anxiolytic effects of benzodiazepines.  In contrast, when animals were conditioned and tested in different environments, dark-startle responses were not significantly different from those in nonshocked rats, and treatment with FG 8205 or bretazenil had no effect.  Thus, conditioning and testing animals in different environments may provide a more effective means of distinguishing anxiolytic from nonspecific drug effects in the rat FPS test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIIXsvzvcLBbVg90H21EOLACvtfcHk0liWxZ0WRrhd2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1Ohurk%253D&md5=43a0c04dc1b5a46869c740db3261068f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuscott%26aufirst%3DM.%2BR.%26aulast%3DCook%26aufirst%3DG.%2BP.%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26atitle%3DContextual%2520fear%2520conditioning%2520and%2520baseline%2520startle%2520responses%2520in%2520the%2520rat%2520fear-potentiated%2520startle%2520test%253A%2520a%2520comparison%2520of%2520benzodiazepine%252Fgamma-aminobutyric%2520acid-A%2520receptor%2520agonists%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2000%26volume%3D11%26issue%3D6%26spage%3D495%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Brignell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, H. V.</span><span> </span><span class="NLM_article-title">Drugs, sweat, and fears: a comparison of the effects of diazepam and methylphenidate on fear conditioning</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_year" style="font-weight: bold;">2006</span> <span class="NLM_volume">186</span><span class="NLM_issue">4</span> <span class="NLM_fpage">504</span> <span class="NLM_lpage">516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2006&pages=504-516&issue=4&author=C.+M.+Brignellauthor=H.+V.+Curran&title=Drugs%2C+sweat%2C+and+fears%3A+a+comparison+of+the+effects+of+diazepam+and+methylphenidate+on+fear+conditioning"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrignell%26aufirst%3DC.%2BM.%26aulast%3DCurran%26aufirst%3DH.%2BV.%26atitle%3DDrugs%252C%2520sweat%252C%2520and%2520fears%253A%2520a%2520comparison%2520of%2520the%2520effects%2520of%2520diazepam%2520and%2520methylphenidate%2520on%2520fear%2520conditioning%26jtitle%3DPsychopharmacology%26date%3D2006%26volume%3D186%26issue%3D4%26spage%3D504%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Fendt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanselow, M. S.</span><span> </span><span class="NLM_article-title">The neuroanatomical and neurochemical basis of conditioned fear</span> <span class="citation_source-journal">Neurosci. Behav. Rev.</span><span class="NLM_year" style="font-weight: bold;">1999</span> <span class="NLM_volume">23</span><span class="NLM_issue">5</span> <span class="NLM_fpage">743</span> <span class="NLM_lpage">760</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=10392663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A280%3ADyaK1MzhvFygtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1999&pages=743-760&issue=5&author=M.+Fendtauthor=M.+S.+Fanselow&title=The+neuroanatomical+and+neurochemical+basis+of+conditioned+fear"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The neuroanatomical and neurochemical basis of conditioned fear</span></div><div class="casAuthors">Fendt M; Fanselow M S</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience and biobehavioral reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">743-60</span>
        ISSN:<span class="NLM_cas:issn">0149-7634</span>.
    </div><div class="casAbstract">After a few pairings of a threatening stimulus with a formerly neutral cue, animals and humans will experience a state of conditioned fear when only the cue is present.  Conditioned fear provides a critical survival-related function in the face of threat by activating a range of protective behaviors.  The present review summarizes and compares the results of different laboratories investigating the neuroanatomical and neurochemical basis of conditioned fear, focusing primarily on the behavioral models of freezing and fear-potentiated startle in rats.  On the basis of these studies, we describe the pathways mediating and modulating fear.  We identify several key unanswered questions and discuss possible implications for the understanding of human anxiety disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmLJwxXXyjLF1C8OJBvdfbfW6udTcc2ebFqzah3T34s7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1MzhvFygtg%253D%253D&md5=cba45817b3372e5a74ca99a2203e85f4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFendt%26aufirst%3DM.%26aulast%3DFanselow%26aufirst%3DM.%2BS.%26atitle%3DThe%2520neuroanatomical%2520and%2520neurochemical%2520basis%2520of%2520conditioned%2520fear%26jtitle%3DNeurosci.%2520Behav.%2520Rev.%26date%3D1999%26volume%3D23%26issue%3D5%26spage%3D743%26epage%3D760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Harris, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, R. F.</span><span> </span><span class="NLM_article-title">Contextual control over the expression of fear in rats conditioned under a benzodiazepine</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_year" style="font-weight: bold;">2001</span> <span class="NLM_volume">156</span> <span class="NLM_fpage">92</span> <span class="NLM_lpage">97</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2001&pages=92-97&author=J.+A.+Harrisauthor=R.+F.+Westbrook&title=Contextual+control+over+the+expression+of+fear+in+rats+conditioned+under+a+benzodiazepine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DJ.%2BA.%26aulast%3DWestbrook%26aufirst%3DR.%2BF.%26atitle%3DContextual%2520control%2520over%2520the%2520expression%2520of%2520fear%2520in%2520rats%2520conditioned%2520under%2520a%2520benzodiazepine%26jtitle%3DPsychopharmacology%26date%3D2001%26volume%3D156%26spage%3D92%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Harris, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, R. F.</span><span> </span><span class="NLM_article-title">The benzodiazepine midazolam does not impair Pavlovian fear conditioning but regulates when and where that fear is expressed</span> <span class="citation_source-journal">J. Exp. Psychol. Anim. Behav. Process</span><span class="NLM_year" style="font-weight: bold;">1999</span> <span class="NLM_volume">25</span> <span class="NLM_fpage">236</span> <span class="NLM_lpage">246</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1037%2F0097-7403.25.2.236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=10331922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A280%3ADyaK1M3mtVOruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1999&pages=236-246&author=J.+A.+Harrisauthor=R.+F.+Westbrook&title=The+benzodiazepine+midazolam+does+not+impair+Pavlovian+fear+conditioning+but+regulates+when+and+where+that+fear+is+expressed"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The benzodiazepine midazolam does not impair Pavlovian fear conditioning but regulates when and where fear is expressed</span></div><div class="casAuthors">Harris J A; Westbrook R F</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental psychology. Animal behavior processes</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-46</span>
        ISSN:<span class="NLM_cas:issn">0097-7403</span>.
    </div><div class="casAbstract">Rats were injected with a benzodiazepine (midazolam) and shocked after presentation of an auditory conditioned stimulus (CS).  They were then tested for fear reactions (freezing) to the CS in either the original context or a 2nd context after either a short (1-day) or long (21-day) retention interval.  Rats tested in the original context froze less after 1 day than rats tested after that interval in the 2nd context or rats tested after 21 days.  Moreover, rats tested after the long interval in the original context froze less than rats tested after that interval in the 2nd context.  Therefore, midazolam does not impair the acquisition of conditioned fear but regulates when and where that fear is expressed.  These effects of midazolam were interpreted as a contextually controlled deficit in the expression of conditioned fear that is similar to that associated with latent inhibition and extinction (M.  E.  Bouton, 1993).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS43YlxwWB0ve2qxNLjzXe8fW6udTcc2ebrJodI4yri97ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3mtVOruw%253D%253D&md5=876bbf7e3313c6c9622814644b917338</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1037%2F0097-7403.25.2.236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252F0097-7403.25.2.236%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DJ.%2BA.%26aulast%3DWestbrook%26aufirst%3DR.%2BF.%26atitle%3DThe%2520benzodiazepine%2520midazolam%2520does%2520not%2520impair%2520Pavlovian%2520fear%2520conditioning%2520but%2520regulates%2520when%2520and%2520where%2520that%2520fear%2520is%2520expressed%26jtitle%3DJ.%2520Exp.%2520Psychol.%2520Anim.%2520Behav.%2520Process%26date%3D1999%26volume%3D25%26spage%3D236%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xunqing Dong, Panpan Ma, Tao Zhang, Hitesh B. Jalani, Guigen Li, <span class="NLM_string-name hlFld-ContribAuthor">Hongjian Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Iridium-Catalyzed CâH Amination of Weinreb Amides: A Facile Pathway toward Anilines and Quinazolin-2,4-diones. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (20)
                                     , 13096-13107. <a href="https://doi.org/10.1021/acs.joc.0c01789" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01789</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01789%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DIridium-Catalyzed%252BC%2525E2%252580%252593H%252BAmination%252Bof%252BWeinreb%252BAmides%25253A%252BA%252BFacile%252BPathway%252Btoward%252BAnilines%252Band%252BQuinazolin-2%25252C4-diones%26aulast%3DDong%26aufirst%3DXunqing%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27072020%26date%3D02102020%26date%3D24092020%26volume%3D85%26issue%3D20%26spage%3D13096%26epage%3D13107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jennifer B.  Treweek</span>, <span class="hlFld-ContribAuthor ">Amanda J.  Roberts</span>, and <span class="hlFld-ContribAuthor ">Kim D.  Janda</span>. </span><span class="cited-content_cbyCitation_article-title">Superadditive Effects of Ethanol and Flunitrazepam: Implications of Using Immunopharmacotherapy as a Therapeutic. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2010,</strong> <em>7 </em>
                                    (6)
                                     , 2056-2068. <a href="https://doi.org/10.1021/mp900293a" title="DOI URL">https://doi.org/10.1021/mp900293a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/mp900293a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fmp900293a%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DSuperadditive%252BEffects%252Bof%252BEthanol%252Band%252BFlunitrazepam%25253A%252BImplications%252Bof%252BUsing%252BImmunopharmacotherapy%252Bas%252Ba%252BTherapeutic%26aulast%3DTreweek%26aufirst%3DJennifer%2BB.%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D2009%26date%3D2010%26date%3D24%252011%25202009%26date%3D17%252008%25202010%26date%3D13%252008%25202010%26date%3D17092010%26date%3D06122010%26date%3D17082010%26volume%3D7%26issue%3D6%26spage%3D2056%26epage%3D2068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jui-Kang  Tsai</span>, <span class="hlFld-ContribAuthor ">Chia-Nan  Yen</span>, <span class="hlFld-ContribAuthor ">Cheng-Sheng  Chen</span>, <span class="hlFld-ContribAuthor ">Tzung-Jeng  Hwang</span>, <span class="hlFld-ContribAuthor ">Shao-Tsu  Chen</span>, <span class="hlFld-ContribAuthor ">Tzu-Ting  Chen</span>, <span class="hlFld-ContribAuthor ">Chih-Hung  Ko</span>, <span class="hlFld-ContribAuthor ">Po-Wen  Su</span>, <span class="hlFld-ContribAuthor ">Yu-Ping  Chang</span>, <span class="hlFld-ContribAuthor ">Jin-Jia  Lin</span>, <span class="hlFld-ContribAuthor ">Cheng-Fang  Yen</span>. </span><span class="cited-content_cbyCitation_article-title">Prevalence and clinical correlates of flunitrazepam-related complex sleep behaviors. </span><span class="cited-content_cbyCitation_journal-name">Psychiatry and Clinical Neurosciences</span><span> <strong>2017,</strong> <em>71 </em>
                                    (3)
                                     , 198-203. <a href="https://doi.org/10.1111/pcn.12472" title="DOI URL">https://doi.org/10.1111/pcn.12472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/pcn.12472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fpcn.12472%26sid%3Dliteratum%253Aachs%26jtitle%3DPsychiatry%2520and%2520Clinical%2520Neurosciences%26atitle%3DPrevalence%252Band%252Bclinical%252Bcorrelates%252Bof%252Bflunitrazepam-related%252Bcomplex%252Bsleep%252Bbehaviors%26aulast%3DTsai%26aufirst%3DJui-Kang%26date%3D2017%26date%3D2016%26volume%3D71%26issue%3D3%26spage%3D198%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xia  Li</span>, <span class="hlFld-ContribAuthor ">Victoria B.  Risbrough</span>, <span class="hlFld-ContribAuthor ">Chelsea  Cates-Gatto</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Kaczanowska</span>, <span class="hlFld-ContribAuthor ">M.G.  Finn</span>, <span class="hlFld-ContribAuthor ">Amanda J.  Roberts</span>, <span class="hlFld-ContribAuthor ">Athina  Markou</span>. </span><span class="cited-content_cbyCitation_article-title">Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2013,</strong> <em>70 </em>, 156-167. <a href="https://doi.org/10.1016/j.neuropharm.2013.01.018" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2013.01.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2013.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2013.01.018%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DComparison%252Bof%252Bthe%252Beffects%252Bof%252Bthe%252BGABAB%252Breceptor%252Bpositive%252Bmodulator%252BBHF177%252Band%252Bthe%252BGABAB%252Breceptor%252Bagonist%252Bbaclofen%252Bon%252Banxiety-like%252Bbehavior%25252C%252Blearning%25252C%252Band%252Bmemory%252Bin%252Bmice%26aulast%3DLi%26aufirst%3DXia%26date%3D2013%26volume%3D70%26spage%3D156%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David A  Gorelick</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetic strategies for treatment of drug overdose and addiction. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2012,</strong> <em>4 </em>
                                    (2)
                                     , 227-243. <a href="https://doi.org/10.4155/fmc.11.190" title="DOI URL">https://doi.org/10.4155/fmc.11.190</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.11.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.11.190%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DPharmacokinetic%252Bstrategies%252Bfor%252Btreatment%252Bof%252Bdrug%252Boverdose%252Band%252Baddiction%26aulast%3DGorelick%26aufirst%3DDavid%2BA%26date%3D2012%26volume%3D4%26issue%3D2%26spage%3D227%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0002.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design and preparation of flunitrazepam hapten RCA: (A) molecular structure of flunitrazepam; (B) synthesis of hapten RCA. Reagents and conditions are as follows: (i) <i>N</i>,<i>O</i>-dimethylhydroxylamine, EtOH; (ii) <sup><i>n</i></sup>BuLi, 2-fluorobromobenzene, â100 Â°C, THF, then HCl; (iii) Boc-Glu-(O<i>t</i>Bu)-OH, HATU, DIEA, 75 Â°C, 1,2-dichloroethane; (iv) TFA/CH<sub>2</sub>Cl<sub>2</sub>, then pyridine, 75 Â°C; (v) NaH, 0 Â°C, THF, then CH<sub>3</sub>I; (vi) KNO<sub>3</sub>, fuming H<sub>2</sub>SO<sub>4</sub>, room temp, then ice-cold DCM/water; (vii) <i>tert</i>-butyl aminobutyrate hydrochloride, PyBOP, DIEA, DCM, then TFA/CH<sub>2</sub>Cl<sub>2</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Flunitrazepam dose dependent impairment on rotarod performance. Approximately 20 min before testing, mouse groups received an ip injection of 0.03, 0.06, or 0.09 mg/kg flunitrazepam dissolved in 0.5% Tween-80 in isotonic saline, or an equivalent volume of 0.5% Tween-80 in isotonic saline. Values are expressed as the mean Â± SEM of three balance attempts on the test day, with the speed of the rotating rod at fall for each attempt normalized to the subjectâs average peak performance during rotarod training.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of flunitrazepam intoxication and immunization with mAb RCA3A3 (RF, RS groups) on rotarod performance. Flunitrazepam (VF, RF; black bars) or 0.5% Tween-80 in isotonic saline (VS, RS; gray bars) ip injections were given 20 min prior to rotarod testing. Bars indicate the group mean Â± SEM for all rotarod balance trials on the day of drug administration. Individual subject data were calculated by normalizing the speed of the rotating rod upon the subjectâs fall for all balance attempts on the test day to the average peak performance (e.g., mean speed upon fall) of that subject from the last training day. A repeated measures ANOVA was used to evaluate the statistical significance of rotarod impairment in VF mice compared VS, RS, and RF mice: (â) <i>p</i> < 0.05; (â ) <i>p</i> = 0.058.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Flunitrazepam-induced sedation as depicted by locomotor activity response. Mice were passively immunized (iv) with mAb RCA3A3 (dashed line) or vehicle isotonic saline solution (solid line) 3 days before ip injection of flunitrazepam ((â¼) VF, (â) RF) or 0.5% Tween-80 in isotonic saline ((â») VS, (â) RS). Data, which reflect locomotor activity monitoring for 15 min following ip injection, are expressed as the group mean Â± SEM of activity counts (photobeam breaks) summated across 3 min intervals for each mouse. Statistical significance is shown for the third through fifth time intervals: (â) <i>p</i> < 0.05 and (ââ) <i>p</i> < 0.01 for comparison of VF and VS mice; (â ) <i>p</i> < 0.05 for comparison of VF and RF mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Fear behavior resulting from contextual conditioning in vehicle (left) and RCA3A3-immunized (right) mice. Gray bars depict ip injection of vehicle (0.5% Tween-80 in isotonic saline; VS, VF), and black bars indicate ip injection of flunitrazepam (dissolved in 0.5% Tween-80 in isotonic saline; VF, RF). Mice were fear conditioned to the cage context 20 min after ip injection and then tested for their contextual fear memory 24 h later. A decrease in freezing behavior reflects a disruption of fear memory consolidation. Data for time spent freezing over the entire context test session are presented as the mean Â± SEM. Statistical significance, as calculated using the unpaired Studentâs <i>t</i> test, compares the freezing behavior of the VF group to that of VS, RS, and RF groups: (ââ) <i>p</i> < 0.01; (âââ) <i>p</i> < 0.005; (â ) <i>p</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/medium/jm-2008-00506v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Freezing response to the cued stimulus in the CS+ test. Vehicle (VS, VF) and immunized (RS, RF) mice were evaluated for their cued fear memory 48 h after ip injection (VF, RF, flunitrazepam, black bars; VS, RS, vehicle, gray bars) and fear conditioning. All mice spent minimal time freezing before presentation of the tone (A), which indicates that the cage was adequately disguised to mask any contextual cues. Upon exposure to the cued stimulus (tone) during the second time interval (B), VS, RS, and RF mice showed significant increases in freezing behavior while VF mice display less freezing compared to control levels. Data are expressed as the mean Â± SEM of time spent freezing within either interval (A or B) of the CS+ test, and statistical significance represents results from the unpaired Studentâs <i>t</i> test comparing VF group data to VS, RS, and RF group data: (â) <i>p</i> < 0.05; (ââ) <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2008/jmcmar.2008.51.issue-21/jm800506v/production/images/large/jm-2008-00506v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm800506v&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23887" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23887" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 44 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Meijler, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirsching, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Development of immunopharmacotherapy against drugs of abuse</span> <span class="citation_source-journal">Curr. Drug Discovery Technol.</span><span class="NLM_year" style="font-weight: bold;">2004</span> <span class="NLM_volume">1</span><span class="NLM_issue">1</span> <span class="NLM_fpage">77</span> <span class="NLM_lpage">89</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.2174%2F1570163043484851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16472221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVKjuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=77-89&issue=1&author=M.+M.+Meijlerauthor=M.+Matsushitaauthor=P.+Wirschingauthor=K.+D.+Janda&title=Development+of+immunopharmacotherapy+against+drugs+of+abuse"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Development of immunopharmacotherapy against drugs of abuse</span></div><div class="casAuthors">Meijler, Michael M.; Matsushita, Masayuki; Wirsching, Peter; Janda, Kim D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Discovery Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-89</span>CODEN:
                <span class="NLM_cas:coden">CDDTAF</span>;
        ISSN:<span class="NLM_cas:issn">1570-1638</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug addiction is a major worldwide medical and social problem that continues to escalate.  The addiction syndrome is remarkably similar between different drugs of abuse, and can be characterized as a chronic relapsing brain disorder with neurobiol. changes that lead to a compulsion to take a drug with loss of control over drug intake.  Presently used medications for the treatment of dependence disorders are based on drugs that are either agonists or antagonists of drugs of abuse, and have yielded only limited success.  Immunopharmacotherapy is based on the generation or administration of antibodies that are capable of binding the targeted drug before it can reach the brain, whereas replacement strategies based on agonists or antagonists of these drugs generally cause many undesired side effects.  A large amt. of data has been gathered in recent years on the effects of active and passive immunization against cocaine, nicotine, PCP and methamphetamine in animal models, suggesting potential efficacy of these treatments in humans; and clin. trials are currently underway for vaccines against cocaine and nicotine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqebJXLnhegrLVg90H21EOLACvtfcHk0li3YGIk5S25wQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVKjuro%253D&md5=cc97cd7866258e9ce5345eff69788a17</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F1570163043484851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570163043484851%26sid%3Dliteratum%253Aachs%26aulast%3DMeijler%26aufirst%3DM.%2BM.%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DWirsching%26aufirst%3DP.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DDevelopment%2520of%2520immunopharmacotherapy%2520against%2520drugs%2520of%2520abuse%26jtitle%3DCurr.%2520Drug%2520Discovery%2520Technol.%26date%3D2004%26volume%3D1%26issue%3D1%26spage%3D77%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Kosten, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, S. M.</span><span> </span><span class="NLM_article-title">Immunotherapy for the treatment of drug abuse</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_year" style="font-weight: bold;">2005</span> <span class="NLM_volume">108</span><span class="NLM_issue">1</span> <span class="NLM_fpage">76</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2Fj.pharmthera.2005.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16023218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVartr3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2005&pages=76-85&issue=1&author=T.+Kostenauthor=S.+M.+Owens&title=Immunotherapy+for+the+treatment+of+drug+abuse"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy for the treatment of drug abuse</span></div><div class="casAuthors">Kosten, Thomas; Owens, S. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-85</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Antibody therapy (as either active or passive immunization) is designed primarily to prevent drugs of abuse from entering the central nervous system (CNS).  Antidrug antibodies reduce rush, euphoria, and drug distribution to the brain at doses that exceed the apparent binding capacity of the antibody.  This is accomplished through a pharmacokinetic antagonism, which reduces the amt. of drug in the brain, the rate of clearance across the blood-brain barrier, and the vol. of drug distribution.  Because the antibodies remain primarily in the circulatory system, they have no apparent central nervous system side effects.  Active immunization with drug-protein conjugate vaccines has been tested for cocaine, heroin, methamphetamine, and nicotine in animal, with 1 cocaine and 3 nicotine vaccines in Phase 2 human trials.  Passive immunization with high affinity monoclonal antibodies has been tested for cocaine, methamphetamine, nicotine, and phencyclidine (PCP) in preclin. animal models.  Antibodies have 2 immediate clin. applications in drug abuse treatment: to treat drug overdose and to reduce relapse to drug use in addicted patients.  The specificity of the therapies, the lack of addiction liability, minimal side effects, and long-lasting protection against drug use offer major therapeutic benefit over conventional small mol. agonists and antagonists.  Immunotherapies can also be combined with other antiaddiction medications and enhance behavioral therapies.  Current immunotherapies already show efficacy, but improved antigen design and antibody engineering promise highly specific and rapidly developed treatments for both existing and future addictions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrzCobv3_CXbVg90H21EOLACvtfcHk0lgB44kDHHSqPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVartr3K&md5=3423b1e9cfe928ce5ecd9ede4632dfd2</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DKosten%26aufirst%3DT.%26aulast%3DOwens%26aufirst%3DS.%2BM.%26atitle%3DImmunotherapy%2520for%2520the%2520treatment%2520of%2520drug%2520abuse%26jtitle%3DPharmacol.%2520Ther.%26date%3D2005%26volume%3D108%26issue%3D1%26spage%3D76%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Pentel, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufek, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roiko, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesage, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keyler, D. E.</span><span> </span><span class="NLM_article-title">Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_year" style="font-weight: bold;">2006</span> <span class="NLM_volume">317</span><span class="NLM_issue">2</span> <span class="NLM_fpage">660</span> <span class="NLM_lpage">666</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1124%2Fjpet.105.097873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16407464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFamur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2006&pages=660-666&issue=2&author=P.+R.+Pentelauthor=M.+B.+Dufekauthor=S.+A.+Roikoauthor=M.+G.+Lesageauthor=D.+E.+Keyler&title=Differential+effects+of+passive+immunization+with+nicotine-specific+antibodies+on+the+acute+and+chronic+distribution+of+nicotine+to+brain+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats</span></div><div class="casAuthors">Pentel, P. R.; Dufek, M. B.; Roiko, S. A.; LeSage, M. G.; Keyler, D. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">660-666</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Vaccination against nicotine blocks or attenuates nicotine-related behaviors relevant to addiction in rats.  Passive immunization with nicotine-specific antibodies is an alternative to vaccination with the potential advantages of allowing control of antibody dose and affinity.  Here, the effects of 2 antibodies on the distribution of nicotine to brain were evaluated during chronic nicotine administration in rats; the monoclonal antibody Nic311 (Kd = 60 nM) and nicotine-specific antiserum (Kd = 1.6 nM).  Nicotine was administered via repeated i.v. bolus doses over 2 days and antibody was administered during the first day.  Neither antibody appreciably reduced the chronic accumulation of nicotine in brain, despite high protein binding of nicotine in serum (98.9%) and a 73% redn. in the unbound serum nicotine concn. with the highest Nic311 dose.  However, both antibodies substantially reduced the early distribution of nicotine to brain 5 min after a dose.  The higher affinity antibody was no more effective than Nic311.  The highest Nic311 dose produced serum antibody levels 10 times higher than those reported with vaccination.  The efficacy of Nic311 was dose-related, with the highest dose producing a 76% decrease in the early distribution of nicotine to brain.  These findings, along with previous data, suggest that the primary effect of passive immunization is to slow, rather than prevent, the distribution of nicotine to brain.  In the setting of chronic nicotine dosing, antibodies with a moderate affinity for nicotine produced substantial effects on the early distribution of nicotine to brain and were as effective as higher affinity antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnmMHR7aJ7cLVg90H21EOLACvtfcHk0lgB44kDHHSqPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFamur8%253D&md5=82178544c9a0347f5d64ffb2b5d5ee5d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.097873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.097873%26sid%3Dliteratum%253Aachs%26aulast%3DPentel%26aufirst%3DP.%2BR.%26aulast%3DDufek%26aufirst%3DM.%2BB.%26aulast%3DRoiko%26aufirst%3DS.%2BA.%26aulast%3DLesage%26aufirst%3DM.%2BG.%26aulast%3DKeyler%26aufirst%3DD.%2BE.%26atitle%3DDifferential%2520effects%2520of%2520passive%2520immunization%2520with%2520nicotine-specific%2520antibodies%2520on%2520the%2520acute%2520and%2520chronic%2520distribution%2520of%2520nicotine%2520to%2520brain%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D317%26issue%3D2%26spage%3D660%26epage%3D666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Utzinger, R.</span><span> </span><span class="NLM_article-title">Hapten-immunological studies on mescaline</span> <span class="citation_source-journal">Psychopharmacologia</span><span class="NLM_year" style="font-weight: bold;">1975</span> <span class="NLM_volume">41</span><span class="NLM_issue">3</span> <span class="NLM_fpage">301</span> <span class="NLM_lpage">304</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1007%2FBF00428941" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=807928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADyaE2MXhs1ykt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1975&pages=301-304&issue=3&author=R.+Utzinger&title=Hapten-immunological+studies+on+mescaline"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Hapten-immunological studies on mescaline</span></div><div class="casAuthors">Utzinger, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacologia</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-4</span>CODEN:
                <span class="NLM_cas:coden">PSYPAG</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">Antibodies with mescaline binding specificity were raised in rabbits by immunization with conjugates of bovine serum albumin with mescaline or its analog 3,4,5-trimethoxyphenylacetic acid.  Immunized rats were given mescaline and their behavior was compared with that of nonimmunized controls.  In immunized rats, the effects of mescaline (breathing frequency and crawling were milder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTqDUwUppdW7Vg90H21EOLACvtfcHk0lgB44kDHHSqPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXhs1ykt74%253D&md5=be7bee90f7340dc1e3455251b57bf7df</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2FBF00428941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00428941%26sid%3Dliteratum%253Aachs%26aulast%3DUtzinger%26aufirst%3DR.%26atitle%3DHapten-immunological%2520studies%2520on%2520mescaline%26jtitle%3DPsychopharmacologia%26date%3D1975%26volume%3D41%26issue%3D3%26spage%3D301%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Fox, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantak, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollinger, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botka, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schad, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenstein, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gefter, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Exley, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swain, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briner, T. J.</span><span> </span><span class="NLM_article-title">Efficacy of a therapeutic cocaine vaccine in rodent models</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_year" style="font-weight: bold;">1996</span> <span class="NLM_volume">2</span> <span class="NLM_fpage">1129</span> <span class="NLM_lpage">1132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1038%2Fnm1096-1129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=8837612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADyaK28Xmt1Wmsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=1129-1132&author=B.+S.+Foxauthor=K.+M.+Kantakauthor=M.+A.+Edwardsauthor=K.+M.+Blackauthor=B.+K.+Bollingerauthor=A.+J.+Botkaauthor=T.+L.+Frenchauthor=T.+L.+Thompsonauthor=V.+C.+Schadauthor=J.+L.+Greensteinauthor=M.+L.+Gefterauthor=M.+A.+Exleyauthor=P.+A.+Swainauthor=T.+J.+Briner&title=Efficacy+of+a+therapeutic+cocaine+vaccine+in+rodent+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a therapeutic cocaine vaccine in rodent models</span></div><div class="casAuthors">Fox, Barbara S.; Kantak, Kathleen M.; Edwards, Melissa A.; Black, Kerry M.; Bollinger, Brenda K.; Botka, Alison J.; French, Tammy L.; Thompson, Terry L.; Schad, Victoria C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1129-1132</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Cocaine abuse is a major medical and public health concern in the United States, with approx. 2.1 million people dependent on cocaine.  Pharmacol. approaches to the treatment of cocaine addiction have thus far been disappointing, and new therapies are urgently needed.  This paper describes an immunol. approach to cocaine addiction.  Antibody therapy for neutralization of abused drugs has been described previously, including a recent paper demonstrating the induction of anti-cocaine antibodies.  However, both the rapidity of entry of cocaine into the brain and the high doses of cocaine frequently encountered have created challenges for an antibody-based therapy.  Here the authors demonstrate that antibodies are efficacious in an animal model of addn.  I.v. cocaine self-administration in rats was inhibited by passive transfer of an anti-cocaine monoclonal antibody.  To actively induce anti-cocaine antibodies, a cocaine vaccine was developed that generated a high-titer, long-lasting antibody response in mice.  Immunized mice displayed a significant change in cocaine pharmacokinetics, with decreased levels of cocaine measured in the brain of immunized mice only 30 s after i.v. administration of cocaine.  These data establish the feasibility of a therapeutic cocaine vaccine for the treatment of cocaine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4daqGudoVAbVg90H21EOLACvtfcHk0ljsUEhbCRYSag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmt1Wmsr8%253D&md5=eab16288d4ed29af066f5c0d449092a4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnm1096-1129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1096-1129%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DB.%2BS.%26aulast%3DKantak%26aufirst%3DK.%2BM.%26aulast%3DEdwards%26aufirst%3DM.%2BA.%26aulast%3DBlack%26aufirst%3DK.%2BM.%26aulast%3DBollinger%26aufirst%3DB.%2BK.%26aulast%3DBotka%26aufirst%3DA.%2BJ.%26aulast%3DFrench%26aufirst%3DT.%2BL.%26aulast%3DThompson%26aufirst%3DT.%2BL.%26aulast%3DSchad%26aufirst%3DV.%2BC.%26aulast%3DGreenstein%26aufirst%3DJ.%2BL.%26aulast%3DGefter%26aufirst%3DM.%2BL.%26aulast%3DExley%26aufirst%3DM.%2BA.%26aulast%3DSwain%26aufirst%3DP.%2BA.%26aulast%3DBriner%26aufirst%3DT.%2BJ.%26atitle%3DEfficacy%2520of%2520a%2520therapeutic%2520cocaine%2520vaccine%2520in%2520rodent%2520models%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D1129%26epage%3D1132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Valentine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayersohn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessinger, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, S. M.</span><span> </span><span class="NLM_article-title">Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_year" style="font-weight: bold;">1996</span> <span class="NLM_volume">278</span><span class="NLM_issue">2</span> <span class="NLM_fpage">709</span> <span class="NLM_lpage">716</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=8768722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADyaK28XkvFKjt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=1996&pages=709-716&issue=2&author=J.+L.+Valentineauthor=M.+Mayersohnauthor=W.+D.+Wessingerauthor=L.+W.+Arnoldauthor=S.+M.+Owens&title=Antiphencyclidine+monoclonal+Fab+fragments+reverse+phencyclidine-induced+behavioral+effects+and+ataxia+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats</span></div><div class="casAuthors">Valentine, John L.; Mayersohn, Michael; Wessinger, William D.; Arnold, Larry W.; Owens, S. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">709-716</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Antiphencyclidine monoclonal antibody binding fragments (anti-PCP Fab) were studied in rats as a possible treatment for phencyclidine (PCP) overdose.  Each male Sprague-Dawley rat (n = 4 per group) received an i.v. dose of 1 mg/kg of PCP followed 5 min later (as toxicity maximized) by the one of three treatments in a random cross-over design.  The treatments were 1 mL of saline, a nonspecific polyclonal human FAb, or a high affinity (Kd - 1.8 nM) anti-PCP monoclonal Fab.  The doses of the nonspecific and anti-PCP Fab were 0.3, 1.0 and 3.0 times the mole equiv. (mol-eq) dose of PCP.  Changes in locomotor activity and ataxia were the best indicators of PCP-induced behaviors among several time-dependent behavioral changes that were evaluated.  PCP administration followed by saline treatment resulted in increases in locomotor activity and ataxia that declined to base line after 35 to 40 min.  Anti-PCP FAb at 1.0 and 3.0 times the mol-eq dose of PCP significantly (P < 0.5) and rapidly reversed PCP-induced behaviors to base-line values.  Although the 0.3 mol-eq dose of Fab appeared to slightly decrease the behavioral toxicity, the effects were not statistically different from controls in most cases.  No significant effects on PCP-induced behaviors were obsd. after any dose of nonspecific Fab.  In addn., pharmacol. and immunol. specificity were tested further by treatment of MK-801 {(+)-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine-}-induced behavioral effects.  MK-801 is a PCP-like, noncompetitive N-methyl-D-aspartate receptor antagonist which is structurally unrelated to PCP.  The anti-PCP Fab treatment had no effect on MK-801-induced locomotor activity.  These data clearly show that the anti-PCP FAb is a specific PCP antagonist that can rapidly reverse PCP-induced behavioral toxicity in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkvIqzC3hawbVg90H21EOLACvtfcHk0ljsUEhbCRYSag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XkvFKjt7o%253D&md5=ce6973d0c2f60ed1d2156caad2a276d6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DValentine%26aufirst%3DJ.%2BL.%26aulast%3DMayersohn%26aufirst%3DM.%26aulast%3DWessinger%26aufirst%3DW.%2BD.%26aulast%3DArnold%26aufirst%3DL.%2BW.%26aulast%3DOwens%26aufirst%3DS.%2BM.%26atitle%3DAntiphencyclidine%2520monoclonal%2520Fab%2520fragments%2520reverse%2520phencyclidine-induced%2520behavioral%2520effects%2520and%2520ataxia%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1996%26volume%3D278%26issue%3D2%26spage%3D709%26epage%3D716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Kantak, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipman, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovanoni, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, B. S.</span><span> </span><span class="NLM_article-title">Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_year" style="font-weight: bold;">2000</span> <span class="NLM_volume">148</span><span class="NLM_issue">3</span> <span class="NLM_fpage">251</span> <span class="NLM_lpage">262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2000&pages=251-262&issue=3&author=K.+M.+Kantakauthor=S.+L.+Collinsauthor=E.+G.+Lipmanauthor=J.+Bondauthor=K.+Giovanoniauthor=B.+S.+Fox&title=Evaluation+of+anti-cocaine+antibodies+and+a+cocaine+vaccine+in+a+rat+self-administration+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKantak%26aufirst%3DK.%2BM.%26aulast%3DCollins%26aufirst%3DS.%2BL.%26aulast%3DLipman%26aufirst%3DE.%2BG.%26aulast%3DBond%26aufirst%3DJ.%26aulast%3DGiovanoni%26aufirst%3DK.%26aulast%3DFox%26aufirst%3DB.%2BS.%26atitle%3DEvaluation%2520of%2520anti-cocaine%2520antibodies%2520and%2520a%2520cocaine%2520vaccine%2520in%2520a%2520rat%2520self-administration%2520model%26jtitle%3DPsychopharmacology%26date%3D2000%26volume%3D148%26issue%3D3%26spage%3D251%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hardin, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessinger, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenger, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proksch, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurenzana, E., M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, S. M.</span><span> </span><span class="NLM_article-title">A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_year" style="font-weight: bold;">2002</span> <span class="NLM_volume">302</span> <span class="NLM_fpage">119</span> <span class="NLM_lpage">126</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1124%2Fjpet.302.1.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=12065708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1Sgu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2002&pages=119-126&author=J.+S.+Hardinauthor=W.+D.+Wessingerauthor=G.+R.+Wengerauthor=J.+W.+Prokschauthor=E.%2C+M.+Laurenzanaauthor=S.+M.+Owens&title=A+single+dose+of+monoclonal+anti-phencyclidine+IgG+offers+long-term+reductions+in+phencyclidine+behavioral+effects+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats</span></div><div class="casAuthors">Hardin, J. Shane; Wessinger, William D.; Wenger, Galen R.; Proksch, Joel W.; Laurenzana, Elizabeth M.; Owens, S. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-126</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">These studies tested the hypothesis that a single dose of high-affinity anti-phencyclidine monoclonal antibody (anti-PCP mAb) provides long-term protection against behavioral effects of repeated PCP administration in rats.  Rats were treated with saline, nonspecific bovine IgG (NS-IgG), or anti-PCP mAb (1.0 g/kg).  The next morning, the rats were challenged with escalating i.v. doses of PCP (0.32, 0.56, and 1.0 mg/kg) at 90-min intervals.  This regimen was repeated every 3 days for 2 wk.  In the saline and NS-IgG control groups, PCP yielded reproducible and linear dose-dependent effects that remained const. during the expt.  In contrast, the anti-PCP mAb treatment blocked PCP effects on day 1, and sustained significant redns. in drug effects for the entire 2-wk expt.  Brain PCP concns. (detd. at study termination) were reduced by â¼55%, whereas serum concns. were increased over 4000% compared with controls.  Thus, a single dose of antibody medication provided long-term redns. in drug effects and brain concns., beyond the expected capacity of the drug-antibody interaction.  These data challenge current concepts about in vivo dose dependence and unimol. interaction between antibody binding sites and small mols. and establish that neuroprotection by mAbs may have an unique mechanism of action.  Because PCP is a prototype for drugs that have been difficult to treat due to complex actions at multiple sites within the brain, these studies may provide a new approach for treating a wide range of CNS acting drugs or chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv_5d1wtsHPbVg90H21EOLACvtfcHk0lglT0EUACBI-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1Sgu7s%253D&md5=8069f38dccaf07afecc4add7e5547817</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1124%2Fjpet.302.1.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.302.1.119%26sid%3Dliteratum%253Aachs%26aulast%3DHardin%26aufirst%3DJ.%2BS.%26aulast%3DWessinger%26aufirst%3DW.%2BD.%26aulast%3DWenger%26aufirst%3DG.%2BR.%26aulast%3DProksch%26aufirst%3DJ.%2BW.%26aulast%3DLaurenzana%26aufirst%3DE.%252C%2BM.%26aulast%3DOwens%26aufirst%3DS.%2BM.%26atitle%3DA%2520single%2520dose%2520of%2520monoclonal%2520anti-phencyclidine%2520IgG%2520offers%2520long-term%2520reductions%2520in%2520phencyclidine%2520behavioral%2520effects%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D302%26spage%3D119%26epage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gentry, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurenzana, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terlea, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, S. M.</span><span> </span><span class="NLM_article-title">Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_year" style="font-weight: bold;">2006</span> <span class="NLM_volume">6</span> <span class="NLM_fpage">968</span> <span class="NLM_lpage">977</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2Fj.intimp.2006.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16644483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvV2qtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=968-977&author=W.+B.+Gentryauthor=E.+M.+Laurenzanaauthor=D.+K.+Williamsauthor=J.+R.+Westauthor=R.+J.+Bergauthor=T.+Terleaauthor=S.+M.+Owens&title=Safety+and+efficiency+of+an+anti-%28%2B%29-methamphetamine+monoclonal+antibody+in+the+protection+against+cardiovascular+and+central+nervous+system+effects+of+%28%2B%29-methamphetamine+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats</span></div><div class="casAuthors">Gentry, W. Brooks; Laurenzana, Elizabeth M.; Williams, D. Keith; West, Jeremy R.; Berg, Renata J.; Terlea, Teodora; Owens, S. Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">968-977</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The purpose of these studies was to det. if a high-affinity, anti-(+)-methamphetamine (METH) monoclonal antibody (mAb6H4; K D = 11 nM) protects against METH-induced central nervous and cardiovascular system effects in rats.  Rats (n = 5 per group) received one of three anti-METH mAb6H4 doses, equal to 0.32, 0.56 or 1 times the mole equiv. (mol-eq) amt. of METH in the body following a 1 mg/kg iv METH dose.  Each rat was challenged with METH (1 mg/kg, iv) 1 and 4 days after the anti-METH mAb dose.  The 1 mol-eq anti-METH mAb dose significantly reduced the duration of METH-induced locomotor activity (horizontal locomotion and rearing events), heart rate and blood pressure effects from 2 to 3 h to about an hour.  This resulted in a significant redn. in total locomotor activity and the area under the hemodynamic effect vs. time curve for heart rate and blood pressure.  In addn., the time to peak locomotor activity was decreased after the 1 mol-eq mAb dose vs. the lower doses.  These changes were limited to the first METH challenge.  The responses to the second METH challenge were not different from baseline.  The peak hemodynamic and locomotor activity values were unchanged after both challenges.  These results indicate anti-METH mAb6H4 can safely reduce the hemodynamic and locomotor effects of METH given one day after anti-METH IgG, and that the mAb is safe when administered in the absence of METH.  These results are important because they indicate these antibody medications have simultaneous beneficial effects in multiple organ systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo81fIrakWfMbVg90H21EOLACvtfcHk0lglT0EUACBI-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvV2qtLo%253D&md5=fcf02027c48c7e871c3f8ffa69d8c141</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2006.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2006.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DGentry%26aufirst%3DW.%2BB.%26aulast%3DLaurenzana%26aufirst%3DE.%2BM.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DWest%26aufirst%3DJ.%2BR.%26aulast%3DBerg%26aufirst%3DR.%2BJ.%26aulast%3DTerlea%26aufirst%3DT.%26aulast%3DOwens%26aufirst%3DS.%2BM.%26atitle%3DSafety%2520and%2520efficiency%2520of%2520an%2520anti-%2528%252B%2529-methamphetamine%2520monoclonal%2520antibody%2520in%2520the%2520protection%2520against%2520cardiovascular%2520and%2520central%2520nervous%2520system%2520effects%2520of%2520%2528%252B%2529-methamphetamine%2520in%2520rats%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2006%26volume%3D6%26spage%3D968%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Carrera, M. R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trigo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirshing, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_year" style="font-weight: bold;">2005</span> <span class="NLM_volume">81</span> <span class="NLM_fpage">709</span> <span class="NLM_lpage">714</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2Fj.pbb.2005.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16005948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1Wrt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2005&pages=709-714&author=M.+R.+A.+Carreraauthor=J.+M.+Trigoauthor=P.+Wirshingauthor=A.+J.+Robertsauthor=K.+D.+Janda&title=Evaluation+of+the+anticocaine+monoclonal+antibody+GNC92H2+as+an+immunotherapy+for+cocaine+overdose"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose</span></div><div class="casAuthors">Carrera, M. Rocio A.; Trigo, Jose Manuel; Wirsching, Peter; Roberts, Amanda J.; Janda, Kim D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">709-714</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.  Current protein-based technol. offers a new therapeutic venue by which antibodies bind the drug in the blood stream, inactivating its toxic effects.  The therapeutic potential of the anticocaine antibody GNC92H2 was examd. using a model of cocaine overdose.  Swiss albino mice prepd. with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg.  GNC92H2 was delivered 30 min before, concomitantly or 3 min after cocaine treatment.  Significant blockade of cocaine toxicity was obsd. with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.  Importantly, GNC92H2 prevented death even post-cocaine injection.  The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIzIqClQiCRbVg90H21EOLACvtfcHk0ljWwObWnv2yIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1Wrt7k%253D&md5=59b8d1333b75c98a762fa2cb70f498f1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2005.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2005.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DCarrera%26aufirst%3DM.%2BR.%2BA.%26aulast%3DTrigo%26aufirst%3DJ.%2BM.%26aulast%3DWirshing%26aufirst%3DP.%26aulast%3DRoberts%26aufirst%3DA.%2BJ.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DEvaluation%2520of%2520the%2520anticocaine%2520monoclonal%2520antibody%2520GNC92H2%2520as%2520an%2520immunotherapy%2520for%2520cocaine%2520overdose%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2005%26volume%3D81%26spage%3D709%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Malin, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lake, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saldana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvin, M. L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keyler, D. E.</span><span> </span><span class="NLM_article-title">Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_year" style="font-weight: bold;">2001</span> <span class="NLM_volume">68</span><span class="NLM_issue">1</span> <span class="NLM_fpage">87</span> <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2FS0091-3057%2800%2900436-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=11274712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD3MXit1Sis7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2001&pages=87-92&issue=1&author=D.+H.+Malinauthor=J.+R.+Lakeauthor=A.+Linauthor=M.+Saldanaauthor=L.+Balchauthor=M.+L.+L.+Irvinauthor=H.+Chandrasekaraauthor=C.+L.+Alvaradoauthor=Y.+Hiedaauthor=D.+E.+Keyler&title=Passive+immunization+against+nicotine+prevents+nicotine+alleviation+of+nicotine+abstinence+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome</span></div><div class="casAuthors">Malin, D. H.; Lake, J. R.; Lin, A.; Saldana, M.; Balch, L.; Irvin, M. L. L.; Chandrasekara, H.; Alvarado, C. L.; Hieda, Y.; Keyler, D. E.; Pentel, P. R.; Ennifar, S.; Basham, L. E.; Naso, R.; Fattom, A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-92</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Passive immunization against nicotine interferes with its locomotor and pressor effects.  The current study detd. whether immunization could prevent another nicotine action: the reversal of nicotine abstinence syndrome.  IgG contg. 4.4-5.6% nicotine-specific antibody was isolated from rabbits immunized with 3'-amino-methyl-nicotine conjugated to a carrier protein.  Twenty rats were rendered dependent by 7 days of s.c. infusion of 3.15 mg/kg/day nicotine (expressed as the base).  Upon termination of nicotine infusion, each rat was injected i.p. with 150 mg of IgG from normal serum (n=13) or from nicotine antiserum (n=7).  Twenty-two and one-half hours later, all rats were obsd. over 15 min for baseline nicotine abstinence signs.  Two and one-half hours after baseline observations, seven of the 13 rats pretreated with control IgG and all seven rats pretreated with nicotine-specific IgG were then challenged by 0.12 mg/kg (s.c.) nicotine.  The remaining six rats pretreated with control IgG were challenged with saline alone.  All rats were then obsd. again for abstinence signs.  Nicotine injection caused significantly less redn. of abstinence signs in the immunized rats.  The nicotine effect in immunized rats was comparable to the saline effect in nonimmunized rats.  Immunization also significantly reduced free serum nicotine concn. and nicotine distribution to the brain.  These results raise the possibility that immunization might prevent nicotine consumption from relieving the discomforts of smoking cessation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyJdeu6txRYLVg90H21EOLACvtfcHk0ljWwObWnv2yIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXit1Sis7o%253D&md5=c1029cddbbb9c71066a67366d932a6d0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2800%2900436-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252800%252900436-6%26sid%3Dliteratum%253Aachs%26aulast%3DMalin%26aufirst%3DD.%2BH.%26aulast%3DLake%26aufirst%3DJ.%2BR.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DSaldana%26aufirst%3DM.%26aulast%3DBalch%26aufirst%3DL.%26aulast%3DIrvin%26aufirst%3DM.%2BL.%2BL.%26aulast%3DChandrasekara%26aufirst%3DH.%26aulast%3DAlvarado%26aufirst%3DC.%2BL.%26aulast%3DHieda%26aufirst%3DY.%26aulast%3DKeyler%26aufirst%3DD.%2BE.%26atitle%3DPassive%2520immunization%2520against%2520nicotine%2520prevents%2520nicotine%2520alleviation%2520of%2520nicotine%2520abstinence%2520syndrome%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2001%26volume%3D68%26issue%3D1%26spage%3D87%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Mattila, M. A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larni, H. M.</span><span> </span><span class="NLM_article-title">Flunitrazepam: a review of its pharmacological properties and therapeutic use</span> <span class="citation_source-journal">Drugs</span><span class="NLM_year" style="font-weight: bold;">1980</span> <span class="NLM_volume">20</span><span class="NLM_issue">5</span> <span class="NLM_fpage">353</span> <span class="NLM_lpage">374</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1980&pages=353-374&issue=5&author=M.+A.+K.+Mattilaauthor=H.+M.+Larni&title=Flunitrazepam%3A+a+review+of+its+pharmacological+properties+and+therapeutic+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMattila%26aufirst%3DM.%2BA.%2BK.%26aulast%3DLarni%26aufirst%3DH.%2BM.%26atitle%3DFlunitrazepam%253A%2520a%2520review%2520of%2520its%2520pharmacological%2520properties%2520and%2520therapeutic%2520use%26jtitle%3DDrugs%26date%3D1980%26volume%3D20%26issue%3D5%26spage%3D353%26epage%3D374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Berezhnoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyfeler, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonthier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwob, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goeldner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigel, E.</span><span> </span><span class="NLM_article-title">On the benzodiazepine binding pocket in GABAA receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_year" style="font-weight: bold;">2004</span> <span class="NLM_volume">279</span><span class="NLM_issue">5</span> <span class="NLM_fpage">3160</span> <span class="NLM_lpage">3168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=3160-3168&issue=5&author=D.+Berezhnoyauthor=Y.+Nyfelerauthor=A.+Gonthierauthor=H.+Schwobauthor=M.+Goeldnerauthor=E.+Sigel&title=On+the+benzodiazepine+binding+pocket+in+GABAA+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerezhnoy%26aufirst%3DD.%26aulast%3DNyfeler%26aufirst%3DY.%26aulast%3DGonthier%26aufirst%3DA.%26aulast%3DSchwob%26aufirst%3DH.%26aulast%3DGoeldner%26aufirst%3DM.%26aulast%3DSigel%26aufirst%3DE.%26atitle%3DOn%2520the%2520benzodiazepine%2520binding%2520pocket%2520in%2520GABAA%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26issue%3D5%26spage%3D3160%26epage%3D3168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Drummer, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syrjanen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordner, S. M.</span><span> </span><span class="NLM_article-title">Deaths involving the benzodiazepine flunitrazepam</span> <span class="citation_source-journal">Am. J. Forensic Med. Pathol.</span><span class="NLM_year" style="font-weight: bold;">1993</span> <span class="NLM_volume">14</span><span class="NLM_issue">3</span> <span class="NLM_fpage">238</span> <span class="NLM_lpage">243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=8311057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A280%3ADyaK2c7ksVKiug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1993&pages=238-243&issue=3&author=O.+H.+Drummerauthor=M.+L.+Syrjanenauthor=S.+M.+Cordner&title=Deaths+involving+the+benzodiazepine+flunitrazepam"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Deaths involving the benzodiazepine flunitrazepam</span></div><div class="casAuthors">Drummer O H; Syrjanen M L; Cordner S M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of forensic medicine and pathology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">238-43</span>
        ISSN:<span class="NLM_cas:issn">0195-7910</span>.
    </div><div class="casAbstract">A study of eight deaths involving the benzodiazepine flunitrazepam was performed to assess the contribution of this drug to the fatalities.  Coronial deaths in Victoria in the 2-year period to mid-1991 were selected in which either flunitrazepam or flunitrazepam and ethanol were the principal toxicological findings.  All bodies were subject to a full autopsy by forensic pathologists, and a full toxicological examination.  No significant pathology was found at autopsy in any case.  Very high concentrations of 7-aminoflunitrazepam, a metabolite of flunitrazepam, were present in all cases.  In four cases no other significant drug was detected, whereas in the other four cases there were significant concentrations of ethanol (mean 1.6 g/L).  In these two groups of cases the concentrations of 7-aminoflunitrazepam were 0.45 mg/L and 0.16 mg/L, respectively.  Only moderate levels of flunitrazepam were detected, suggesting that 7-aminoflunitrazepam is produced postmortem and may be an important marker of flunitrazepam usage.  The causes of death in these eight cases were probably either flunitrazepam toxicity or a combination of flunitrazepam and ethanol toxicity.  Only one case appeared likely to have been a suicide.  Our observations in these cases suggest that flunitrazepam may cause death in the absence of other drugs or significant disease.  The presence of ethanol reduces the amount of flunitrazepam needed to cause death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmLnoI-iZ4iFUIs6wFK5xJfW6udTcc2eY3ra5L0iL-L7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c7ksVKiug%253D%253D&md5=e4c91e6381713c754188095c15634179</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrummer%26aufirst%3DO.%2BH.%26aulast%3DSyrjanen%26aufirst%3DM.%2BL.%26aulast%3DCordner%26aufirst%3DS.%2BM.%26atitle%3DDeaths%2520involving%2520the%2520benzodiazepine%2520flunitrazepam%26jtitle%3DAm.%2520J.%2520Forensic%2520Med.%2520Pathol.%26date%3D1993%26volume%3D14%26issue%3D3%26spage%3D238%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Farre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teran, M.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roset, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torrens, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cami, J.</span><span> </span><span class="NLM_article-title">Abuse liability of flunitrazepam among methadone-maintained patients</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_year" style="font-weight: bold;">1998</span> <span class="NLM_volume">140</span> <span class="NLM_fpage">486</span> <span class="NLM_lpage">495</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=1998&pages=486-495&author=M.+Farreauthor=M.-T.+Teranauthor=P.+N.+Rosetauthor=M.+Masauthor=M.+Torrensauthor=J.+Cami&title=Abuse+liability+of+flunitrazepam+among+methadone-maintained+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFarre%26aufirst%3DM.%26aulast%3DTeran%26aufirst%3DM.-T.%26aulast%3DRoset%26aufirst%3DP.%2BN.%26aulast%3DMas%26aufirst%3DM.%26aulast%3DTorrens%26aufirst%3DM.%26aulast%3DCami%26aufirst%3DJ.%26atitle%3DAbuse%2520liability%2520of%2520flunitrazepam%2520among%2520methadone-maintained%2520patients%26jtitle%3DPsychopharmacology%26date%3D1998%26volume%3D140%26spage%3D486%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Gambi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimaldi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giampietro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Bernardis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferro, F. M.</span><span> </span><span class="NLM_article-title">Flunitrazepam a benzodiazepine most used among drug abusers</span> <span class="citation_source-journal">Int. J. Immunopathol. Pharmacol.</span><span class="NLM_year" style="font-weight: bold;">1999</span> <span class="NLM_volume">12</span><span class="NLM_issue">3</span> <span class="NLM_fpage">157</span> <span class="NLM_lpage">159</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=12783645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktFWm" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1999&pages=157-159&issue=3&author=F.+Gambiauthor=C.+M.+Contiauthor=M.+R.+Grimaldiauthor=L.+Giampietroauthor=B.+De+Bernardisauthor=F.+M.+Ferro&title=Flunitrazepam+a+benzodiazepine+most+used+among+drug+abusers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Flunitrazepam a benzodiazepine most used among drug abusers</span></div><div class="casAuthors">Gambi, F.; Conti, C. M. V.; Grimaldi, M. R.; Giampietro, L.; De Berardis, D.; Ferro, F. M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Immunopathology and Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-159</span>CODEN:
                <span class="NLM_cas:coden">IJIPE4</span>;
        ISSN:<span class="NLM_cas:issn">0394-6320</span>.
    
            (<span class="NLM_cas:orgname">Biomedical Research Press</span>)
        </div><div class="casAbstract">A review with 19 refs.  Flunitrazepam (FZ) is a sedative/hypnotic nitro-benzodiazepine.  This drug has been accepted by both patients and physicians and in the last 20 yr flunitrazepam has been included and studied in many clin. trials so, in many countries, flunitrazepam is one of the most prescribed hypnotic.  Since 1980 it has been found that FZ began to be a popular drug among drug abusers all over the word.  However, little is known about the difference between Fz and other Benzodiazepines in capacity to produce physiol. dependence or in ability to produce drug taking or drug seeking behavior.  Flunitrazepam has little risk of abuse by the vast majority of patients; however when the drug is taken i. v. or intranasally, its effect is much faster and risk of abuse is much greater.  In this report we examine the reasons why some populations of drug abusers prefer flunitrazepam over the other benzodiazepines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVKySlI7xe2bVg90H21EOLACvtfcHk0lhi36eKygIokQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktFWm&md5=1bc3bf12775100898fca7dd2795815f6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGambi%26aufirst%3DF.%26aulast%3DConti%26aufirst%3DC.%2BM.%26aulast%3DGrimaldi%26aufirst%3DM.%2BR.%26aulast%3DGiampietro%26aufirst%3DL.%26aulast%3DDe%2BBernardis%26aufirst%3DB.%26aulast%3DFerro%26aufirst%3DF.%2BM.%26atitle%3DFlunitrazepam%2520a%2520benzodiazepine%2520most%2520used%2520among%2520drug%2520abusers%26jtitle%3DInt.%2520J.%2520Immunopathol.%2520Pharmacol.%26date%3D1999%26volume%3D12%26issue%3D3%26spage%3D157%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Mintzer, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, R. R.</span><span> </span><span class="NLM_article-title">An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers</span> <span class="citation_source-journal">Behav. Pharmacol.</span><span class="NLM_year" style="font-weight: bold;">2005</span> <span class="NLM_volume">16</span><span class="NLM_issue">7</span> <span class="NLM_fpage">579</span> <span class="NLM_lpage">584</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1097%2F01.fbp.0000172736.11994.3c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16170235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWntrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=579-584&issue=7&author=M.+Z.+Mintzerauthor=R.+R.+Griffiths&title=An+abuse+liability+comparison+of+flunitrazepam+and+triazolam+in+sedative+drug+abusers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers</span></div><div class="casAuthors">Mintzer, M. Z.; Griffiths, R. R.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">579-584</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The present double-blind, placebo-controlled study compared the acute effects of oral administration of the benzodiazepine hypnotics flunitrazepam (6 mg/70 kg) and triazolam (1 and 2 mg/70 kg) on measures relevant to abuse liability as well as on psychomotor performance and observer- and participant-rated measures of drug effects in nine sedative drug abusers.  Anal. of participant-rated measures collected 24 h after drug administration (next-day; assessing the overall effects of the drug received 24 h earlier) indicated that flunitrazepam, but neither triazolam dose, produced significant increases relative to placebo in next-day ratings of drug liking, the amt. of money the drug would be worth on the street, and the amt. of money the participant would be willing to pay for the drug on the street.  Importantly, these abuse liability differences between flunitrazepam and triazolam were present at a dose of flunitrazepam (6 mg/70 kg) that produced overall drug effects that were comparable to, or significantly less than, those of a high triazolam dose (2 mg/70 kg).  Consistent with results of a previous study in our lab., these results suggest that flunitrazepam may have a greater abuse liability than triazolam, and that this abuse liability difference emerges on measures taken 24 h after drug administration but not on same-day measures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs__K4IOyKwbVg90H21EOLACvtfcHk0lhi36eKygIokQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWntrrM&md5=0e220335b07bb56be33783ad289c9f71</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2F01.fbp.0000172736.11994.3c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.fbp.0000172736.11994.3c%26sid%3Dliteratum%253Aachs%26aulast%3DMintzer%26aufirst%3DM.%2BZ.%26aulast%3DGriffiths%26aufirst%3DR.%2BR.%26atitle%3DAn%2520abuse%2520liability%2520comparison%2520of%2520flunitrazepam%2520and%2520triazolam%2520in%2520sedative%2520drug%2520abusers%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2005%26volume%3D16%26issue%3D7%26spage%3D579%26epage%3D584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Schwartz, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, A. B.</span><span> </span><span class="NLM_article-title">Rohypnol, the date rape drug</span> <span class="citation_source-journal">Clin. Pediatr.</span><span class="NLM_year" style="font-weight: bold;">1998</span> <span class="NLM_volume">37</span> <span class="NLM_fpage">321</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1177%2F000992289803700508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=9597300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A280%3ADyaK1c3lvFGrug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=321&author=R.+H.+Schwartzauthor=A.+B.+Weaver&title=Rohypnol%2C+the+date+rape+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Rohypnol, the date rape drug</span></div><div class="casAuthors">Schwartz R H; Weaver A B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pediatrics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">321</span>
        ISSN:<span class="NLM_cas:issn">0009-9228</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzRK5dUlcSBWlSCSgBhwJFfW6udTcc2ebLKI6jJs3OXLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3lvFGrug%253D%253D&md5=410e1379c7fb79c26d34e84b85c013ac</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1177%2F000992289803700508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F000992289803700508%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DR.%2BH.%26aulast%3DWeaver%26aufirst%3DA.%2BB.%26atitle%3DRohypnol%252C%2520the%2520date%2520rape%2520drug%26jtitle%3DClin.%2520Pediatr.%26date%3D1998%26volume%3D37%26spage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Smith, K. M.</span><span> </span><span class="NLM_article-title">Drugs used in acquaintance rape</span> <span class="citation_source-journal">J. Am. Pharm. Assoc.</span><span class="NLM_year" style="font-weight: bold;">1999</span> <span class="NLM_volume">39</span> <span class="NLM_fpage">519</span> <span class="NLM_lpage">583</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1999&pages=519-583&author=K.+M.+Smith&title=Drugs+used+in+acquaintance+rape"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DK.%2BM.%26atitle%3DDrugs%2520used%2520in%2520acquaintance%2520rape%26jtitle%3DJ.%2520Am.%2520Pharm.%2520Assoc.%26date%3D1999%26volume%3D39%26spage%3D519%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span> <span class="citation_source-book">DEA Congressional Testimony</span>, House Commerce Committee Subcommittee on Oversight and Investigations, 106th Congress, 1st Session; <span class="NLM_publisher-name">U.S. Drug Enforcement Administration</span>: <span class="NLM_publisher-loc">Springfield, VA</span>, <span class="NLM_year">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=DEA+Congressional+Testimony%2C+House+Commerce+Committee+Subcommittee+on+Oversight+and+Investigations%2C+106th+Congress%2C+1st+Session%3B+U.S.+Drug+Enforcement+Administration%3A+Springfield%2C+VA%2C+1999."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DDEA%2520Congressional%2520Testimony%26pub%3DU.S.%2520Drug%2520Enforcement%2520Administration%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valvano, N. L.</span><span> </span><span class="NLM_article-title">Synthesis of 2-aminobenzophenones via rapid halogenâlithium exchange in the presence of a 2-amino-<i>N</i>-methoxy-<i>N</i>-methylbenzamide</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_year" style="font-weight: bold;">1991</span> <span class="NLM_volume">56</span> <span class="NLM_fpage">3750</span> <span class="NLM_lpage">3752</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00011a066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1991&pages=3750-3752&author=S.+V.+Fryeauthor=M.+C.+Johnsonauthor=N.+L.+Valvano&title=Synthesis+of+2-aminobenzophenones+via+rapid+halogen%E2%88%92lithium+exchange+in+the+presence+of+a+2-amino-N-methoxy-N-methylbenzamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjo00011a066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00011a066%26sid%3Dliteratum%253Aachs%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DJohnson%26aufirst%3DM.%2BC.%26aulast%3DValvano%26aufirst%3DN.%2BL.%26atitle%3DSynthesis%2520of%25202-aminobenzophenones%2520via%2520rapid%2520halogen%25E2%2588%2592lithium%2520exchange%2520in%2520the%2520presence%2520of%2520a%25202-amino-N-methoxy-N-methylbenzamide%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1991%26volume%3D56%26spage%3D3750%26epage%3D3752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Carpino, L. A.</span><span> </span><span class="NLM_article-title">1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_year" style="font-weight: bold;">1993</span> <span class="NLM_volume">115</span> <span class="NLM_fpage">4397</span> <span class="NLM_lpage">4398</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00063a082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1993&pages=4397-4398&author=L.+A.+Carpino&title=1-Hydroxy-7-azabenzotriazole.+An+efficient+peptide+coupling+additive"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fja00063a082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00063a082%26sid%3Dliteratum%253Aachs%26aulast%3DCarpino%26aufirst%3DL.%2BA.%26atitle%3D1-Hydroxy-7-azabenzotriazole.%2520An%2520efficient%2520peptide%2520coupling%2520additive%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1993%26volume%3D115%26spage%3D4397%26epage%3D4398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Sternbach, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fryer, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metlesics, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stempel, A.</span><span> </span><span class="NLM_article-title">Quinazolines and 1,4-benzodiazepines. V. <i>o</i>-Aminobenzophenones</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_year" style="font-weight: bold;">1962</span> <span class="NLM_volume">27</span><span class="NLM_issue">11</span> <span class="NLM_fpage">3781</span> <span class="NLM_lpage">3788</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo01058a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1962&pages=3781-3788&issue=11&author=L.+H.+Sternbachauthor=R.+I.+Fryerauthor=W.+Metlesicsauthor=G.+Sachauthor=A.+Stempel&title=Quinazolines+and+1%2C4-benzodiazepines.+V.+o-Aminobenzophenones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjo01058a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01058a009%26sid%3Dliteratum%253Aachs%26aulast%3DSternbach%26aufirst%3DL.%2BH.%26aulast%3DFryer%26aufirst%3DR.%2BI.%26aulast%3DMetlesics%26aufirst%3DW.%26aulast%3DSach%26aufirst%3DG.%26aulast%3DStempel%26aufirst%3DA.%26atitle%3DQuinazolines%2520and%25201%252C4-benzodiazepines.%2520V.%2520o-Aminobenzophenones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1962%26volume%3D27%26issue%3D11%26spage%3D3781%26epage%3D3788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Sternbach, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fryer, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metlesics, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiger, N.</span><span> </span><span class="NLM_article-title">Quinazolinesand 1,4-benzodiazepines. X. Nitro-substituted 5-phenyl-1,4-benzodiazepine derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_year" style="font-weight: bold;">1963</span> <span class="NLM_volume">6</span> <span class="NLM_fpage">261</span> <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00339a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1963&pages=261-265&author=L.+H.+Sternbachauthor=R.+I.+Fryerauthor=O.+Kellerauthor=W.+Metlesicsauthor=G.+Sachauthor=N.+Steiger&title=Quinazolinesand+1%2C4-benzodiazepines.+X.+Nitro-substituted+5-phenyl-1%2C4-benzodiazepine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm00339a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00339a010%26sid%3Dliteratum%253Aachs%26aulast%3DSternbach%26aufirst%3DL.%2BH.%26aulast%3DFryer%26aufirst%3DR.%2BI.%26aulast%3DKeller%26aufirst%3DO.%26aulast%3DMetlesics%26aufirst%3DW.%26aulast%3DSach%26aufirst%3DG.%26aulast%3DSteiger%26aufirst%3DN.%26atitle%3DQuinazolinesand%25201%252C4-benzodiazepines.%2520X.%2520Nitro-substituted%25205-phenyl-1%252C4-benzodiazepine%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1963%26volume%3D6%26spage%3D261%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Carrera, M. R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirshing, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koob, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Suppression of psychoactive effects of cocaine by active immunization</span> <span class="citation_source-journal">Nature</span><span class="NLM_year" style="font-weight: bold;">1995</span> <span class="NLM_volume">378</span><span class="NLM_issue">6558</span> <span class="NLM_fpage">727</span> <span class="NLM_lpage">730</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=1995&pages=727-730&issue=6558&author=M.+R.+A.+Carreraauthor=J.+A.+Ashleyauthor=L.+H.+Parsonsauthor=P.+Wirshingauthor=G.+F.+Koobauthor=K.+D.+Janda&title=Suppression+of+psychoactive+effects+of+cocaine+by+active+immunization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarrera%26aufirst%3DM.%2BR.%2BA.%26aulast%3DAshley%26aufirst%3DJ.%2BA.%26aulast%3DParsons%26aufirst%3DL.%2BH.%26aulast%3DWirshing%26aufirst%3DP.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DSuppression%2520of%2520psychoactive%2520effects%2520of%2520cocaine%2520by%2520active%2520immunization%26jtitle%3DNature%26date%3D1995%26volume%3D378%26issue%3D6558%26spage%3D727%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Carrera, M. R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirsching, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koob, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Cocaine vaccines: antibody protection against relapse in a rat model</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_year" style="font-weight: bold;">2000</span> <span class="NLM_volume">97</span><span class="NLM_issue">11</span> <span class="NLM_fpage">6202</span> <span class="NLM_lpage">6206</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=6202-6206&issue=11&author=M.+R.+A.+Carreraauthor=J.+A.+Ashleyauthor=B.+Zhouauthor=P.+Wirschingauthor=G.+F.+Koobauthor=K.+D.+Janda&title=Cocaine+vaccines%3A+antibody+protection+against+relapse+in+a+rat+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarrera%26aufirst%3DM.%2BR.%2BA.%26aulast%3DAshley%26aufirst%3DJ.%2BA.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DWirsching%26aufirst%3DP.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DCocaine%2520vaccines%253A%2520antibody%2520protection%2520against%2520relapse%2520in%2520a%2520rat%2520model%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2000%26volume%3D97%26issue%3D11%26spage%3D6202%26epage%3D6206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Deroche, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caine, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyser, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polis, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koob, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gold, L. H.</span><span> </span><span class="NLM_article-title">Differences in the liability to self-administer intravenous cocaine between C57BL/6 Ã SJL and BALB/cByJ mice</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_year" style="font-weight: bold;">1997</span> <span class="NLM_volume">57</span><span class="NLM_issue">3</span> <span class="NLM_fpage">429</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2FS0091-3057%2896%2900439-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=9218267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADyaK2sXkt1yiu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=429-440&issue=3&author=V.+Derocheauthor=S.+B.+Caineauthor=C.+J.+Heyserauthor=I.+Polisauthor=G.+F.+Koobauthor=L.+H.+Gold&title=Differences+in+the+liability+to+self-administer+intravenous+cocaine+between+C57BL%2F6+%C3%97+SJL+and+BALB%2FcByJ+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Differences in the liability to self-administer intravenous cocaine between C57BL/6 Ã SJL and BALB/cByJ mice</span></div><div class="casAuthors">Deroche, V.; Caine, S. B.; Heyser, C. J.; Polis, I.; Koob, G. F.; Gold, L. H.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-440</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Application of animal models of psychostimulant abuse for experimentation in mice is becoming increasingly important for studying the contribution of genetic differences, as well as the roles of selected (targeted) genes, in specific behaviors.  The purpose of this study was to investigate strain differences in cocaine self-administration behavior between C57BL/6 Ã SJL hybrid mice and BALB/cByJ mice.  These two strains were chosen because BALB/cByJ mice have a well-developed behavioral pharmacol. profile, and hybrid strains on a C57BL/6 background are commonly used for generating transgenic expressing and knockout mutant mice.  C57BL/6 Ã SJL mice dose-dependently acquired cocaine self-administration (1.0 mg/kg/injection but not 0.25 mg/kg/injection) by responding selectively in the active nose-poke hole and maintaining stable levels of daily drug intake; they also exhibited a characteristic inverted-U-shaped cocaine dose-effect function.  BALB/cByJ mice failed to acquire cocaine self-administration at either dose under the same test conditions.  The strain differences obsd. in self-administration did not seem to be attributed to other behavioral differences because the two strains exhibited similar amts. of spontaneous nose-poking in the absence of reinforcers, and BALB/cByJ mice responded more than C57BL/6 Ã SJL mice in a food-reinforced nose-poke operant task.  Importantly, the dose-effect function for the motor stimulating effects of cocaine (3.8-30 mg/kg i.p.) suggests enhanced sensitivity but reduced efficacy of cocaine in stimulating motor activity in BALB/cByJ mice relative to the C57BL/6 Ã SJL hybrid mice.  These results indicate that the decreased liability of BALB/cByJ mice to acquire cocaine self-administration is not the result of differences in spontaneous activity or performance, but may reflect different sensitivities to the reinforcing, or rate-disrupting, properties of cocaine.  The data support an influence of genetic background in the liability to self-administer cocaine.  Thus, a hypothesis is proposed that the decreased liability of BALB/cByJ mice to acquire cocaine self-administration is related to differences in brain monoamine systems linked to the high "emotionality" profile of BALB/c mice in novel or fearful situations, including perhaps cocaine administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJeNeEDGg_47Vg90H21EOLACvtfcHk0lhDXtlZQpZJeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt1yiu7w%253D&md5=fbce8f49a6078cf2ac97c1d07b5d4e60</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2896%2900439-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252896%252900439-X%26sid%3Dliteratum%253Aachs%26aulast%3DDeroche%26aufirst%3DV.%26aulast%3DCaine%26aufirst%3DS.%2BB.%26aulast%3DHeyser%26aufirst%3DC.%2BJ.%26aulast%3DPolis%26aufirst%3DI.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26aulast%3DGold%26aufirst%3DL.%2BH.%26atitle%3DDifferences%2520in%2520the%2520liability%2520to%2520self-administer%2520intravenous%2520cocaine%2520between%2520C57BL%252F6%2520%25C3%2597%2520SJL%2520and%2520BALB%252FcByJ%2520mice%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D1997%26volume%3D57%26issue%3D3%26spage%3D429%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Isomura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirsching, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_year" style="font-weight: bold;">2001</span> <span class="NLM_volume">66</span><span class="NLM_issue">12</span> <span class="NLM_fpage">4115</span> <span class="NLM_lpage">4121</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo001442w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=4115-4121&issue=12&author=S.+Isomuraauthor=P.+Wirschingauthor=K.+D.+Janda&title=An+immunotherapeutic+program+for+the+treatment+of+nicotine+addiction%3A+hapten+design+and+synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjo001442w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo001442w%26sid%3Dliteratum%253Aachs%26aulast%3DIsomura%26aufirst%3DS.%26aulast%3DWirsching%26aufirst%3DP.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DAn%2520immunotherapeutic%2520program%2520for%2520the%2520treatment%2520of%2520nicotine%2520addiction%253A%2520hapten%2520design%2520and%2520synthesis%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26issue%3D12%26spage%3D4115%26epage%3D4121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Matsushita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, T. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirsching, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Cocaine catalytic antibodies: the primary importance of linker effects</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_year" style="font-weight: bold;">2001</span> <span class="NLM_volume">11</span><span class="NLM_issue">2</span> <span class="NLM_fpage">87</span> <span class="NLM_lpage">90</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=87-90&issue=2&author=M.+Matsushitaauthor=T.+Z.+Hoffmanauthor=J.+A.+Ashleyauthor=B.+Zhouauthor=P.+Wirschingauthor=K.+D.+Janda&title=Cocaine+catalytic+antibodies%3A+the+primary+importance+of+linker+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DT.%2BZ.%26aulast%3DAshley%26aufirst%3DJ.%2BA.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DWirsching%26aufirst%3DP.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DCocaine%2520catalytic%2520antibodies%253A%2520the%2520primary%2520importance%2520of%2520linker%2520effects%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26issue%3D2%26spage%3D87%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Meijler, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altobell, L. J.,  III.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirsching, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">A new strategy for improved nicotine vaccines using conformationally constrained haptens</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_year" style="font-weight: bold;">2003</span> <span class="NLM_volume">125</span><span class="NLM_issue">47</span> <span class="NLM_fpage">164</span> <span class="NLM_lpage">165</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2003&pages=164-165&issue=47&author=M.+M.+Meijlerauthor=M.+Matsushitaauthor=L.+J.+Altobellauthor=P.+Wirschingauthor=K.+D.+Janda&title=A+new+strategy+for+improved+nicotine+vaccines+using+conformationally+constrained+haptens"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeijler%26aufirst%3DM.%2BM.%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DAltobell%26aufirst%3DL.%2BJ.%26aulast%3DWirsching%26aufirst%3DP.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DA%2520new%2520strategy%2520for%2520improved%2520nicotine%2520vaccines%2520using%2520conformationally%2520constrained%2520haptens%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2003%26volume%3D125%26issue%3D47%26spage%3D164%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Ino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Positional linker effects in haptens for cocaine immunopharmacotherapy</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_year" style="font-weight: bold;">2007</span> <span class="NLM_volume">17</span><span class="NLM_issue">15</span> <span class="NLM_fpage">4280</span> <span class="NLM_lpage">4283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4280-4283&issue=15&author=A.+Inoauthor=T.+J.+Dickersonauthor=K.+D.+Janda&title=Positional+linker+effects+in+haptens+for+cocaine+immunopharmacotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIno%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DT.%2BJ.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DPositional%2520linker%2520effects%2520in%2520haptens%2520for%2520cocaine%2520immunopharmacotherapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D15%26spage%3D4280%26epage%3D4283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Qi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijler, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altobell, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koob, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirsching, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janda, K. D.</span><span> </span><span class="NLM_article-title">Delta-9-tetrahydrocannabinol immunochemical studies: haptens, monoclonal antibodies, and a convenient synthesis of radiolabeled delta-9-tetrahydrocannabinol</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_year" style="font-weight: bold;">2005</span> <span class="NLM_volume">48</span><span class="NLM_issue">23</span> <span class="NLM_fpage">7389</span> <span class="NLM_lpage">7399</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050442r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7389-7399&issue=23&author=L.+Qiauthor=N.+Yamamotoauthor=M.+M.+Meijlerauthor=L.+J.+Altobellauthor=G.+F.+Koobauthor=P.+Wirschingauthor=K.+D.+Janda&title=Delta-9-tetrahydrocannabinol+immunochemical+studies%3A+haptens%2C+monoclonal+antibodies%2C+and+a+convenient+synthesis+of+radiolabeled+delta-9-tetrahydrocannabinol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm050442r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050442r%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DL.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DMeijler%26aufirst%3DM.%2BM.%26aulast%3DAltobell%26aufirst%3DL.%2BJ.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26aulast%3DWirsching%26aufirst%3DP.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DDelta-9-tetrahydrocannabinol%2520immunochemical%2520studies%253A%2520haptens%252C%2520monoclonal%2520antibodies%252C%2520and%2520a%2520convenient%2520synthesis%2520of%2520radiolabeled%2520delta-9-tetrahydrocannabinol%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D23%26spage%3D7389%26epage%3D7399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Fryer, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z. Q.</span><span> </span><span class="NLM_article-title">The rational design and synthesis of haptens having specific activity as full agonists or full antagonists at the benzodiazepine receptor</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_year" style="font-weight: bold;">1990</span> <span class="NLM_volume">47</span><span class="NLM_issue">10</span> <span class="NLM_fpage">833</span> <span class="NLM_lpage">840</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1990&pages=833-840&issue=10&author=R.+I.+Fryerauthor=Z.+Q.+Gu&title=The+rational+design+and+synthesis+of+haptens+having+specific+activity+as+full+agonists+or+full+antagonists+at+the+benzodiazepine+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFryer%26aufirst%3DR.%2BI.%26aulast%3DGu%26aufirst%3DZ.%2BQ.%26atitle%3DThe%2520rational%2520design%2520and%2520synthesis%2520of%2520haptens%2520having%2520specific%2520activity%2520as%2520full%2520agonists%2520or%2520full%2520antagonists%2520at%2520the%2520benzodiazepine%2520receptor%26jtitle%3DLife%2520Sci.%26date%3D1990%26volume%3D47%26issue%3D10%26spage%3D833%26epage%3D840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Peterson, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunnell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goforth, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, S. M.</span><span> </span><span class="NLM_article-title">Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_year" style="font-weight: bold;">2007</span> <span class="NLM_volume">322</span><span class="NLM_issue">1</span> <span class="NLM_fpage">30</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1124%2Fjpet.106.117150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=17452421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntl2jsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=30-39&issue=1&author=E.+C.+Petersonauthor=M.+Gunnellauthor=Y.+Cheauthor=R.+L.+Goforthauthor=F.+I.+Carrollauthor=R.+Henryauthor=H.+Liuauthor=S.+M.+Owens&title=Using+hapten+design+to+discover+therapeutic+monoclonal+antibodies+for+treating+methamphetamine+abuse"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse</span></div><div class="casAuthors">Peterson, Eric C.; Gunnell, Melinda; Che, Yingni; Goforth, Robyn L.; Carroll, F. Ivy; Henry, Ralph; Liu, Huimin; Owens, S. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">When generating monoclonal antibodies (mAb) against small mols., the chem. compn. and mol. orientation of the drug-like hapten on the antigen is a crucial determinant.  This is esp. important when attempting to discover therapeutic mAb against the drugs of abuse (+)-methamphetamine [(+)-METH], (+)-amphetamine [(+)-AMP], and the related compd. (+)-3,4-methylenedioxymethamphetamine [(+)-MDMA, the plus isomer in the racemic mixt. known as MDMA or ecstasy].  The goal of these studies was to design and synthesize (+)-METH-like haptens with structural attributes that could make them effective for generating monoclonal antibodies for treating medical problems assocd. with these stimulant drugs of abuse.  Five prototype (+)-METH-like haptens, which mimic structural aspects of these drugs, were synthesized and used to generate mAb.  After screening for anti-(+)-METH IgG antibodies in more than 25,000 potential mouse hybridoma cell lines, one prototype mAb from each of the 5 haptens was selected and studied in detail for mol. properties and preclin. efficacy.  The amino acid sequences of the IgG-variable regions, structural models, affinity, and ligand specificity of each mAb were then used to help elucidate important therapeutic characteristics.  Four of these antibodies exhibited high affinity and specificity to (+)-METH and (+)-MDMA; whereas one antibody (designated mAb4G9) exhibited high affinity and specificity to (+)-METH, (+)-MDMA, and (+)-AMP, without significant cross-reactivity against other METH-like ligands, over-the-counter medications, or endogenous neurotransmitters.  Considered together, discovery of mAb4G9 and the other antibodies in this report represent an important step in understanding the process for custom design of drug class-specific therapeutic antibodies for the treatment of drug addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKlOI-7pwFvbVg90H21EOLACvtfcHk0lizL7jcDVTbiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntl2jsbg%253D&md5=f9a28b07d1dee11337b955f4f0975032</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.117150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.117150%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DE.%2BC.%26aulast%3DGunnell%26aufirst%3DM.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DGoforth%26aufirst%3DR.%2BL.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DHenry%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DOwens%26aufirst%3DS.%2BM.%26atitle%3DUsing%2520hapten%2520design%2520to%2520discover%2520therapeutic%2520monoclonal%2520antibodies%2520for%2520treating%2520methamphetamine%2520abuse%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26issue%3D1%26spage%3D30%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Castellano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavone, F.</span><span> </span><span class="NLM_article-title">Effects of flunitrazepam on passive avoidance behaviour in mice subjected to immobilization stress or familiarized with the testing apparatus</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_year" style="font-weight: bold;">1986</span> <span class="NLM_volume">22</span><span class="NLM_issue">1</span> <span class="NLM_fpage">91</span> <span class="NLM_lpage">95</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2F0166-4328%2886%2990084-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=3024662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADyaL2sXht1OrsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1986&pages=91-95&issue=1&author=C.+Castellanoauthor=F.+Pavone&title=Effects+of+flunitrazepam+on+passive+avoidance+behaviour+in+mice+subjected+to+immobilization+stress+or+familiarized+with+the+testing+apparatus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of flunitrazepam on passive avoidance behavior in mice subjected to immobilization stress or familiarized with the testing apparatus</span></div><div class="casAuthors">Castellano, Claudio; Pavone, Flaminia</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-5</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    </div><div class="casAbstract">The effects of flunitrazepam  [1622-62-4] on passive avoidance behavior were investigated in DBA/2 mice.  In a first set of expts. retention performance impairment was obsd. in mice injected with the drug immediately but not 120 min after training.  In a second set of expts., immobilization stress enhanced, while familiarization with the app. decreased, the effects of flunitrazepam, suggesting involvement of emotional factors.  All the effects obsd. were antagonized by naltrexone, showing involvement of opioid receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3q4maGK6_7LVg90H21EOLACvtfcHk0lizL7jcDVTbiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXht1OrsA%253D%253D&md5=231f3c4d3a7371bf2770b3315932ed3e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2F0166-4328%2886%2990084-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0166-4328%252886%252990084-7%26sid%3Dliteratum%253Aachs%26aulast%3DCastellano%26aufirst%3DC.%26aulast%3DPavone%26aufirst%3DF.%26atitle%3DEffects%2520of%2520flunitrazepam%2520on%2520passive%2520avoidance%2520behaviour%2520in%2520mice%2520subjected%2520to%2520immobilization%2520stress%2520or%2520familiarized%2520with%2520the%2520testing%2520apparatus%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D1986%26volume%3D22%26issue%3D1%26spage%3D91%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Bowers, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehner, J. M.</span><span> </span><span class="NLM_article-title">Differential sensitivity to the anxiolytic effects of ethanol and flunitrazepam in PKCgamma null mutant mice</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_year" style="font-weight: bold;">2001</span> <span class="NLM_volume">69</span> <span class="NLM_fpage">99</span> <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2FS0091-3057%2801%2900510-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=11420074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksVGrt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2001&pages=99-110&author=B.+J.+Bowersauthor=K.+J.+Elliottauthor=J.+M.+Wehner&title=Differential+sensitivity+to+the+anxiolytic+effects+of+ethanol+and+flunitrazepam+in+PKCgamma+null+mutant+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Differential sensitivity to the anxiolytic effects of ethanol and flunitrazepam in PKCÎ³ null mutant mice</span></div><div class="casAuthors">Bowers, B. J.; Elliott, K. J.; Wehner, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">99-110</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Tests of ethanol effects in PKCÎ³ null mutant mice have indicated that PKCÎ³ plays a role in initial sensitivity to ethanol-induced sedation, hypothermia, and GABAA receptor function and impacts neurochem. pathways mediating anxiety.  The present study was undertaken to evaluate whether the decreased sensitivity to ethanol previously obsd. in these mice generalized to the anxiolytic effects of ethanol.  PKCÎ³ null mutant mice and wild-type controls were tested in the elevated-plus maze, the black/white box, and the mirrored chamber after ethanol (0, 1.0, 1.25, 1.5 g/kg) or flunitrazepam (FNZ) (0, 0.015, 0.03, 0.06 mg/kg).  Results indicated that although both genotypes exhibited anxiolytic responses to ethanol in the elevated plus-maze, null mutant mice were less sensitive than wild-type control mice; however, in the black/white box, PKCÎ³ null mutants were more sensitive than controls to the anxiolytic effects of FNZ.  Neither ethanol nor FNZ produced anxiolytic responses in the mirrored chamber for either genotype.  These results suggest that PKCÎ³ differentially mediates anxiolytic responses to ethanol and FNZ and that this relationship interacts with each drug's efficacy in reducing anxiety-related behaviors specific to each of the three mazes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFJN8VYuiJxbVg90H21EOLACvtfcHk0lizL7jcDVTbiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksVGrt7k%253D&md5=bb8dbb9744d508bd9299c873d3093ccc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2801%2900510-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252801%252900510-X%26sid%3Dliteratum%253Aachs%26aulast%3DBowers%26aufirst%3DB.%2BJ.%26aulast%3DElliott%26aufirst%3DK.%2BJ.%26aulast%3DWehner%26aufirst%3DJ.%2BM.%26atitle%3DDifferential%2520sensitivity%2520to%2520the%2520anxiolytic%2520effects%2520of%2520ethanol%2520and%2520flunitrazepam%2520in%2520PKCgamma%2520null%2520mutant%2520mice%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2001%26volume%3D69%26spage%3D99%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">SaviÄ, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ObradoviÄ, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">UgresiÄ, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Linn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BokonjiÄ, D. R.</span><span> </span><span class="NLM_article-title">Benzodiazepine site inverse agonists and locomotor activity in rats: bimodal and biphasic influence</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_year" style="font-weight: bold;">2006</span> <span class="NLM_volume">84</span><span class="NLM_issue">1</span> <span class="NLM_fpage">35</span> <span class="NLM_lpage">42</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2Fj.pbb.2006.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=16725185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmslyku7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2006&pages=35-42&issue=1&author=M.+M.+Savi%C4%87author=D.+I.+Obradovi%C4%87author=N.+D.+Ugresi%C4%87author=J.+M.+Cookauthor=W.+Yinauthor=M.+Van+Linnauthor=D.+R.+Bokonji%C4%87&title=Benzodiazepine+site+inverse+agonists+and+locomotor+activity+in+rats%3A+bimodal+and+biphasic+influence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Benzodiazepine site inverse agonists and locomotor activity in rats: Bimodal and biphasic influence</span></div><div class="casAuthors">Savic, Miroslav M.; Obradovic, Dragan I.; Ugresic, Nenad D.; Cook, James M.; Yin, Wenyuan; Van Linn, Michael; Bokonjic, Dubravko R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-42</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Benzodiazepine site inverse agonists may increase or decrease locomotor activity in rodents, depending on the exptl. settings.  We have compared the behavioral responses to environmental novelty of rats treated with the non-selective inverse agonist DMCM (2 mg/kg) and the Î±1-subunit affinity-selective inverse agonist 3-EBC (15 mg/kg).  The behavior in spontaneous locomotor assay (during 45 min) and elevated plus maze (EPM) was automatically recorded.  In the EPM, general activity-related parameters were similarly decreased, whereas only DMCM inhibited open-arm activity.  In the locomotor assay, both compds. depressed locomotion in the first 15 min and activity in the central zone of the chamber.  However, the influence of 3-EBC was less pronounced.  The Î±1-subunit selective antagonist Î²-CCt (15 mg/kg) attenuated locomotor depression, but not the central-zone avoidance elicited by DMCM.  When habituated to the chamber, DMCM-treated animals emitted a plateau phase of activity, which disappeared by adding Î²-CCt.  Hence, inhibition of activity in exposed areas may be mediated by non-Î±1-subunits, whereas both Î±1 and non-Î±1-subunits may participate in suppression of activity in more protective areas of an app.  Hyperlocomotion in habituated animals may depend primarily on the Î±1-subunit.  Moreover, the bimodal influence of inverse agonists on locomotion can be biphasic, observable in the same expt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7v3lQdNdCc7Vg90H21EOLACvtfcHk0lgWdQk1Kcm31A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmslyku7k%253D&md5=0693b25f56d798a92d78c02a8ac0cbba</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2006.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2006.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%25C4%2587%26aufirst%3DM.%2BM.%26aulast%3DObradovi%25C4%2587%26aufirst%3DD.%2BI.%26aulast%3DUgresi%25C4%2587%26aufirst%3DN.%2BD.%26aulast%3DCook%26aufirst%3DJ.%2BM.%26aulast%3DYin%26aufirst%3DW.%26aulast%3DVan%2BLinn%26aufirst%3DM.%26aulast%3DBokonji%25C4%2587%26aufirst%3DD.%2BR.%26atitle%3DBenzodiazepine%2520site%2520inverse%2520agonists%2520and%2520locomotor%2520activity%2520in%2520rats%253A%2520bimodal%2520and%2520biphasic%2520influence%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2006%26volume%3D84%26issue%3D1%26spage%3D35%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">DeLorey, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBrady, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lameh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loew, G. H.</span><span> </span><span class="NLM_article-title">Influence of benzodiazepine binding site ligands on fear-conditioned contextual memory</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_year" style="font-weight: bold;">2001</span> <span class="NLM_volume">426</span><span class="NLM_issue">1â2</span> <span class="NLM_fpage">45</span> <span class="NLM_lpage">54</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2FS0014-2999%2801%2901199-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=11525770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmt1Kkurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2001&pages=45-54&issue=1%E2%88%922&author=T.+M.+DeLoreyauthor=R.+C.+Linauthor=B.+McBradyauthor=X.+Heauthor=J.+M.+Cookauthor=J.+Lamehauthor=G.+H.+Loew&title=Influence+of+benzodiazepine+binding+site+ligands+on+fear-conditioned+contextual+memory"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of benzodiazepine binding site ligands on fear-conditioned contextual memory</span></div><div class="casAuthors">DeLorey, T. M.; Lin, R. C.; McBrady, B.; He, X.; Cook, J. M.; Lameh, J.; Loew, G. H.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">45-54</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Eight compds. that bind to the benzodiazepine binding site on the Î³-amino butyric acidA (GABAA) receptor were assessed for their influence on contextual memory, an aspect of memory affected in various cognitive disorders including Alzheimer's disease.  Using a Pavlovian fear-conditioning paradigm, each ligand was evaluated in C57Bl/6 mice in regards to its direct affect on contextual memory and whether the ligand could attenuate scopolamine-induced contextual memory impairment.  Of the eight ligands tested, one impaired contextual memory (agonist), six attenuated scopolamine-induced contextual memory impairment (inverse agonists), and one antagonized the ability of an inverse agonist to attenuate scopolamine-induced contextual memory impairment.  Hence, further demonstrating the bi-directional influence benzodiazepine binding site ligands are able to exert on memory modulation.  This study serves as an initial starting point in the development of pharmacol. tools to be used in deciphering how GABAA receptors influence contextual memory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLUexfDv6LGbVg90H21EOLACvtfcHk0lgWdQk1Kcm31A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmt1Kkurs%253D&md5=a7c610a75448d5fe99a280cbfaeb4082</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2801%2901199-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252801%252901199-2%26sid%3Dliteratum%253Aachs%26aulast%3DDeLorey%26aufirst%3DT.%2BM.%26aulast%3DLin%26aufirst%3DR.%2BC.%26aulast%3DMcBrady%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DCook%26aufirst%3DJ.%2BM.%26aulast%3DLameh%26aufirst%3DJ.%26aulast%3DLoew%26aufirst%3DG.%2BH.%26atitle%3DInfluence%2520of%2520benzodiazepine%2520binding%2520site%2520ligands%2520on%2520fear-conditioned%2520contextual%2520memory%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D426%26issue%3D1%25E2%2588%25922%26spage%3D45%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Blanchard, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griebel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, R. J.</span><span> </span><span class="NLM_article-title">The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_year" style="font-weight: bold;">2003</span> <span class="NLM_volume">463</span><span class="NLM_issue">1â3</span> <span class="NLM_fpage">97</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1016%2FS0014-2999%2803%2901276-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=12600704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsVanu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2003&pages=97-116&issue=1%E2%88%923&author=D.+C.+Blanchardauthor=G.+Griebelauthor=R.+J.+Blanchard&title=The+mouse+defense+test+battery%3A+pharmacological+and+behavioral+assays+for+anxiety+and+panic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic</span></div><div class="casAuthors">Blanchard, D. Caroline; Griebel, Guy; Blanchard, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">97-116</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review. The Mouse Defense Test Battery was developed from tests of defensive behaviors in rats, reflecting earlier studies of both acute and chronic responses of lab. and wild rodents to threatening stimuli and situations.  It measures flight, freezing, defensive threat and attack, and risk assessment in response to an unconditioned predator stimulus, as well as pretest activity and post-threat (conditioned) defensiveness to the test context.  Factor analyses of these indicate four factors relating to cognitive and emotional aspects of defense, flight, and defensiveness to the test context.  In the Mouse Defense Test Battery, GABAA-benzodiazepine anxiolytics produce consistent redns. in defensive threat/attack and risk assessment, while panicolytic and panicogenic drugs selectively reduce and enhance, resp., flight.  Effects of GABAA-benzodiazepine, serotonin, and neuropeptide ligands in the Mouse Defense Test Battery are reviewed.  This review suggests that the Mouse Defense Test Battery is a sensitive and appropriate tool for preclin. evaluation of drugs potentially effective against defense-related disorders such as anxiety and panic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb5XWnQLrZsbVg90H21EOLACvtfcHk0ljcU7jk6zO5Hw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsVanu7k%253D&md5=27c3f278e68b3cecaada05cf107ee1bd</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2803%2901276-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252803%252901276-7%26sid%3Dliteratum%253Aachs%26aulast%3DBlanchard%26aufirst%3DD.%2BC.%26aulast%3DGriebel%26aufirst%3DG.%26aulast%3DBlanchard%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520mouse%2520defense%2520test%2520battery%253A%2520pharmacological%2520and%2520behavioral%2520assays%2520for%2520anxiety%2520and%2520panic%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D463%26issue%3D1%25E2%2588%25923%26spage%3D97%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Guscott, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bristow, L. J.</span><span> </span><span class="NLM_article-title">Contextual fear conditioning and baseline startle responses in the rat fear-potentiated startle test: a comparison of benzodiazepine/gamma-aminobutyric acid-A receptor agonists</span> <span class="citation_source-journal">Behav. Pharmacol.</span><span class="NLM_year" style="font-weight: bold;">2000</span> <span class="NLM_volume">11</span><span class="NLM_issue">6</span> <span class="NLM_fpage">495</span> <span class="NLM_lpage">504</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=11103915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1Ohurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2000&pages=495-504&issue=6&author=M.+R.+Guscottauthor=G.+P.+Cookauthor=L.+J.+Bristow&title=Contextual+fear+conditioning+and+baseline+startle+responses+in+the+rat+fear-potentiated+startle+test%3A+a+comparison+of+benzodiazepine%2Fgamma-aminobutyric+acid-A+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Contextual fear conditioning and baseline startle responses in the rat fear-potentiated startle test: a comparison of benzodiazepine/Î³-aminobutyric acid-A receptor agonists</span></div><div class="casAuthors">Guscott, M. R.; Cook, G. P.; Bristow, L. J.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">495-504</span>CODEN:
                <span class="NLM_cas:coden">BPHAEL</span>;
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">In the rat, fear-potentiated startle (FPS) test animals are first trained to assoc. brief light presentations with a mild elec. footshock and then tested for startle responses to acoustic stimuli, delivered either in darkness (i.e., basal startle) or after the conditioning stimulus.  Following light presentation the magnitude of the startle response is markedly increased, and the test is commonly used to distinguish anxiolytic drug effects (i.e., a redn. in FPS) from nonspecific effects such as sedation/muscle relaxation.  However, recent studies suggest that the environment in which the animal is trained may also contribute towards the acquisition of a conditioned fear response (i.e., contextual fear conditioning) and that this may elevate startle responses recorded in the dark.  The present study, therefore, compared the benzodiazepine/GABAA receptor agonist chlordiazepoxide with the partial agonists FG 8205 and bretazenil, which are known to have a reduced propensity to produce sedation/myorelaxation;, the study used two different FPS procedures: (i) conditioning and testing in stabilimeter chambers, and (ii) conditioning and testing in different environments.  FPS could be demonstrated in both procedures, and treatment with chlordiazepoxide, FG 8205 or bretazenil dose-dependently attenuated the response.  However, animals conditioned and tested in stabilimeter chambers also showed a significant increase in dark-startle amplitudes compared with nonshocked rats, suggesting that this response was elevated by contextual fear conditioning.  Furthermore, despite clear differences in side-effect liabilities, FG 8205 and bretazenil reduced dark-startle responses, suggesting that this measure is also sensitive to the anxiolytic effects of benzodiazepines.  In contrast, when animals were conditioned and tested in different environments, dark-startle responses were not significantly different from those in nonshocked rats, and treatment with FG 8205 or bretazenil had no effect.  Thus, conditioning and testing animals in different environments may provide a more effective means of distinguishing anxiolytic from nonspecific drug effects in the rat FPS test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIIXsvzvcLBbVg90H21EOLACvtfcHk0ljcU7jk6zO5Hw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1Ohurk%253D&md5=43a0c04dc1b5a46869c740db3261068f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuscott%26aufirst%3DM.%2BR.%26aulast%3DCook%26aufirst%3DG.%2BP.%26aulast%3DBristow%26aufirst%3DL.%2BJ.%26atitle%3DContextual%2520fear%2520conditioning%2520and%2520baseline%2520startle%2520responses%2520in%2520the%2520rat%2520fear-potentiated%2520startle%2520test%253A%2520a%2520comparison%2520of%2520benzodiazepine%252Fgamma-aminobutyric%2520acid-A%2520receptor%2520agonists%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2000%26volume%3D11%26issue%3D6%26spage%3D495%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Brignell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, H. V.</span><span> </span><span class="NLM_article-title">Drugs, sweat, and fears: a comparison of the effects of diazepam and methylphenidate on fear conditioning</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_year" style="font-weight: bold;">2006</span> <span class="NLM_volume">186</span><span class="NLM_issue">4</span> <span class="NLM_fpage">504</span> <span class="NLM_lpage">516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2006&pages=504-516&issue=4&author=C.+M.+Brignellauthor=H.+V.+Curran&title=Drugs%2C+sweat%2C+and+fears%3A+a+comparison+of+the+effects+of+diazepam+and+methylphenidate+on+fear+conditioning"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrignell%26aufirst%3DC.%2BM.%26aulast%3DCurran%26aufirst%3DH.%2BV.%26atitle%3DDrugs%252C%2520sweat%252C%2520and%2520fears%253A%2520a%2520comparison%2520of%2520the%2520effects%2520of%2520diazepam%2520and%2520methylphenidate%2520on%2520fear%2520conditioning%26jtitle%3DPsychopharmacology%26date%3D2006%26volume%3D186%26issue%3D4%26spage%3D504%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Fendt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanselow, M. S.</span><span> </span><span class="NLM_article-title">The neuroanatomical and neurochemical basis of conditioned fear</span> <span class="citation_source-journal">Neurosci. Behav. Rev.</span><span class="NLM_year" style="font-weight: bold;">1999</span> <span class="NLM_volume">23</span><span class="NLM_issue">5</span> <span class="NLM_fpage">743</span> <span class="NLM_lpage">760</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=10392663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A280%3ADyaK1MzhvFygtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1999&pages=743-760&issue=5&author=M.+Fendtauthor=M.+S.+Fanselow&title=The+neuroanatomical+and+neurochemical+basis+of+conditioned+fear"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The neuroanatomical and neurochemical basis of conditioned fear</span></div><div class="casAuthors">Fendt M; Fanselow M S</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience and biobehavioral reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">743-60</span>
        ISSN:<span class="NLM_cas:issn">0149-7634</span>.
    </div><div class="casAbstract">After a few pairings of a threatening stimulus with a formerly neutral cue, animals and humans will experience a state of conditioned fear when only the cue is present.  Conditioned fear provides a critical survival-related function in the face of threat by activating a range of protective behaviors.  The present review summarizes and compares the results of different laboratories investigating the neuroanatomical and neurochemical basis of conditioned fear, focusing primarily on the behavioral models of freezing and fear-potentiated startle in rats.  On the basis of these studies, we describe the pathways mediating and modulating fear.  We identify several key unanswered questions and discuss possible implications for the understanding of human anxiety disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmLJwxXXyjLF1C8OJBvdfbfW6udTcc2eaniZiyfv8YbLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1MzhvFygtg%253D%253D&md5=cba45817b3372e5a74ca99a2203e85f4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFendt%26aufirst%3DM.%26aulast%3DFanselow%26aufirst%3DM.%2BS.%26atitle%3DThe%2520neuroanatomical%2520and%2520neurochemical%2520basis%2520of%2520conditioned%2520fear%26jtitle%3DNeurosci.%2520Behav.%2520Rev.%26date%3D1999%26volume%3D23%26issue%3D5%26spage%3D743%26epage%3D760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Harris, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, R. F.</span><span> </span><span class="NLM_article-title">Contextual control over the expression of fear in rats conditioned under a benzodiazepine</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_year" style="font-weight: bold;">2001</span> <span class="NLM_volume">156</span> <span class="NLM_fpage">92</span> <span class="NLM_lpage">97</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2001&pages=92-97&author=J.+A.+Harrisauthor=R.+F.+Westbrook&title=Contextual+control+over+the+expression+of+fear+in+rats+conditioned+under+a+benzodiazepine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DJ.%2BA.%26aulast%3DWestbrook%26aufirst%3DR.%2BF.%26atitle%3DContextual%2520control%2520over%2520the%2520expression%2520of%2520fear%2520in%2520rats%2520conditioned%2520under%2520a%2520benzodiazepine%26jtitle%3DPsychopharmacology%26date%3D2001%26volume%3D156%26spage%3D92%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Harris, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, R. F.</span><span> </span><span class="NLM_article-title">The benzodiazepine midazolam does not impair Pavlovian fear conditioning but regulates when and where that fear is expressed</span> <span class="citation_source-journal">J. Exp. Psychol. Anim. Behav. Process</span><span class="NLM_year" style="font-weight: bold;">1999</span> <span class="NLM_volume">25</span> <span class="NLM_fpage">236</span> <span class="NLM_lpage">246</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm800506v&amp;key=10.1037%2F0097-7403.25.2.236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm800506v&amp;key=10331922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm800506v&amp;key=1%3ACAS%3A280%3ADyaK1M3mtVOruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1999&pages=236-246&author=J.+A.+Harrisauthor=R.+F.+Westbrook&title=The+benzodiazepine+midazolam+does+not+impair+Pavlovian+fear+conditioning+but+regulates+when+and+where+that+fear+is+expressed"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The benzodiazepine midazolam does not impair Pavlovian fear conditioning but regulates when and where fear is expressed</span></div><div class="casAuthors">Harris J A; Westbrook R F</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental psychology. Animal behavior processes</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-46</span>
        ISSN:<span class="NLM_cas:issn">0097-7403</span>.
    </div><div class="casAbstract">Rats were injected with a benzodiazepine (midazolam) and shocked after presentation of an auditory conditioned stimulus (CS).  They were then tested for fear reactions (freezing) to the CS in either the original context or a 2nd context after either a short (1-day) or long (21-day) retention interval.  Rats tested in the original context froze less after 1 day than rats tested after that interval in the 2nd context or rats tested after 21 days.  Moreover, rats tested after the long interval in the original context froze less than rats tested after that interval in the 2nd context.  Therefore, midazolam does not impair the acquisition of conditioned fear but regulates when and where that fear is expressed.  These effects of midazolam were interpreted as a contextually controlled deficit in the expression of conditioned fear that is similar to that associated with latent inhibition and extinction (M.  E.  Bouton, 1993).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS43YlxwWB0ve2qxNLjzXe8fW6udTcc2ebFuJ2ExQVPXbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3mtVOruw%253D%253D&md5=876bbf7e3313c6c9622814644b917338</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1037%2F0097-7403.25.2.236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252F0097-7403.25.2.236%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DJ.%2BA.%26aulast%3DWestbrook%26aufirst%3DR.%2BF.%26atitle%3DThe%2520benzodiazepine%2520midazolam%2520does%2520not%2520impair%2520Pavlovian%2520fear%2520conditioning%2520but%2520regulates%2520when%2520and%2520where%2520that%2520fear%2520is%2520expressed%26jtitle%3DJ.%2520Exp.%2520Psychol.%2520Anim.%2520Behav.%2520Process%26date%3D1999%26volume%3D25%26spage%3D236%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-si1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i35"><a href="/doi/suppl/10.1021/jm800506v">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_84361"></div></div></div></div></div><hr /></hr><p class="last"><sup>1</sup>H and <sup>13</sup>C NMR spectra and HPLC traces of compounds <b>4</b>â<b>6</b> and the RCA hapten. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm800506v/suppl_file/jm800506v_si_001.pdf">jm800506v_si_001.pdf (1.23 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm800506v&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Fjm800506v%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2008.51.issue-21%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm800506v" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                338KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67990b7718aa25a5","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
